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ABBREVIATIONS
The standard abbreviations used in this dissertation follow IUPAC rules. All the 
abbreviations are defined also in the text when they are introduced for the first time. 
The abbreviations mentioned only once are not included in this list.
bp Base pairs
ATM Ataxia-telangiectasia
BRCA1 BReast CAncer 1 gene
CERES Composite Exonic Regulatory Elements of Splicing gene
CFTR Cystic Fibrosis Transmembrane conductance Regulator
cDNA copy DNA
DAZAP1 Deleted in AZoospermia Associated Protein 1
DNA Deoxyribonucleic acid
dNTPs Deoxynucleoside triphosphate (A, C, G and T)
DTT Dithiothreitol
EDTA Ethylenediamine tetra-acetic acid
ESE Exonic Splicing Enhancer
ESS Exonic Splicing Silencer
hnRNP Heterogenous nuclear ribonucleoprotein
Hep3B Human hepatocarcinoma cells
IPTG Isopropyl-d-thiogalactopyranoside
ISE Intronic Splicing Enhancer
ISS Intronic Splicing Silencer
kb Kilobase
11
kDa Kilodalton
nt Nucleotides
N Nucleotide (A or C or G or T)
NF1 Neurofibromatosis type I gene
PBS Phosphate buffer saline
PCR Polymerase Chain Reaction
Pu Purine (G or A)
Py Pyrimidine (T or C)
RNA Ribonucleic acid
RNA Pol II RNA polymerase II
RRM RNA Recognition Motif
SDS N-lauroylsarcosine sodium salt
SELEX Systematic Evolution of Ligands by Exponential Enrichment
SMN Survival of Motor Neuron
snRNA Small nuclear RNA
snRNP small nuclear RiboNucleoProtein
SR Serine-arginine-rich protein
ss splice site
TBE Tris-borate-EDTA
U2AF U2 snRNP Auxiliary Factor
ABSTRACT
Exonic mutations can result in altered protein function by affecting exon recognition 
during splicing. To understand this mechanism I have extensively evaluated the 
exonic regulatory elements affected by the disease G to T mutation at position +6 of 
BRCA1 exon 18. This substitution induces the exclusion of the exon and it has been 
suggested that it disrupts an ASF/SF2-dependent enhancer. Using a pulldown assay 
with an internal standard, I show that WT and T6 sequences bind ASF/SF2 with 
similar efficiency, which is significantly lower compared to the binding to a typical 
enhancer derived from the fibronectin EDA exon. Consistent with the absence of an 
ASF/SF2 enhancing effect, siRNA depletion of ASF/SF2 did not induce exon WT 
exclusion indicating that ASF/SF2 is not essential for BRCA1 exon 18 splicing. 
However, depletion or overexpression of ASF/SF2 resulted in a decrease or increase 
of T6 exon 18 inclusion, respectively. By a series of exonic deletions in the WT and 
T6 BRCA1 minigenes, an enhancer sequence was identified in position 23-32 which 
mediates the observed T6-specific, ASF/SF2-dependent splicing activation. 
Furthermore, extensive mutations analysis indicated that the T6 mutant creates a 
sequence with a predominantly inhibitory function. Double site-directed mutations 
showed that the point mutations affecting the “TAG” sequence, between +6 and +8 
positions, completely restore normal splicing. Indeed, RNA protein interaction and 
siRNA experiments showed that the skipping of T6 BRCA1 exon 18 is due to the 
creation of a silencer element. This sequence specifically binds to the proteins 
hnRNP A1/A2 and to DAZAP1. By siRNA experiments, DAZAP1 and hnRNP 
A1/A2 are shown to be involved redundantly in the regulation of the defective 
BRCA1 exon 18. The present results support a gain-of-function model for the
BRCA1 T6 exon 18 and indicate that the binding of the hnRNP A1/A2 and DAZAP1 
is the primary determinant of exon skipping.
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1 INTRODUCTION
The accuracy of intron removal and exon junction during pre-mRNA splicing is 
determined principally by the recognition of the splicing consensus sequences at the 
5’ and 3’ exon splice sites. More discrete elements such as exonic or intronic splicing 
enhancers and silencers are also required for regulating pre-mRNA splicing 
(Cartegni, Chew et al. 2002). Several lines of evidence indicated that nucleotide 
modifications can be deleterious for normal pre-mRNA splicing by disrupting these 
regulatory sequences or by creating new cryptic ones. As a result, each nucleotide 
variant has to be considered as a potential candidate for promoting splicing 
alterations even if located in intronic sequences or classified as a translationally- 
silent mutation (Pagani and Baralle 2004).
Over recent years numerous disease associated point mutations have been associated 
with a defective splicing process making the study of the connection between 
aberrant splicing and occurrence of disease a central issue in the medical research 
field (Faustino and Cooper 2003; Garcia-Bianco, Baraniak et al. 2004; Pagani and 
Baralle 2004). The study of splicing mutations mechanisms increased our general 
knowledge of different splicing components and improved the understanding of the 
various network of interactions between cis-acting elements and trans-acting factors. 
However, the determinants of splicing regulation are still poorly understood as 
emphasized by many examples of splicing systems that are not easy to model due to 
their enormous complexity (Singh 2007).
Therefore, one of the key issues raised in molecular diagnosis is the accurate 
interpretation of the biological consequences of nucleotide variants and their related 
effect on splicing process. A correct classification of splicing mutations is essential
15
for understanding structure-function relationships at the protein level, for 
considering the individual phenotypic risk in familiar diseases and for developing 
new therapeutic strategies (Cartegni, Chew et al. 2002).
1.1 Pre-mRNA splicing reaction.
1.1.1 Overview of pre-mRNA splicing processing.
Splicing reaction is an essential step in the post-transcriptional regulation of gene 
expression in eukaryotes. This process is structurally and functionally associated 
with the nucleus and occurs in a complex termed the spliceosome (Maniatis and 
Reed 2002). Most eukaryotic genes are transcribed as long precursor molecules 
containing the coding portions of the transcript (exons) separated by multiple non­
coding intervening sequences (introns). In order to generate mature transcripts 
introns must be precisely removed from the pre-mRNA and exons have to be joined 
together (Staley and Guthrie 1998).
The first system used to study mRNA splicing and the structure of the pre-mRNA 
molecule was the late stage of adenovirus infection. The presence of introns was in 
fact discovered in the non-coding regions of the adenovirus (Berget, Moore et al. 
1977; Chow, Gelinas et al. 1977). Subsequent to the characterization of RNA 
splicing process in viruses, the presence of introns was also reported as a general 
feature of eukaryotic genes. Jeffreys and Flavell in fact described the presence of a 
“large insert” in the coding sequence of rabbit beta-globin gene in 1977. A year after, 
Chambon and colleagues reported that the chicken ovalbumin gene contains seven 
coding sequences (exons) separated by six intervening sequences (introns) showing 
the exact positions where the coding sequences for ovalbumin mRNA are interrupted 
inside the genome (Breathnach, Benoist et al. 1978). Moreover they found that the
16
sequences at exon-intron boundaries carry common features, probably with the 
function of unique excision-ligation common points to all boundaries (Breathnach, 
Benoist et al. 1978). Interestingly, these consensus sequences were also present in 
vertebrate, plant and yeast suggesting that the splicing process is evolutionarily 
conserved (Padgett, Grabowski et al. 1986).
In mammalian cells, the spliceosome machinery is present within nuclear boundaries 
(Maniatis and Reed 2002) showing a dynamic but precise nuclear-localization 
pattern that is usually termed “speckled pattern”. Nuclear speckles function as 
storage and modification compartments that can provide splicing factors to active 
transcription sites. Several studies showed that splicing factors are recruited from 
speckles to sites of transcription and when transcription is inhibited splicing factors 
accumulate in enlarged, rounded speckles (Lamond and Spector 2003).
On the other hand, a clear functional role for the spliceosome in extra-nuclear 
domains has not been clearly described. However recent studies have reported 
splicing activity in isolated rat neuronal dendrites (Glanzer, Miyashiro et al. 2005) 
and in human anucleate platelets (Denis, Tolley et al. 2005), suggesting the presence 
of a “nonnuclear” splicing in these specialized cells.
The complete formation of mature RNA (mRNA) requires not only the splicing 
reaction but also other processes and modifications. The mRNA biogenesis in fact 
comprises a complex network of dynamic and functional interactions (Fig. 1.1) 
between the elongating RNA Pol II and different processing machines responsible 
for capping, polyadenylation, nuclear surveillance and mRNAs export (Bentley 
2002; Bentley 2005). Distinct and highly complex cellular machines can carry out 
each of these steps in the gene-expression process even if growing evidence suggests 
the existence of “gene-expression factories” in which these individual processes are 
functionally connected. Indeed, several studies have delineated functional
17
relationships among these processes leading to the idea that they occur co- 
transcriptionally (Bentley 2002; Bentley 2005).
r  r *  .
>  ReleaseTranscription
Gapping
RNA processing Splldng
3* Poly A
mRNA export
T< c . u'Surveillance
Figure 1.1: A complex network of coupled interactions in gene expression.
The major processes of gene expression are indicated on the left and each step of the 
transcription is shown at the top of the picture by the red arrow. “Release” indicates 
the release of the mature mRNA from the site of transcription. The splicing step is 
only part of the entire RNA processing that includes also the capping and the 
polyadenilation, as shown in blue. It is important to notice that splicing is also 
connected with other gene expression steps like transcription, mRNA export, 
nonsense mediated decay (NMD) and RNA degradation as indicated by the black 
arrows. The black arrows show in fact physical and/or functional coupling between 
different steps in gene expression. Each arrow is documented by published studies. 
Figure adapted from Maniatis and Reed (Maniatis and Reed 2002).
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1.1.2 The chemistry of splicing reaction.
Splicing of pre-mRNA requires the interaction and cooperation of several small 
RNAs and a large number of proteins in order to remove introns and join exons. 
However, splicing from a chemical point of view is quite simple: it occurs in two 
transesterification reactions (Lamond 1993; Moore and Sharp 1993).
Conserved motifs in the nucleotide sequences, at the intron-exon boundaries, act as 
essential splicing signals in the chemical part of the splicing reaction. A “GU” at the 
exon-intron junction defines the 5’splice site (5’ss) and an “AG” at the other intron- 
exon junction together with the polyprimidine tract and the A nucleotide at the 
branch point identify the 3’ splice site (3’ss).
During the first step of the splicing reaction, the 2’-hydroxyl group of an A residue at 
the branch site attacks the phosphate at the 5’ss (Fig. 1.2). This leads to cleavage of 
the 5’ exon 1 from the intron and the concerted ligation of the intron 5’ end to the 
branch-point 2’-hydroxyl. This step produces two reaction intermediates, a detached 
5’ exon 1 and an intron/3’-exon 2 fragment in a lariat configuration containing a 
branched A nucleotide at the branch point (Fig. 1.2).
The second transesterification step consists of the attack of the 3’-hydroxyl of the 
detached exonl on the phosphate at the 3’ end of the intron. This step results in the 
ligation via phosphodiester bond of the two exons and the release of the intron, still 
in the form of a lariat (Fig. 1.2). The lariat is then “debranched” to give a linear 
excised intron, which is usually rapidly degraded.
19
intron
2 'A ,
First
transesterification
0 “0  =  3' oxygen of 
exon 1 
0  = 2' oxygen of 
branch-point A
. * = 3"oxygen of 
intron
0~—P=0
Second
transesterification
—3 ’
0=P Spliced exons
O*
Excised lariat 
intron
Figure 1.2: Schematic representation of the RNA splicing reaction.
Exons are represented by the pink and red rectangles. The specific adenine 
nucleotide of the branch point is indicated with an “A”. Splicing takes place in two 
catalytic steps that involves two consecutive trans-esterification reactions.
In the first step of splicing, an adenine residue of the branch point in the intron 
sequence carries out a nucleophilic attacks the 5’ splice site of the exonl and cuts the 
sugar-phosphate backbone of the RNA at this point. This reaction generates two 
splicing intermediates: the free exon 1 and the lariat-exon 2.
In the second reaction, the ester bond between the 5' phosphorous of exon 2 and the 
3' oxygen (light blue) of the intron is exchanged for an ester bond with the 3' oxygen 
of exon 1, releasing the intron as a lariat structure and joining the two exons. Figure 
adapted from Lodish (Lodish 2000).
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1.1.3 Pre-mRNA Splicing is catalyzed by the Spliceosome.
The pre-mRNA splicing reaction catalysis requires the formation of a highly 
dynamic macromolecular complex called spliceosome composed of several small 
nuclear ribonucleoproteins (snRNPs) and a large number non-snRNP splicing factors 
(Rappsilber, Ryder et al. 2002; Jurica and Moore 2003). Several studies, in a variety 
of systems, have revealed that the essential components of the snRNPs include five 
uridine-rich RNAs that are classified as snRNAs-Ul, U2, U4, U5 and U6. Each 
snRNP consists of a small stable RNA bound by a specific set of proteins, plus 
numerous other less stably associated splicing factors (Will and Luhrmann 2001). In 
addition to the five snRNPs, the spliceosome involves many non-snRNP factors but 
their exact nature and number is not known (Rappsilber, Ryder et al. 2002; Jurica 
and Moore 2003).
Spliceosome formation consists of a precise and ordered assembly/disassembly of 
the different snRNP particles and non-snRNP splicing factors onto the pre-mRNA 
substrate prior splicing catalysis. Several kinds of interactions like RNA-RNA base 
pairing, RNA-protein and protein-protein binding, together with different 
conformational rearrangements are carried out for the production of a mature RNA. 
In mammals, distinct intermediates in spliceosome assembly pathway have been 
detected (Fig. 1.3). The E, A and B complexes contain unspliced pre-mRNA whereas 
the C complex has the products of catalytic step I of the splicing reaction (exon 1 and 
lariat-exon 2). Two complexes, one containing the spliced exons (D complex) and 
the other containing the excised lariat intron (i complex), are the products of catalytic 
step II of the splicing reaction (Reed 2000). Although the earliest assembly step (E 
complex) is energy independent, subsequent spliceosomal steps require NTP 
hydrolysis (Staley and Guthrie 1998).
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The E (early) or commitment complex assembly starts with the recognition of the 
5’ss driven by the U1 snRNP in an ATP-independent manner (Fig.l.3a). This 
interaction is mediated by base pairing of the U1 snRNA with the 5’ss, as well as by 
protein-protein and protein-pre-mRNA interaction involving U1-70K and Ul-C 
proteins (Will, Rumpler et al. 1996). The other important event that occurs during the 
E complex formation is the recognition of the 3’ss. In higher eukaryotes, the AG at 
intron/exon junction together with the adjacent polypyrimydine tract is identified 
through interactions with the dimeric U2 Auxiliary Factor (U2AF). The subunit 
U2AF65 recognizes the polypyrimidine tract (Valcarcel, Gaur et al. 1996) and the 
AG dinucleotide at the 3’ss interacts with the U2AF35 subunit (Wu, Romfo et al. 
1999). The branch point, usually located 20-40 nucleotides (nt) upstream the 3’ss 
within the intron, is recognized by the branch point binding protein (BBP/SF1) 
(Berglund, Chua et al. 1997).
The formation of the A complex is characterized by the recruitment of the U2 snRNP 
that replaces the BBP/SF1 factor to the conserved branch site sequence (Fig. 1.3b). 
This U2-branch site ATP-dependent binding is mediated by U2 snRNA base pairing 
and by U2 snRNP protein-pre-mRNA interactions through SF3b and SF3a subunits 
(Gozani, Feld et al. 1996). However, U2 snRNP was also identified as a component 
of a purified, functional E complex (Hong, Bennett et al. 1997). The U2 snRNP 
seems to bind loosely to the pre-mRNA in the E complex via the integral U2-snRNP- 
associated protein SF3b, and then through an ATP-dependent process leads to stable 
binding to the branch point replacing SF1 (Das, Zhou et al. 2000).
Then the ATP-dependent addition of U4/U6*U5 snRNPs, in which the U4 and U6 
snRNAs are base paired, to the spliceosomal complex characterizes the transition 
from the A to B complex (Fig. 1.3c). However recent studies reported that the tri- 
snRNPs are able to interact with the 5’ss and the upstream 5’ exon at earlier step of
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spliceosome assembly (Maroney, Romfo et al. 2000). Although B complex contains 
all of the snRNPs components required for splicing, it lacks a catalytic center. In 
order to activate the spliceosome, the complex B undergoes marked RNA-RNA 
rearrangements that involve the displacement of U1 snRNP at the 5’ss by U6 snRNP, 
the disruption of the U4/U6 base pairing interaction and the formation of an intricate 
network of interactions among the U6, U2 snRNAs and the pre-mRNA (Fig. 1.3d). 
The U2 and U6 snRNAs are extensively base-paired with one another and with the 
branch site sequence and 5’ss respectively providing a structural basis for 
juxtaposing the branch site and 5’ss for the first catalytic step (Reed 2000; 
Boehringer, Makarov et al. 2004). All these rearrangements contribute to the fidelity 
of 5’ss recognition and support the contact with the branch point generating the 
activated B complex (B* complex) (Turner, Norman et al. 2004). The formation of 
B* complex promotes the first catalytic step of splicing in order to generate the free 
5’ exon and the lariat-3’ exon intermediates. This step is followed by the formation 
of the C complex, in which the second catalytic step of splicing reaction takes place 
(Fig.l.3e). The U5 snRNA, together with the U2 and U6 snRNAs, is involved in 
aligning the exons for the second catalytic step through a highly conserved stem loop 
(O'Keefe, Norman et al. 1996). In addition the presence of a large highly conserved 
component of the U5 snRNP associated protein, the Prp8 factor, seems to stabilise 
these interactions. Prp8 had previously been shown to crosslink to both the 5'ss and 
3'ss, as well as to the exons flanking these two splice sites (Umen and Guthrie 1995). 
In addition, Collins and Guthrie have reported that a specific region of this factor 
affects a tertiary interaction between both the 5’ss and 3’ss and U6 snRNA (Collins 
and Guthrie 1999).
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Figure 1.3: Spliceosome assembly.
The spliceosome assembles onto the pre-mRNA in a stepwise manner.
(a) The E (early) or commitment complex assembly starts with the recognition of the 
5’ss the branch point and 3’ss mediated by the U1 snRNP, BBP/SF1 and U2AF 
factors, respectively, (b) The A complex is then generated by the recruitment of the 
U2 snRNP to the branch point adenosine in an ATP-dependent manner. Inhibitors of 
kinases and helicases can block this step, (c) The U4/U6*U5 tri-snRNP a full 
spliceosome is required for the transition to the complex B. This complex is shown in 
square brackets because the interactions of U4/U6*U5 with specific regions of the 
pre-mRNA are not well defined, (d) Dissociation of U4 and U1 from the later 
complex leads to spliceosome activation, B* complex. This step requires 
dephosphorylation of proteins that can be inhibited by phosphatase inhibitors, (e) 
Rearrangement involving U2, U5 and U6 snRNPs allows the formation of the C 
complex. The final step is characterized by the release of splicing products and 
recycling of snRNPs. Figure adapted from Tazi, Durand et al. (Tazi, Durand et al. 
2005).
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It is still debatable whether RNA, proteins or both, ultimately catalyzes splicing. 
Although a large number of proteins are known to be part of spliceosome, there is 
now growing evidence that the catalytic component of the spliceosome may be RNA 
based (Valadkhan and Manley 2001; Valadkhan, Mohammadi et al. 2007). Firstly, in 
vitro-transcribed U2 and U6 RNA fragments in the absence of any protein 
components are able to form intermolecular base pairing, similar to those obtained in 
the spliceosome. Secondly, the addition of a small branch-site like RNA 
oligonucleotides to this U2/U6 RNA complex was able to trigger, in the complete 
absence of proteins, a nucleophilic attack of the branchpoint adenosine on a distinct 
nucleotide within U6. The final product is a lariat-like structure between U6 and the 
branchpoint oligonucleotides (Valadkhan and Manley 2001; Valadkhan, 
Mohammadi et al. 2007). Nevertheless, in vivo, protein components of the 
spliceosome play an essential role in the assembly and stabilization of a catalytically 
active spliceosome.
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1.2 Recognition of the exon: the cis-acting elements.
Exon recognition is principally achieved through the splice site, small consensus 
sequences located at the intron/exon junctions (Fig. 1.4). The canonical consensus 
sequence called 5’splice site marks the exon/intron junction at the 5’ end of the 
intron. In mammals only the first two nucleotides GU of the intron are conserved 
although they are not the only important bases (Aebi, Homig et al. 1987). At the 
other intron/exon boundary there is the 3’splice site region that comprises three 
conserved elements: the branch point, the polypyrimidine tract and the conserved AG 
dinucleotide at the extreme 3’ end of the intron (Shapiro and Senapathy 1987).
The definition of splice site sequence as strong or weak depends on the higher or 
lower level of similarity to the standard consensus sequences that characterize the 
exon/intron boundaries. Over the last years, several computational methodologies 
have been developed to predict the position of 5’ss and 3’ss and the strength of the 
identified motif. These methods are based on nucleotide frequencies matrices, neural 
networks and interdependencies between nucleotides at different positions of the 
consensus sequences (Shapiro and Senapathy 1987).
It is important to notice that the sequences that match the 5’ss and 3’ss are very 
common within intron sequences and sometimes even stronger than the real splice 
sites. These intronic splice sites normally define pseudo-exons that are not included 
in mature mRNAs (Sun and Chasin 2000). The fact that the splicing machinery is 
able to recognize the correct splice sites, even if they are weak, distant from each 
other and surrounded by several pseudo 5’ss and 3’ss, means that these consensus 
elements are by no means sufficient to define exon-intron junctions. In fact, the 
accurate recognition of splice sites in vivo is the result of a combinatorial regulatory 
mechanism that comprises additional cis-acting regulatory elements (Fig. 1.5).
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Figure 1.4: Schematic representation of exon-intron boundaries.
The two exons are represented by the red and pink boxes respectively. Between them 
are reported the consensus sequences present within an intron. The arrows indicate 
the position of the 5’ (GU) and 3’ (AG) splice site and the branch point (A). The 
polypyrimidine tract, rich in pyrimidines, is highlighted by a blue rectangle. There 
are several conserved nucleotides near the sequences surrounding the intron-exon 
junctions that act as essential splicing signals. The frequency of each nucleotide in an 
alignment of conserved sequences from 1,683 human introns is indicated below. N 
means any base. To note only the universally conserved nucleotides are the 
dinucleotide cores of the 5’ and 3’ splice together with the branch point (A) showed 
100% of frecquency of occurrence. Figure adapted from Lodish (Lodish 2000).
1.2.1 The 5’ splice site (5’ss).
The 5’ss motif in higher eukaryotes consists of nine partially conserved nucleotides, 
MAG/GURAGU (M indicates A or C, R indicates purines and the slash the exon- 
intron boundary) at the exon-intron junction, spanning from position -3 to +6 (Fig. 
1.4). The underlined GU dinucleotide is universally conserved and mutating one of 
these two nucleotides completely abolishes splicing (Langford, Klinz et al. 1984). 
Recognition of the 5’ss involves a nearly perfect Watson-Crick base pairing with the 
U1 snRNA (Horowitz and Krainer 1994) and guides the early assembly of the 
spliceosome machinery upon the intron. There are strong evidences for the critical 
contribution of the base pairing between 5’ consensus motif and U1 snRNA to 
selection of the 5’ss (Zhuang and Weiner 1986; Seraphin, Kretzner et al. 1988;
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Siliciano and Guthrie 1988). Studies of alternative splicing have shown that 
mutations that improve the match of weak splice sites to the consensus can lead to 
the constitutive recognition of alternatively skipped exon (Huh and Hynes 1993; 
Muro, Iaconcig et al. 1998).
1.2.2 The 3 ’ splice site (3 ’ss).
The intronic element that identifies the 3’ss usually appears several thousand bases 
downstream of the 5’ss. The 3’ border of the intron is defined by three different 
conserved elements (Fig. 1.4): the branch point, the polypyrimidine tract and the 
terminal AG dinucleotide (Reed 1989). Together these elements make up a loosely 
defined 3’ss region, which may be extend up to 100 nt along the intron.
The branch site: The branch point in human introns is highly degenerated, and the 
general consensus sequence, apart from the universally conserved “A”, is defined by 
the YNYURAC motif (R-purine,Y-pyrimidine). Most branch points have been 
mapped within 18-40 nt of the 3’ss (Reed and Maniatis 1988). However, in the case 
of rat a-tropomyosin gene intron 2, the branch point is located 172 nt upstream from 
the 3’ss and nevertheless is essential for the regulation of alternative splicing (Smith 
and Nadal-Ginard 1989). During the early spliceosome assembly, the SF1 factor 
recognises the branch site. Although the sequence specificity of SF1 is low, it can 
discriminate between sequences with general consensus branch site and sequences 
missing the highly conserved adenosine (Berglund, Chua et al. 1997). Subsequently 
the recognition of the branch site involves a base pairing with the U2 snRNA, in 
order to form the spliceosome A complex.
The polvpvrimidine tract: The polypyrimidine track is a run of pyrimidines (eight 
bases in the average intron), located between the branch site and the terminal AG at
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the intron/exon junction. This sequence is more pronounced in mammals than in 
yeast, where the nucleotides composition and the length can vary significantly. The 
65-kDa subunit of U2AF binds the polypyrimidine tract during the formation of the 
early spliceosome complex (Zamore, Patton et al. 1992; Kielkopf, Lucke et al. 2004). 
Due to its position, the polypyrimidine tract is able to affect the recognition of the 
branch point sequences (Reed 1989). It has been shown that progressive deletion of 
the polypyrimidine tract abolishes spliceosome assembly and lariat formation while 
elongating its length can improve the splicing efficiency (Roscigno, Weiner et al. 
1993).
The canonical sequence that characterizes the polypyrimidine tract is composed by a 
poly-uridine tract, whereas, a poly-cytidine tract is not functional (Roscigno, Weiner 
et al. 1993). The proximity of the polypyrimidine tract to the 3’ss is important when 
the pyrimidine length is limiting. Shortening the number of continuous uridines 
implies the localization of these uridines immediately adjacent to the 3’ss AG. Vice 
versa, a polypyrimidine tract containing high number of uridines is a competitive 
pyrimidine stretch regardless of the distance between the branch point and 
polypyrimidine tract itself (Coolidge, Seely et al. 1997). A functional polypyrimidine 
tract does not absolutely require continuous uridines. In constitutively included exon 
3 of the human Apolipoprotein-AII (Apo All) the “polypyrimidine tract” is 
composed of a (GT)i6 dinucleotide repeats (Shelley, Sharpe et al. 1985).
The terminal AG dinucleotide: The terminal AG dinucleotide defines the 3’ border of 
the intron, just downstream the polypyrimidine. This site is characterised by the short 
YAG/G sequence (Y denotes pyrimidines; the slash indicates the intron-exon 
boundary and the underlined nucleotides are conserved). Even if it is essential for the 
second step of splicing catalyses, no base-pairing interactions with snRNAs are
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involved in recognizing this sequence. During the early step of spliceosome 
assembly is recognised by the U2AF35 subunit (Wu, Romfo et al. 1999).
1.2.3 Minor introns class.
Metazoan genes have been found to contain a rare class of introns that carry highly 
conserved splice sites that differ from the canonical consensus sequences and are 
excised by distinct spliceosome (Hall and Padgett 1994). This minor class of introns 
seems to be most prevalent in human and vertebrates, representing 0.15%-0.34% of 
all introns (Burge, Padgett et al. 1998). Because these new introns have an AT and 
AC ends, which deviates from the nearly invariant GT-AG, they are termed AT-AC 
introns. However, more extensive genomic database searches revealed that AT-AC 
termini are not the only defining feature of minor-class introns. In fact, most minor- 
class introns carry the canonical GT-AG ends, and, very rarely, major-class introns 
have AT-AC termini (Sharp and Burge 1997). Several studies showed that a minor 
intron is characterized by a longer and more tightly constrained consensus sequence 
at the 5’ss and at the branch site, as well as by the lack of a polypyrimidine tract 
upstream of the 3’ss (Sharp and Burge 1997; Burge, Padgett et al. 1998).
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1.3 Additional cis-acting elements.
In order to generate a correct and mature mRNAs, the exons have to be precisely 
identified among the intronic sequences by the spliceosome. Paradoxically the 
mammalian junctions that define an exon are weakly conserved and more degenerate 
with respect to yeast canonical cis-elements. These elements are necessary but are by 
no means sufficient to define exon/intron junctions. Early experiments in 1987 have 
shown that internal exonic sequences far from the 5’ and 3’ss were essential for exon 
recognition (Mardon, Sebastio et al. 1987). Thus, in addition to the conventional 
splicing signals located at exon-intron boundaries, other cis-elements in pre-mRNA 
that regulate splicing have been extensively characterized (Cartegni, Chew et al. 
2002). These elements localized both in exon and intron sequences, act by 
stimulating or inhibiting the use of specific splice sites (Fig. 1.5). Depending on their 
location and their function, these elements are referred as exonic splicing enhancers 
(ESE) and silencers (ESS) or intronic splicing enhancers (ISE) or silencers (ISS) 
(Cartegni, Chew et al. 2002). Several studies have revealed a non random 
distribution of these splicing regulatory sequences. There is a higher density of 
enhancers in real exons than in pseudoexons and introns, and vice versa for the 
silencers sequences (Sironi, Menozzi et al. 2004; Zhang and Chasin 2004). Although 
these additional elements are often conserved between species, highly degenerate 
sequence motifs characterized these elements, making difficult their identification. It 
has to be noticed that a cis-acting element can have overlapping functions as reported 
for the cystic fibrosis transmembrane conductance regulator gene (CFTR) exons 9 
and 12 (Pagani, Buratti et al. 2003; Pagani, Stuani et al. 2003). In this case, it may be 
more appropriate to talk about composite exonic regulatory elements of splicing 
(CERES).
31
Several features such as nearby sequence composition, the intronic/exonic position 
(Wang and Burge 2008) and the secondary structure can deeply influence the nature 
of these elements (Buratti and Baralle 2004). For instance, a cis-acting element could 
be strictly connected with its context location and when moved in a heterologous 
context the element fails to regulate splicing. In other cases the location of a 
regulatory element relative to the pre-mRNA deeply influences the nature of the 
element itself (Wang and Burge 2008). For example, G triplets, through the hnRNP 
H (heterogenous nuclear ribonucleoprotein H) binding, commonly enhance splicing 
when located downstream of the 5’ss within intron sequence (McCullough and 
Berget 1997; Chou, Rooke et al. 1999; Caputi and Zahler 2001) but they behave as 
splicing silencers when located in exons (Chen, Kobayashi et al. 1999; Caputi and 
Zahler 2001). Splicing elements can operate in an additive way, since the presence of 
several copies increase the effect on splicing regulation, either improving the affinity 
of the associated factor (Dominguez and Allain 2006) or increasing the copy 
numbers of the recruited factor (Wang, Rolish et al. 2004). Different regulatory 
elements can also act in a cooperative fashion. The exonic UAGG motif and intronic 
GGGG motif overlapping the 5’ss can function cooperatively in the silencing of the 
brain-specific Cl cassette exon of the glutamate NMDA R1 receptor gene (Han, Yeo 
et al. 2005). All these different types of auxiliary cis-acting elements contribute 
significantly to recognition of the correct exons and in addition to their known role in 
alternative splicing, contribute significantly to the regulation of constitutive splicing 
(Cartegni, Chew et al. 2002; Black 2003).
32
Intron
SR proteins
Exon Intron
y n y u r a y j j  y Y y y y y y n a g <
siteVBranch site1 3 '-splice sit
hnRNPs
AG g t r a g
Regulatory
complexoa
ESS 5'-splice site
Figure 1.5: Regulatory elements in pre-mRNA splicing
Schematic representation of the possible distribution of canonical and additional 
splicing cis-acting elements. The canonical splicing signals that define the exon 
boundaries are relatively short and poorly conserved sequences. Only the GU at 5’ 
end and the AG at 3’ end together with the the branch-point adenosine are conserved 
(the consensus nucleotides are highlighted in red).
The polypyrimidine tract of variable length (represented by “y”, cytosine or thymine) 
is reported upstream of the 3'-splice site. The basal components of the splicing 
machinery bind to the consensus sequences and promote assembly of the splicing 
complex. The U1 snRNP binds to the 5'-splice site, the U2 snRNP recognizes the 
branch site and the U2AF localizes to polypirimide tract and 3’splice site sequences. 
Additional enhancer and silencer elements in the exons (ESE; ESS) and/or introns 
(ISE; ISS) allow the correct splice sites to be distinguished from the many cryptic 
splice sites that have identical signal sequences.
Trans-acting splicing factors can interact with enhancers and silencers and can 
accordingly be divided into two main groups: members of the serine arginine (SR) 
family of proteins and of the heterogeneous nuclear ribonucleoprotein particles 
(hnRNPs). In general, SR protein binding at ESE facilitates exon recognition 
whereas hnRNPs are inhibitory. Figure adapted from Pagani and Baralle (Pagani and 
Baralle 2004).
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1.3.1 Splicing enhancers.
Exonic splicing enhancers (ESEs) were identified and extensively studied as 
regulators of alternative splicing (Black 2003) but they have also been implicated in 
some constitutive splicing event (Lavigueur, La Branche et al. 1993; Schaal and 
Maniatis 1999). Enhancer sequences have been the subject of many studies and most, 
but not all, are know to be recognized by members of the serine-arginine-rich protein 
family (SR) (Fig. 1.5) (Graveley 2000). ESEs, throughout SR proteins binding 
(Fig. 1.6), drive the exon definition by recruiting splicing factors and/or by 
antagonizing the action of nearby splicing silencer elements (Cartegni, Chew et al. 
2002).
Diverse array of sequences can function as enhancers: most of them contain extended 
purine-rich sequences (more than 65% purine rich), but a second class of sequences 
lacking stretches of purines was also described (Tian and Kole 1995). In fact, studies 
conducted by Schaal and Maniatis identified pyrimidine-rich enhancers that are more 
than 67% pyrimidine-rich and function such as strong enhancers (Schaal and 
Maniatis 1999). Several groups, through the functional systematic evolution of 
ligands by exponential enrichment (SELEX) identified other functional ESE 
sequences. The SELEX carried out both in vivo (Coulter, Landree et al. 1997) and in 
vitro (Tian and Kole 1995; Schaal and Maniatis 1999; Boukis and Bruzik 2001), 
allowed the discovery of several both purine- and non-purine-rich enhancer. 
Furthermore this method was utilized to identify sequences that can act as ESEs in 
response to specific SR proteins characterizing SR-protein-specific sequence motifs 
(Liu, Zhang et al. 1998; Liu, Chew et al. 2000). These ESE motifs identified contain 
short (6-8nt), degenerate and sometimes partially overlapping sequences. The 
frequencies of individual nucleotides at each position were used to derive score
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matrices in order to predict the location of SR protein-specific putative ESEs (Liu, 
Zhang et al. 1998; Liu, Chew et al. 2000) and design an ESEfinder web-based 
program (http://rulai.cshl.edu/tools/ESE/) (Cartegni, Wang et al. 2003).
In order to identify enhancer sequences some ab initio computational approaches 
have also been developed. For instance, the RESCUE-ESE (Relative Enhancer and 
Silencer Classification by Unanimous Enrichment) identifies putative ESE motifs by 
selecting hexamers that are enriched in exons against introns and weak against strong 
splice site scores (Fairbrother, Yeh et al. 2002; Fairbrother, Yeo et al. 2004). 
Similarly, the PESX approach (Putative Exonic Splicing Enhancers/Silencers) allows 
the identification of putative exonic splicing regulatory elements by comparing over­
represented octamers in internal non-coding exons versus unspliced pseudo exons 
and the 5’ untranslated regions of intronless genes. Oligonucleotides that are 
sufficiently overrepresented in noncoding exons are selected as PESE elements 
(Zhang and Chasin 2004; Zhang, Kangsamaksin et al. 2005).
A typical example of an exon bearing an exonic splicing enhancer (ESE) is the 
fibronectin EDA exon. Using a minigene transfection approach it was determined 
that the central part of the EDA exon is required for its inclusion into mRNA 
(Mardon, Sebastio et al. 1987). Then, Lavigueur et al. mapped the element required 
for EDA exon inclusion to a 9 nt purine-rich motif (5’-GAAGAAGAC-3’) 
(Lavigueur, La Branche et al. 1993). Another group identified the same purine-rich 
sequence as a positive cis-acting element through transfection experiments (Caputi, 
Casari et al. 1994). In addition the ESE within the EDA exon has been found to 
interact with splicing factors belonging to a family of SR proteins (Lavigueur, La 
Branche et al. 1993).
A great number of intronic enhancers have been also characterized (Zheng 2004), but 
fewer large-scale screenings have been performed for these elements, compared with
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the exonic ones. Most of the intronic enhancer regions have been identified by the 
study of disease-causing point mutations. Several of these mutations have been 
described to occur in the +20 to +40 regions downstream of the 3’ss causing the 
exclusion .of the neighbouring exon from the mRNA. These sequences could be 
necessary in constitutive exon recognition or be involved in specific tissues or 
developmental stages (Venables 2007). A well studied ISE is the G run motif, which 
often occurs in clusters and acts by enhancing adjacent 5’ss or 3’ss (McCullough 
and Berget 1997) and the intronic CA repeats which in several cases can enhance 
splicing of upstream exons (Hui, Hung et al. 2005).
1.3.2 Splicing silencer.
In addition to cis-acting elements able to promote exon inclusion, other sequences 
able to inhibit splicing, exonic or intronic silencers, have been described. About one 
third of randomly selected human genomic DNA fragments (-100 bases long) were 
found to have inhibitory activity in vivo, when inserted within the middle exon 
sequence of the three-exon minigene (Fairbrother and Chasin 2000). These data 
suggested that silencer elements are very frequent, even though only limited number 
has been characterized by mutational analysis (Zheng 2004). Most described 
silencers are intronic elements, but several exonic silencer have been also reported 
(Pozzoli and Sironi 2005).
A typical silencer motif is still less characterized: the sequence can be purine or 
pyrimidine-rich and binds a diverse array of splicing factors (Fairbrother and Chasin
2000). Silencer sequences are generally interacting with the heterogeneous nuclear 
ribonucleoprotein (hnRNP) family (Fig. 1.5) (Cartegni, Chew et al. 2002).
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A silencer sequence can regulate splicing in different ways: by antagonizing the 
function of a nearby ESE or by recruiting factors that interfere with the splicing 
machinery by direct binding, throughout exon looping or by nucleation and 
cooperative binding (Cartegni, Chew et al. 2002; Matlin, Clark et al. 2005). Previous 
studies based on exon repression mechanism have shown that inhibition typically 
occurs during the initial ATP-independent recognition of splice sites. However, the 
dynamic nature of the splicing machinery suggests that any of the intermediates 
along the spliceosome assembly pathway are potential targets for biologically 
relevant regulation (House and Lynch 2006).
Most of inhibitory sequences have been identified through the study of single or a 
few regulated splicing events and the use of biochemical and cell transfection 
experiments (Pozzoli and Sironi 2005). Conversely, recent works have provided lists 
of putative silencers and methods that allowed a systematic identification of these 
splicing repressors. An in vivo fluorescence-based method was developed to 
systematically identify ESSs (Wang, Rolish et al. 2004). To this end, a three exon 
minigene system was used in which the first and the last exons encoded the complete 
green fluorescent protein (GFP) and a library of random decanucleotides was 
inserted in the central exon. The cells positive for GFP signals were selected and the 
putative silencer sequence were characterised (Wang, Rolish et al. 2004; Wang, Xiao 
et al. 2006). Zhang and colleagues proposed a computational approach for screening 
ESSs. The PESS (putative exonic splicing silencers) were identified in 
oligonucleotides underrepresented in noncoding exons (Zhang and Chasin 2004; 
Zhang, Kangsamaksin et al. 2005). The silencer elements identified by wide 
approaches do not relate to any specific exons/mRNA and have been only in part 
validated experimentally. These sequences might provide a useful resource to
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compare putative silencers that will be identified in specific studies on splicing 
regulation (Pozzoli and Sironi 2005).
Several studies, by investigating the complex HIV-1 RNA alternative splicing, 
discovered the presence of exonic inhibitory elements within the tat coding exons. 
The first splicing silencer element identified in exon 2 specifically inhibits splicing at 
the upstream 3’ss flanking this exon (Amendt, Hesslein et al. 1994). By sequence 
analogy with this ESS element in tat exon 2 another negative cis-acting region within 
tat-rev exon 3 has been identified (Amendt, Si et al. 1995).
Similar inhibitory elements within introns, intronic splicing silencers (ISSs), have 
been less systematically studied. Many ISSs have been identified through the study 
of individual alternatively spliced genes (Zheng 2004). A well-known ISS is the 
binding sites for the polypyrimidine tract binding protein (PTB) splicing factors 
(Zheng 2004; Matlin, Clark et al. 2005). PTB normally recognizes pyrimidine-rich 
elements within introns and can function either by antagonizing U2AF65 action or 
by creating a region of silencing across the down regulated exon (Wagner and 
Garcia-Bianco 2001; Sauliere, Sureau et al. 2006). A particular example of intronic 
splicing silencer was described for CFTR exon 9 alternative splicing in which this 
extended region in intron 9 acts like a silencer by recruiting SR proteins (Pagani, 
Buratti et al. 2000).
1.3.3 RNA secondary structure.
The natural tendency of RNAs to fold in highly stable secondary and tertiary 
structures was shown to play an important role in exon definition for particular 
transcripts (Buratti and Baralle 2004). Numerous studies regarding the ability of 
RNA secondary structures to affect the splicing process focused on the conserved
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regions at the exon boundaries (5’ss, 3’ss, and branch site). Although in each case 
different peculiarities are involved, structural elements can hind or permit the 
accessibility of a particular sequence by the splicing factors only to the acceptor site, 
to the donor site, or both. In the particular case of human tau exon 10 a stem-loop 
structure at the 5’ss directly affects the activity of the 5’ss (Grover, Houlden et al. 
1999; Varani, Hasegawa et al. 1999). The stabilization of the secondary structure 
decreases exon inclusion whereas the destabilization of this stem-loop increases 
exon 10 inclusion (Donahue, Muratore et al. 2006). The RNA secondary structure 
can also affect the relative distance between splicing elements determining a 
considerable variation in the splice site usage (Buratti and Baralle 2004).
In addition to splicing consensus sequences, the secondary structure can affect cis- 
acting sequences such as exonic/intronic splicing enhancers (ESE/ ISE) or silencer 
(ESS/ISS). For example, in the fibronectin EDA splicing the secondary structure has 
been shown to play an important role in determining the splicing efficiency (Muro, 
Caputi et al. 1999). In this case, the peculiar secondary structure of the EDA exon 
exposes an ESE element, binding site for ASF/SF2, in a part of a loop region. The 
nearby ESS sequence seems to be determinant for stabilising the secondary structure 
of the RNA in such a way as to allow binding of SR proteins (Muro, Caputi et al. 
1999).
Similarly, for the Survival of Motor Neuron 1 and 2 (SMN1 and 2) genes, Miyaso 
and colleagues have identified an ISE element consisting of a conserved stem loop 
structure in intron 7 (Miyaso, Okumura et al. 2003). Disruption of this structure leads 
to loss of binding of a yet unidentified trans-acting factor affecting the splicing 
process. An in silico analysis has shown that this ISE seems to be present in several 
intron sequences, raising the possibility that this structurally defined regulatory 
element may play a more general role in the splicing process (Miyaso, Okumura et
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al. 2003). Other secondary structures have been described to participate to SMN2 
exon 7 regulation such as a stem-loop element near its 3’ss region (Singh, Androphy 
et al. 2004) and a structure named terminal stem-loop 2 (TSL2) associated with the 
weak 5’ ss (Singh, Singh et al. 2007).
These emerging studies on RNA structure propose the idea that many pre-mRNA 
sequences are capable of folding in well-defined secondary structures in vivo, which 
in turn affect the splicing process (Buratti, Baralle et al. 2006). A recent analysis in 
fact suggested that enhancer and silencer motifs are significantly enriched in single­
stranded regions of pre-mRNA (Hiller, Zhang et al. 2007), implying that pre-mRNA 
secondary structure may play a general role in determining cis-acting element 
function.
1.4 Protein components: trans-acting factors.
Protein components involved in splicing can belong to the small nuclear 
ribonucleoprotein particles (snRNPs) or to the non-snRNP splicing factors (Fig. 1.5). 
Most of these proteins share very similar structural characteristics such as different 
number of RNA binding motifs and/or protein binding domains. These proteins 
usually target short sequence elements adjacent to sites of regulation.
The snRNP are the main components of the catalytic macromolecular complex called 
the spliceosome. The non-snRNP RNA binding proteins can be widely expressed or 
have a restricted expression patterns being involved in general or tissue-specific 
splicing events respectively (David and Manley 2008). Two families of RNA binding 
proteins, the SR proteins and the hnRNP factors, have been described as main 
components of distinct regulatory complexes with functional specificity in the 
splicing process (David and Manley 2008). However, additional tissue-specific 
factors have been described as playing a role in regulating particular splicing events
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like Nova-1/2 (Jensen, Dredge et al. 2000), nPTB (Markovtsov, Nikolic et al. 2000) 
in brain and CELF proteins in striated muscle and brain (Ladd, Charlet et al. 2001).
1.4.1 Small Nuclear Ribonucleoprotein Particles (snRNPs).
The spliceosomal small nuclear ribonucleoprotein particles (snRNP) form part of the 
catalytic macromolecular complex called the spliceosome. The functional 
components of the spliceosome are the snRNPs U l, U2, U4, U5 and U6, responsible 
for splicing the vast majority of pre-mRNA introns (U2-type introns) (Patel and 
Steitz 2003). A group of less abundant snRNPs, U ll, U12, U4atac and U6atac, but 
functionally analogous to the U l, U2, U4 and U6 snRNPs, are components of the so- 
called minor spliceosome and responsible for the excision of a rare class of introns, 
named U 12-type (Hall and Padgett 1996). The U5 snRNP is shared by both 
spliceosomes (Patel and Steitz 2003).
Each snRNP particle consists of a snRNA molecule complexed with a set of eight 
Sm or Sm-like proteins and several specific factors (Will and Liihrmann 2001). The 
snRNAs U l, U2, U4, U5 and U6 are characterized by their small size, metabolic 
stability and a high degree of sequence conservation (Kambach, Walke et al. 1999). 
The snRNAs U l, U2 and U6 to a minor extent have shown great complementarities 
to the splicing consensus sequences. The U l snRNP initiates spliceosome assembly 
by binding to the 5’ss through base pairs between the single-stranded 5’terminal 
sequence of the U l RNA and a conserved stretch of six nucleotides at the 5’ss. 
However, this interaction is switched subsequently for a mutually exclusive base 
pairing interaction with U6 snRNA. Before the 5’ss recognition, the U6 snRNA is 
extensively base paired (amounting to >20 base pairs) with U4 snRNA forming a 
unique U4/U6 particle. The U5 snRNA is then assembled in an ATP dependent
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reaction with the U4/U6 snRNPs giving the U4/U6*U5 three-snRNPs particle 
(Konarska and Sharp 1987). This triple snRNP is believed to escort U6 to the 
spliceosome through its binding to U4 (Staley and Guthrie 1998). The U2 snRNA is 
involved in the branch point recognition, binding to the consensus CUPuAPy 
through a highly conserved stretch presents in its snRNA during the complex A 
formation (Staley and Guthrie 1998). The U5 snRNA has been reported to contain a 
conserved secondary structure and an essential loop involved in directly contacting 
exons sequences at the 5’ss and 3’ss (Turner, Norman et al. 2004).
All the snRNAs are transcribed by RNA polymerase II while U6, and presumably 
U6atac snRNA, are transcribed by the RNA polymerase III (Will and Luhrmann
2001). The assembly of the U6 snRNP probably takes place entirely in the nucleus 
while the other pre-snRNAs are transported to the cytoplasm where snRNP assembly 
is initiated (Fischer, Sumpter et al. 1993). The pre-snRNAs export is dependent on a 
number of factors, including the m7G cap, the cap-binding complex (CBC), the 
export receptor CRMl/Xpol and RanGTP (Will and Luhrmann 2001).
Following their export to the cytoplasm, the snRNA precursors bind with seven Sm 
proteins B’, B, D l, D2, D3, E, F and G in order to form the structural core of 
snRNPs. The Sm proteins form three distinct heteromeric complexes prior to their 
interaction with the highly conserved Sm site of the U l, U2, U4 and U5 snRNAs 
(Raker, Plessel et al. 1996). After the formation of the Sm core, the 7-methyl 
guanosine (m7G) cap of these snRNAs is hypermethylated. Properly assembled Sm 
core, cap methylation and 3’end processing of the snRNAs are required for the 
subsequent nuclear import (Fischer, Sumpter et al. 1993).
The U6 snRNP composition differs from the other particles and contains a set of Sm- 
like (Lsm) proteins. The Sm-like proteins that belong to the Sm protein family are 
specifically required for the assembly of U6 snRNA. This subclass of Sm-like
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proteins shares the conserved structural motif characteristic of all Sm-proteins family 
members (Mayes, Verdone et al. 1999).
Besides Sm and Sm-like proteins, other particle-specific proteins associate with 
snRNAs. For instance the mammalian U l snRNP consists of ten different proteins, 
seven common Sm proteins, and other three (U1-70K, Ul-A and Ul-C) specific for 
U l (Stark, Dube et al. 2001). U1-70K and Ul-A proteins bind directly to the RNA 
and are involved in the splice site recognition and selection, while Ul-C associates 
via protein-protein interactions with U1-70K and other Sm proteins (Nelissen, Will 
et al. 1994). A subset of U2 snRNP proteins also plays a critical role in tethering the 
U2 snRNP to the pre-mRNA. These proteins include the heteromeric splicing factors 
SF3a and SF3b (Brosi, Hauri et al. 1993) and bind the 20 nt region just upstream of 
the branch site in a sequence-independent manner (Gozani, Feld et al. 1996). At least 
five different proteins have been described as associating with U4/U6 snRNP, 
including a 15.5 KDa protein, polypeptides of 20, 60 and 90 KDa that form complex 
with one another (Teigelkamp, Achsel et al. 1998). U5 snRNP particle presents also 
a complex protein composition. Of the six U5 snRNP-specific proteins three are 
NTPases, U5 220 KDa and Brr2p are members of the DEXD/H box family, whereas 
Snull4p is a GTPase connected to translation elongation factor EF-2. Among these 
proteins it has been suggested that the U5 220 KDa factor acts as a protein cofactor 
for RNA-based catalysis in the spliceosome (Turner, Norman et al. 2004).
1.4.2 U2 snRNP auxiliary factor (U2AF).
U2 snRNP auxiliary factor (U2AF) is an essential pre-mRNA splicing factor 
complex that comprises two subunits of 65-kDa (U2AF65) and of 35-kDa 
(U2AF35). The U2AF commits the pre-mRNA to the first ATP-dependent step
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(complex A) of the splicing process by binding the 3’ss and stabilizing the U2 
snRNP association to the branch point (Kielkopf, Lucke et al. 2004).
The U2AF65 subunit specifically recognizes the polypyrimidine tract via its C- 
terminal RNA-binding domain, which consists of two canonical RNA recognition 
motifs (RRMs) and one U2AF homology motif (UHM) (Zamore, Patton et al. 1992; 
Kielkopf, Lucke et al. 2004). U2AF65 also stabilizes the U2 snRNP binding to the 
branch site through its N-terminal arginine- and serine-rich (RS) domain and 
promoting the base pairing (Valcarcel, Gaur et al. 1996). The U2AF35 binding 
domain of U2AF65 is located in the proline-rich region between the RS motif and 
RNA-binding motifs (Kielkopf, Rodionova et al. 2001).
The small subunit U2AF35 is involved the recognition of the essential AG 
dinucleotide at 3’ss during the earliest stage of spliceosome assembly (Merendino, 
Guth et al. 1999; Wu, Romfo et al. 1999). U2AF35 is made of a central UHM motif 
flanked by two zinc fingers in the N-terminal region (Bimey, Kumar et al. 1993; 
Kielkopf, Lucke et al. 2004) while the C-terminus contains an RS domain and a 
glycine tract. U2AF35 binds both U2AF65 and the pre-mRNA through its RRM 
domain (Zhang, Zamore et al. 1992; Kellenberger, Stier et al. 2002).
Both U2AF subunits bind to intronic sequences only during the early steps of 
spliceosome assembly and subsequently are replaced by the U5 snRNP during the 
formation of the B complex (Wu, Romfo et al. 1999; Turner, Norman et al. 2004). In 
addition to constitutive splicing, several studies support the involvement of U2AF in 
the regulation of alternative spliced exons. In some cases, the SR proteins bound to a 
splicing enhancer together with U2AF35, are involved in recruiting U2AF65 to weak 
pyrimidine tracts (Graveley, Hertel et al. 2001). Although substantial evidence 
describes an important role for U2AF35 in enhancer dependent splicing, other 
experiments are inconsistent with this model (Graveley, Hertel et al. 2001). Recent
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experiments have demonstrated that the small U2AF subunit is necessary for 
efficient enhancer-dependent splicing but its RS domain is not required for this 
function (Shepard, Reick et al. 2002).
1.4.3 Serine Arginine rich proteins (SRs).
SR proteins are a family of structurally related RNA binding proteins, highly 
conserved in metazoan cells that play multiple roles in splicing and in general mRNA 
metabolism (Graveley 2000; Huang and Steitz 2005). They contain one or two N- 
terminal RNA-recognition motifs (RRM) and a specific C-terminal domain rich in 
repeating arginines and serines, the “RS” domain (Bimey, Kumar et al. 1993). The 
RNA binding and the RS domains are modular structures and they can be exchanged 
between different SR proteins. Differences among SR proteins structure depend on 
the length of the RS domain and the second RRM domain; when it is present, the 
sequence is often divergent from the canonical consensus sequence (Graveley 2000). 
In addition to SR proteins other factors involved in pre-mRNA metabolism can 
contain a RS domain. These proteins are usually referred as SR-related proteins and 
they include both subunits of U2AF, the U1-70K protein and several ATPases 
(Boucher, Ouzounis et al. 2001).
The structural organization of SR proteins suggests a model for their function. The 
RRM mediates sequence-specific binding to the mRNA, whereas the RS domain 
seems to be involved mainly in protein-protein interactions (Graveley 2000; 
Cartegni, Chew et al. 2002). However, a recent work has reported that the RS 
domains can also be involved in direct RNA contacts during splicing. A specific 
interaction between the RS domain and the branch point was described as promoting 
spliceosome formation (Shen and Green 2004).
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The sequence-specific binding to pre-mRNAs is crucial for the function of SR 
proteins in the earliest step of spliceosome assembly (Graveley 2000; Sanford, Ellis 
et al. 2005). The binding specificity of individual SR protein has been studied using 
the SELEX technique showing that the consensus sequences recognized are highly 
degenerated (Liu, Zhang et al. 1998; Liu, Chew et al. 2000). Other SR proteins, 
indicating a redundancy in their functions, can also bind a target sequence recognized 
by one SR protein. In agreement with this observation, RNAi depletion of most SR 
proteins in C. elegans resulted in no detectable phenotype, suggesting a functional 
overlap among these factors (Longman, Johnstone et al. 2000). However, the 
lethality caused by loss of a SR protein in Drosophila (Ring and Lis 1994) or in the 
chicken DT40 cell line (Wang, Takagaki et al. 1996) argue against a large 
redundancy of SR proteins. Similarly deletion of SRp20, ASF/SF2 and SC35in the 
germ line of mice led to embryonic lethality indicating an essential role of this 
factors in the early embryonic development (Jumaa, Wei et al. 1999; Wang, Xu et al. 
2001; Xu, Yang et al. 2005).
The SR proteins are required both for constitutive and alternative splicing events 
(Sanford, Ellis et al. 2005). Two non-exclusive models have been proposed to 
explain the role of SR protein in pre-mRNA splicing (Fig. 1.6). One model is based 
on the ability of these splicing factors to bind exonic splicing enhancers (ESEs) and 
through their RS domain to recruit and stabilize U l snRNP and U2AF binding to the 
5’ and 3’ss respectively. SR proteins have also been suggested to allow protein- 
protein interactions across introns binding the U1-70K factor and the U2AF35 and 
stimulating the usage of the 5’ and 3’ss (Fig.l.6a) (Cartegni, Chew et al. 2002; 
Sanford, Ellis et al. 2005). In addition SR proteins have also been described in the 
recruitment of the U4/U6 U5 tri-snRNP to the spliceosome during the formation of 
the B complex (Roscigno and Garcia-Bianco 1995). The second model proposes that
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a SR protein, bound to an ESE, can antagonize the negative effect of a juxtaposed 
silencer element (Fig. 1.6b) (Cartegni, Chew et al. 2002; Sanford, Ellis et al. 2005). 
Due to their involvement in splice site selection, specifically in promoting the 
selection of the proximal 5’ (Mayeda and Krainer 1992; Caceres, Stamm et al. 1994) 
and 3’ss (Caceres, Stamm et al. 1994; Bai, Lee et al. 1999), SR proteins have been 
reported to be important players in regulating alternative splicing. They exert a role 
in promoting U2AF binding to weak 3’ss (Wu and Maniatis 1993; Zuo and Maniatis
1996) or antagonizing the activity of negative splicing factor such as hnRNP Al 
(Caceres, Stamm et al. 1994) or other SR proteins (Gallego, Gattoni et al. 1997). SR 
proteins have shown to promote exon inclusion when bound to a target site within 
exons (ESEs); however, in some cases they can act in a negative fashion. The 
negative effect on splicing can be mediated by the binding to an intronic sequence 
(ISS) (Ibrahim el, Schaal et al. 2005; Buratti, Stuani et al. 2007) or by the inhibitory 
property of the protein itself, as reported for SRp 38 (Barnard, Li et al. 2002).
SR protein activity is regulated through phosphorylation/dephosphorylation at 
multiple positions within the RS domain (Stamm 2008). This post-translational 
modification is a crucial step for the splicing organization inside the cell nucleus by 
affecting the RNA-binding activity and sub nuclear localization of the SR proteins 
(Misteli and Spector 1997). While localized predominantly in the nucleus, some (not 
all) SR proteins shuttle continuously between the nucleus and the cytoplasm 
(Caceres, Screaton et al. 1998). The RS domain phosphorylation is required for the 
translocation of the SR proteins from the cytoplasm to the nucleus and also for the 
recruitment of these factors from nuclear speckles (“splicing factor compartments”) 
to the sites of pre-mRNA synthesis (Bourgeois, Lejeune et al. 2004).
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Figure 1.6: Models of SR protein action in ESE dependent splicing.
a) RS-domain-dependent mechanism. A SR protein bound to an exonic splicing 
enhancer (ESE) through its RNA-recognition motifs (RRM) contacts the splicing and 
through its RS domain recruits and stabilizes Ul snRNP and U2AF binding to the 5’ 
and 3’ss, respectively. SR proteins can also allow protein-protein interactions across 
introns binding the U1-70K factor and the U2AF35 stimulating the usage of the 5’ 
and 3’ss. For some ESE-dependent pre-mRNAs, indirect interactions (black arrows) 
are bridged by the splicing co-activator SRml60, which stimulates splicing of some 
ESE-dependent pre-mRNAs and also interacts with the U2 snRNP.
b) RS-domain-independent mechanism. In this case, the main function of the SR 
protein bound to an ESE is to antagonize the negative effect on splicing of an 
inhibitory protein that is bound to a juxtaposed exonic splicing silencer (ESS). The 
SR protein is shown without its RS domain, although this domain is normally present 
and might still promote U2AF binding. Inhibitory interactions are shown in red and 
the putative stimulatory interactions are double-headed arrow. These models are not 
mutually exclusive, and some splicing might involve a combination of these 
mechanisms. Figure adapted from Cartegni, Chew et al. (Cartegni, Chew et al. 2002).
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Phosphorylation is also important for specific RNA recognition, since the high 
positive charge of unphosphorylated RS domains masks the specificity of the RNP 
domains and enhances non-specific binding (Tacke, Chen et al. 1997; Stamm 2008). 
While the functions of SR proteins in pre-mRNA splicing have been extensively 
studied, recent work has demonstrated their roles in numerous other steps of mRNA 
metabolism including mRNA nuclear export, mRNA stability and translation (Huang 
and Steitz 2005; Sanford, Ellis et al. 2005).
ASF/SF2: One of the best known SR proteins is the alternative splicing 
factor/splicing factor 2 (ASF/SF2). Different groups have highlighted the two basic 
properties of this SR protein. ASF/SF2 was described as an essential splicing factor 
necessary for the early step of splicing (Krainer, Conway et al. 1990) and was also 
characterized as an alternative splicing factor able to drive splice site selection (Ge 
and Manley 1990). ASF/SF2 can promote the recruitment of U l snRNP to 5’ss 
(Kohtz, Jamison et al. 1994) to help 5’ss and 3’ss bridging (Wu and Maniatis 1993), 
and plays a role in splicing regulation, through binding to exonic splicing enhancers 
(Sun, Mayeda et al. 1993).
ASF/SF2, together with other SR proteins, is involved in additional roles in gene 
expression. For example, ASF/SF2 remains associated with the spliced mRNA and is 
able to shuttle between the nucleus and the cytoplasm (Caceres, Screaton et al. 
1998), suggesting a role in mRNA export (Huang and Steitz 2005). In addition 
ASF/SF2 seems to regulate the mRNA stability by binding to the 3’UTR and 
enhancing RNA degradation in the cytoplasm (Lemaire, Prasad et al. 2002). 
ASF/SF2 can also stimulate translation of reporter mRNAs by associating with 
translating ribosomes (Sanford, Gray et al. 2004).
Despite these advances in understanding the functions of ASF/SF2 less is known 
about the physiological roles of this protein. Depletion of ASF/SF2 by RNAi resulted
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in lethality in C. elegans (Longmari, Johnstone et al. 2000) and tissue-specific 
deletion in mice resulted in defects in the developing heart (Xu, Yang et al. 2005). 
ASF/SF2 showed also an unexpected role in maintaining genomic stability by 
protecting cells from the deleterious effects of R-loop formation (Li and Manley 
2005). In addition a recent work found that ASF/SF2 is an oncoprotein with roles in 
both the establishment and the maintenance of cell transformation (Kami, de 
Stanchina et al. 2007). In particular, ASF/SF2 has been found to control alternative 
splicing of the oncogene Ron which modulates cell motility (Ghigna, Giordano et al.
2005).
1.4.4 Heterogeneous ribonuclearproteins (hnRNPs).
The heterogeneous ribonuclear proteins (hnRNPs) family is a class of diverse RNA- 
binding proteins that associate with nascent pre-mRNA. These factors remain 
associated with pre-mRNA until its processing is completed and with mRNAs during 
export from nucleus to cytoplasm (Izaurralde and Mattaj 1995).
Approximately >20 proteins have been identified by two-dimensional gel 
electrophoresis of human hnRNP complexes with molecular weight ranging from 34 
(hnRNP A l) to 120 kDa (hnRNP U) (Dreyfuss, Matunis et al. 1993; Dreyfuss, Kim 
et al. 2002). Some hnRNPs are extremely abundant (-100 million copies per 
nucleus), while others are present in lower amount (Kamma, Portman et al. 1995; 
Markovtsov, Nikolic et al. 2000). For many of these proteins multiple isoforms are 
produced by alternative splicing processes. This diversity is further increased by 
post-translational modifications of potential physiological significance, including 
phosphorylation, arginine methylation and SUMOylation (Dreyfuss, Kim et al. 2002; 
Martinez-Contreras, Cloutier et al. 2007).
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The structure of hnRNP proteins is modular and consists of one or more RNA 
binding domains associated with an auxiliary domain often involved in protein- 
protein interactions (Dreyfuss, Matunis et al. 1993). For instance, the hnRNP A/B 
proteins contain two RNP domains at the N-terminus and a Gly-rich auxiliary 
domain at the carboxy end. HnRNP E1-E2 proteins contain three KH domains 
(Ostareck-Lederer et al., 1998). The hnRNP H family members contain two (2H9) or 
three (H, H’ and F) quasi RNA recognition motifs (qRRMs) and one or two glycine 
rich auxiliary domains (Honore, Rasmussen et al. 1995).
The hnRNP proteins show general RNA-binding specificity and individual proteins 
display preference for specific sequences that tend to coincide with sites of 
functional importance in pre-mRNA processing. However, hnRNP proteins generally 
do not bind specific sites exclusively but recognize different RNA sequences with a 
wide spectrum of affinities. This RNA binding ability is further modulated by 
cooperative protein-protein interactions (Dreyfuss, Matunis et al. 1993; Dreyfuss, 
Kim et al. 2002).
The hnRNP proteins frequently mediate splicing repression, particularly through 
binding to exonic splicing silencer elements or by sterical interference with other 
protein interaction (Cartegni, Chew et al. 2002). Nevertheless, depending on the 
position of the splicing regulatory elements hnRNPs can also associate with enhancer 
elements to help exon inclusion (Caputi and Zahler 2002) and a generic role for 
hnRNP Al and F/H proteins in intron definition has been recently proposed 
(Martinez-Contreras, Fisette et al. 2006).
Although many of the hnRNPs localized in the nucleus, a subset of these proteins 
shuttles continuously between nucleus and cytoplasm. This indicates a role of these 
proteins in nuclear export and in other cytoplasm processes (Pinol-Roma and 
Dreyfuss 1992; Martinez-Contreras, Cloutier et al. 2007).
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hnRNP A l: Among the hnRNP proteins, the most abundant and extensively studied 
is hnRNP A l (Mayeda and Krainer 1992). hnRNP Al binds RNA through two RNA 
recognition motifs at its N terminus while the C-terminal domain comprises several 
RGG repeats, which also contribute to RNA binding. In vivo, four arginine residues 
within the RGG repeats of hnRNP A l are methylated and are thought to influence 
the RNA-binding properties (Kim, Merrill et al. 1997). The C-terminus also includes 
the M9 motif, involved in hnRNP A l nuclear import and export (Izaurralde, 
Jarmolowski et al. 1997).
Although at steady state hnRNP Al is predominantly nuclear, it shuttles rapidly 
between nuclear and cytoplasmic compartments (Pinol-Roma and Dreyfuss 1992). 
The shuttling of hnRNP A l is subject to regulation and it has been proposed to have 
a role in cell proliferation, survival, and differentiation of normal and transformed 
cells (Iervolino, Santilli et al. 2002). The endogenous hnRNP A l is weakly 
phosphorylated in cells grown under normal conditions while upon osmotic shock a 
cytoplasmic accumulation of hnRNP A l is induced, concomitant with an increase in 
its phosphorylation state (van der Houven van Oordt, Diaz-Meco et al. 2000).
Since the early 1990s hnRNP A l has been associated with the regulation of 
alternative splicing process (Caceres and Komblihtt 2002). The first hnRNP A l- 
dependent ESS was identified in studies of HIV tat exon 2 regulation (Amendt, 
Hesslein et al. 1994; Amendt, Si et al. 1995). HnRNP Al splicing repression and the 
existence of Al-dependent ESSs have been documented in other numerous examples 
in humans (Del Gatto-Konczak, Olive et al. 1999; Kashima and Manley 2003; 
Disset, Bourgeois et al. 2006).
Despite its extensive characterization only a small number of high affinity sites have 
been obtained by SELEX (Burd and Dreyfuss 1994). Interestingly a recent study, 
based on searching for endogenous hnRNP Al target RNAs, reported a specific
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binding for the pri-miR-18a. This result highlighted a new role for hnRNP A l as 
auxiliary factor involved in miRNA processing (Guil and Caceres 2007).
Several mechanisms have been suggested to explain hnRNP A 1-mediated splicing 
repression. The hnRNP A l antagonizes in a concentration-dependent way the 
activity of SR proteins on the selection of 5’splice site and can bind to certain exon 
splicing silencers to prevent the use of adjacent 3’splice site (Mayeda and Krainer 
1992; Smith and Valcarcel 2000). Another mechanism was elucidated studying the 
alternative splicing of the hnRNP Al transcript itself. The hnRNP A l protein can 
function as splicing repressor, influencing the alternative splicing of its own pre- 
mRNA, by binding to a conserved intronic element present in both introns 
surrounding the alternative exon 7b (Chabot, Blanchette et al. 1997; Blanchette and 
Chabot 1999; Hutchison, LeBel et al. 2002). Cooperation between the two A l 
complexes on these sites was suggested as promoting “ looping-out” of the 
intervening RNA, including exon 7b, thereby inhibiting splicing. 
hnRNP Al is also implicated in various post-splicing activities, such as mRNA 
export (Izaurralde, Jarmolowski et al. 1997), mRNA stability (Hamilton, Bums et al.
1997) and cap-dependent and internal ribosome entry site-mediated translation 
(Svitkin, Ovchinnikov et al. 1996; Bonnal, Pileur et al. 2005). In addition it was 
reported that hnRNP A l has the ability to dismpt the higher order stmcture of 
telomeric DNA indicating a role in telomere maintenance (Zhang, Manche et al.
2006). HnRNP A l in fact binds with high affinity to telomeric single stranded DNA 
sequences (LaBranche, Dupuis et al. 1998; Dallaire, Dupuis et al. 2000) and interacts 
with telomerase RNA in vitro (Fiset and Chabot 2001). A severe hnRNP A l 
reduction in mouse erythroleukemic cells resulted in shortened telomeric repeats, 
which can be lengthened by restoring hnRNP Al expression (LaBranche, Dupuis et 
al. 1998).
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1.5 Alternative splicing.
Mechanisms that increase protein diversity include the usage of multiple 
transcription start sites, alternative pre-mRNA processing, polyadenylation, pre- 
mRNA editing and post-translational modifications. Among these mechanisms, 
alternative pre-mRNA splicing is considered the most important source of protein 
diversity. This process was described in nearly all metazoan organisms as a mode of 
producing functionally diverse polypeptides from a single gene (Maniatis and Tasic
2002). Alternative splicing in fact generates a large number of mRNAs from the 
surprisingly low number of human genes encoding proteins with slight or opposing 
functional differences, with profound biological consequences (Lopez 1998).
The process of alternative splicing is highly regulated in developmental stages and in 
different tissues (Black 2003). Moreover the selection of the correct splicing variants 
in a given cell type and/or in a particular cell condition is considered to be regulated 
by multiple (sometimes overlapping) exonic and/or intronic splicing enhancers and 
silencers (Cartegni, Chew et al. 2002; Ladd and Cooper 2002). Because a single 
primary transcript can have several regions that each undergo alternative splicing, the 
resulting combinatorial effects of selecting different splice sites can be very 
pronounced, and genes that code for tens to hundreds of different isoforms are 
common (Graveley 2001). One of the most striking examples of alternative splicing 
complexity has been described in Drosophila melanogaster axon guidance receptor 
gene, Down syndrome cell-adhesion molecule (Dscam). The pre-mRNA of this gene 
can potentially produce 38,016 different mature transcripts by alternative splicing 
(Schmucker, Clemens et al. 2000). Even if only a subset of these mRNAs is ever 
produced in vivo, this combinatorial use of alternative exons still represents an 
incredible source of diversity, especially given that the entire Drosophila genome 
consists of only -14,000 genes (Adams, Celniker et al. 2000).
At first, in humans, splicing was thought to be only a minor processing pathway 
affecting about 5% of all genes (Sharp 1994), but over time, it became clear that it is 
very abundant. Bioinformatic studies showed that 59% of the 245 genes present on 
chromosome 22 are alternatively spliced, and DNA microarray experiments indicate 
that 74% of all human genes are alternatively spliced (Johnson, Castle et al. 2003), 
suggesting that alternative splicing of human genes is the rule and not the exception. 
Every conceivable pattern of alternative splicing is present in nature (Fig. 1.7). Exons 
can have different 5’ss or 3’ss that can be alternatively used. Single cassette exons 
can reside between two constitutive exons such that the alternative exon is either 
included or skipped. Alternatively, multiple cassette exons can reside between two 
constitutive exons such that the splicing machinery must choose between them. In 
these systems, special mechanisms must enforce the exclusive choice (Smith and 
Nadal-Ginard 1989). Introns can be retained in the mRNA and become translated. 
The 5-terminal exons of a mRNA can be switched through the use of alternative 
promoters and alternative splicing. Similarly, the 3-terminal exons can be switched 
by combining alternative splicing with alternative polyadenylation sites. In addition, 
these individual patterns can be combined in a single transcription unit to produce a 
complex array of splice isoforms. Moreover, changes in alternative splicing can 
modulate transcript expression levels subjecting mRNAs to nonsense-mediated 
decay (NMD) by creating a stop codon within the coding sequence or by altering the 
structure of the gene product by inserting, or deleting, novel protein parts (Faustino 
and Cooper 2003).
The mechanisms that determine which splice site has to be utilized and/or which 
exon has to be chosen in different cell types or developmental stages have still not 
been precisely defined.
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Figure 1.7: Patterns of alternative splicing.
Alternative splicing generates different segments within mRNAs.
Alternative promoters: selection of one of multiple first exons results in variability at 
the 5’ end of the mRNA. Red indicates variable regions within the mRNA and 
encoded protein (7). Alternative splicing of internal exons: the alternative splicing 
patterns for internal exons include the cassette exon (2), alternative 5’ splice sites (5), 
alternative 3’ splice sites (4), intron retention (5), and mutually exclusive exons (6). 
Alternative terminal exons: selection of one of multiple terminal exons results from a 
competition between cleavage at the upstream poly(A) site or splicing to the 
downstream 3’ splice site (7). There are also examples of competition between a 5’ 
splice site and a poly (A) site within an upstream terminal exon (8). Variability at the 
3’ end of the mRNA produces either proteins with different C termini or mRNAs 
with different 3,-UTRs. Figure adapted from Faustino and Cooper (Faustino and 
Cooper 2003).
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^ Much progress has been made in identifying the “combinatorial code” composed by 
cis-acting elements and trans-acting factors involved in the regulation of alternative 
splicing. High-throughput technologies like large-scale sequencing and microarrays 
analysis are providing opportunities to address these key questions (Ben-Dov, 
Hartmann et al. 2008).
1.5.1 Combinatorial control of trans-acting factors.
The information that determines an alternative splicing event is very difficult to 
characterize. Along with the main determinants of exon-intron definition, such as 
splice sites or enhancer/silencer elements, many more splicing factors have been 
involved in splicing regulation. Alternative splicing in mammals in fact is largely 
controlled by combinatorial binding of basal splicing factors to the pre-mRNA. 
Although several tissue-specific factors associated to a particular alternative splice 
site event have been identified (Markovtsov, Nikolic et al. 2000; Ladd, Charlet et al.
2001), the model for splice site choice consists of a selective usage of an exon due to 
the binding of a distinct set of generic splicing factors (Smith and Valcarcel 2000; 
Mabon and Misteli 2005). This combinatorial model is supported by the observation 
that in vivo and in vitro the counteracting activities of multiple antagonistic factors 
can regulate alternative splicing, suggesting that the physiological concentration of 
competing splicing factors is important for regulation of splice site selection 
(Caceres, Stamm et al. 1994; Hanamura, Caceres et al. 1998).
For example, hnRNP Al can modulate splice site selection by antagonizing the 
activity of ASF/SF2 protein (Caceres, Stamm et al. 1994). It was observed that high 
relative concentrations of A l favour the choice of distal 5’ss, an excess of ASF/SF2 
result in the proximal 5’ss choice both in vitro and upon overexpression in vivo
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(Mayeda and Krainer 1992; Caceres, Stamm et al. 1994). The same competitive 
effect between hnRNP A l and ASF/SF2 has been reported also in the case of 
alternative 3’ss selection. In the same manner hnRNP Al promotes the use of the 
distal 3’ss, while ASF/SF2 promotes the use of the proximal 3’ss (Caceres, Stamm et 
al. 1994; Bai, Lee et al. 1999).
In addition to these indirect data, a recent work based on a quantitative single-cell 
imaging provided new evidence for the combinatorial model for alternative splicing 
reporting the first in vivo evidence for a distinct association of splicing factors with 
alternative spliced pre-mRNAs (Mabon and Misteli 2005).
1.6 Exon definition and Intron definition model.
In most of the cases, vertebrate genes contain multiple short exons separated by 
intronic sequences that can be significantly longer. A typical human pre-mRNA 
molecule can be up to 30 kb long and contains about ten exons separated by much 
longer and variable intronic sequences (Hawkins 1988). The average length of an 
internal exon is around 137 nt (Hawkins 1988) and the exons that are more than 300 
nt long or are shorter than 50 nt seem not to be favoured by the splicing machinery 
(Black 1991; Sterner and Berget 1993).
The discrepancy between the lengths of human exons compared to the introns led to 
the proposal of the “exon definition” model (Fig. 1.8A). In this model the exon is the 
unit recognized by the splicing machinery and the splice sites are first paired across 
exons, with subsequent spliceosome assembly proceeding through pairing of 
neighbour exon units (Robberson, Cote et al. 1990; Berget 1995).
Evidence for the exon definition model arises from the observation that the first and 
the last exon require a special mechanism for their recognition. It has been shown 
that 5’ capping and the 5’ss are necessary to define the first exon (Izaurralde, Lewis
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et al. 1994). On the other hand, last exon is defined by 3’ss and polyadenylation 
signal (Niwa and Berget 1991). Moreover, it was shown that the exon length might 
affect splicing. A minimal separation of the sites seems to be required to prevent 
steric hindrance of the factors that recognize the splice sites bordering an exon 
(Black 1991). This indication is supported by the observation that a constitutively 
recognized internal exon was skipped by in vivo splicing machinery if its size was 
smaller that 50 nt (Dominski and Kole 1991). Complementary studies showed that 
the extension of the 18-nt N1 exon of the mouse c-src gene up to 109 nt leads to its 
constitutive inclusion. This finding suggests that the exon is normally skipped 
because it is too short to allow spliceosome assembly at both ends simultaneously 
(Black 1991). Further in vitro analysis on the expansion of internal exons to length 
above 300 nt causes the activation of cryptic splice site located within the exon or 
lead to exon skipping indicating that splicing efficiency is affected by length 
(Robberson, Cote et al. 1990). In fact, less than 1% of the known internal exons in 
vertebrate are longer than 400 nt (Hawkins 1988). Conversely the experiments 
obtained by expanding the central exon in the dihydrofolate reductase minigene with 
random DNA fragments from E.coli, demonstrated that its expansion up to 1200 nt 
does not compromise the correct inclusion into mRNA (Chen and Chasin 1994). To 
explain these data a compensatory relationship between exon and intron size has 
been proposed. In fact, Sterner et al. observed that long internal exons are 
problematic for recognition if they are flanked by long introns, suggesting that these 
exons might be flanked by short introns (Sterner, Carlo et al. 1996). In this case, the 
splice sites can be paired across introns rather than exons as proposed by the "intron 
definition" model (Fig.l.8B). This model in fact suggests that introns are the units 
recognized by the splicing machinery proposing a sort of scanning mechanism where 
the 5' and 3' splice signals are initially recognized and paired across the intron
(Guthrie 1991; Berget 1995). Intron definition is thought to be the predominant way 
of splicing in transcripts containing short introns and long exons (Sterner, Carlo et al. 
1996). Evidence supporting this mechanism arises from observations made in yeast, 
where RNA messengers often have a unique intron and its length is usually below 
100 nt (Goguel and Rosbash 1993).
In Drosophila there are two different classes of introns: long, vertebrate-like introns 
that possess a 3’ pyrimidine tract and short, yeast-like introns that lack this consensus 
sequence (Talerico and Berget 1994). 50% of small introns are less than 100 nt and 
are often flanked by large exons (Hawkins 1988). Mutants of 5’ss and expansion of 
the size of these small introns showed the induction of intron retention and cryptic 
splice site activation, respectively supporting the intron definition model as way of 
recognition (Talerico and Berget 1994).
All these observations suggest mechanistic differences in the process of splice site 
selection in pre-mRNAs containing small exons or small introns. It has been 
indicated that splice sites are initially paired across the shortest distance so both exon 
definition and intron definition might occur in different parts of the pre-mRNA of the 
same gene (Sterner, Carlo et al. 1996).
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Figure 1.8: Exon definition versus intron definition models.
(A) Exon definition model: a vertebrate gene consists of multiple short exons 
separated by considerably longer introns. In this model the exon is recognized as a 
unit during early spliceosome assembly. Multiple factors interact with exonic 
sequences in order to defining the 5’ and the 3’ borders of the exon. SR proteins can 
help this “cross exon” recognition through the binding exonic splicing enhancers 
(ESEs) and recruiting U1 snRNP to the 5’ss, U2AF65 and U2AF35 subunits to the 
PPT and to the 3’ss, respectively.
(B) Intron definition model: it has been proposed for the systems in which pre- 
mRNA has small introns. In this case the intron, rather than exon, is the recognized 
unit. Multiple factors favour the 5’ and the 3’ ss pairing at the intron ends. SR 
proteins function in a “cross intron” recognition complex by bridging together the U 1 
snRNP bound to the upstream 5’ss and the U2AF65 and U2AF35 subunits bound to 
the PPT and to the AG of the downstream 3’ss, respectively. Adapted from Ram and 
Ast (Ram and Ast 2007).
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1.7 Splicing is a co-transcriptional process.
The transcriptional process includes the formation of a pre-initiation complex, the 
transcription initiation, elongation, termination and finally the dissociation of RNA 
polymerase II (Pol II) from the DNA template. Then the pre-mRNA transcript 
undergoes several processing steps including capping, splicing, polyadenylation, 
surveillance and export (Fig. 1.9). In vitro each of these modifications can occur 
independently from the others, as found in reconstituted systems on purified pre- 
mRNA substrates. However, in vivo these reactions influence one another’s 
efficiency revealing a functional relationship among them and indicating that most 
mRNA processing reactions occur co-transcriptionally (Bentley 2002; Bentley 2005). 
These observations led to the proposal that the RNA modifications occur in a “gene 
expression factory” composed of machines linked together for the purposes of 
efficiency and regulation (Bentley 2002; Bentley 2005).
To date, two models have been proposed to explain the connection between the 
different steps of RNA transcription and processing. The “recruitment model” 
derived from the observation that several trans-acting factors can interact directly 
with the RNA Pol II and thus increasing their own concentration in the proximity of 
the nascent transcript (Bentley 2005). The carboxy-terminal domain (CTD) of the 
RNA Pol II in fact has been shown to play a central role in coupling transcription to 
pre-mRNA processing acting as assembly platform for proteins involved both in 
transcription and pre-mRNA processes regulation (Bentley 2005). In particular, 
recent studies reported an important connection between SRp20 and the CTD tail for 
the EDA alternative exon regulation. Mature mRNAs transcribed by a RNA Pol II, 
lacking the CTD tail, showed a much higher percentage of EDA inclusion compared 
to the ones transcribed by the entire RNA Pol II. The CTD-dependent silencing
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seems to be mediated by its ability to recruit the SRp20 splicing factor (de la Mata 
and Komblihtt 2006).
An alternative to the recruitment model is the “kinetic model”, mainly linked to the 
RNA Pol II transcriptional elongation rate (Komblihtt, de la Mata et al. 2004). This 
model was originally proposed by experiments in which RNA Pol II pausing sites 
were artificially introduced into a gene, delaying the transcription of a splicing 
inhibitory element and therefore resulting in higher inclusion levels of an alternative 
exon (Roberts, Gooding et al. 1998). Further evidence supported this model 
indicating that transcription can affect splicing acting at different cis- and trans­
acting levels (Komblihtt, de la Mata et al. 2004). For instance differences in 
promoter architecture have been shown to affect the subsequent selection of the 
fibronectin EDA alternative exon and the CFTR exon 9 (Cramer, Pesce et al. 1997; 
Cramer, Caceres et al. 1999; Pagani, Stuani et al. 2003). However, in vivo most of 
the genes have a single promoter and the regulation of splicing has been reported to 
occur through the binding of different transcription factors. In line with this view it 
has been described that transcriptional activators can affect alternative splicing 
(Nogues, Kadener et al. 2002). Additionally, the presence of enhancer sequences, 
like SV40 next to the promoter can stimulate RNA Pol II elongation while the 
deletion of this enhancer causes a reduction in exon skipping (Kadener, Fededa et al. 
2002).
A less explored factor involved in regulation of splicing via RNA Pol II elongation is 
the chromatin packaging. Changes in its stmcture due to acetylation can alter 
splicing. It was reported in fact that cell treatment with a potent inhibitor of histone 
deacetylation inhibits EDA inclusion (Nogues, Kadener et al. 2002). Recently, a role 
of SWI/SNF chromatin remodelling complex was also described for alternative 
splicing. This factor was shown to stimulate the inclusion of alternative exons in the
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CD45 gene by decreasing the RNA pol II elongation rate and facilitating the 
recruitment of the splicing machinery (Batsche, Yaniv et al. 2006).
A more direct proof for the kinetic model derived from studies on RNA Pol II 
elongation rate (Roberts, Gooding et al. 1998; de la Mata, Alonso et al. 2003). A 
slow Pol II and/or the presence of internal transcriptional stalling sites, results in an 
increased inclusion of alternative exon harbouring a weak 3’ss. By contrast, when a 
highly processive RNA Pol II transcribes the same pre-mRNA, the weak alternative 
splice site is unable to compete with the stronger downstream 3’ss, which results in 
skipping of the alternative exon (de la Mata, Alonso et al. 2003). Recently a 
reciprocal coupling between splicing and transcriptional elongation has also been 
reported. Splicing proteins have been involved in transcriptional elongation in vitro 
(Fong and Zhou 2001) and specific depletion of SC35 showed RNA Pol II 
accumulation and attenuated elongation in vivo (Lin, Coutinho-Mansfield et al. 
2008). Furthermore, it was also described that an efficient RNA Pol II transcription is 
strictly connected with the presence of intronic sequences (Furger, O'Sullivan et al. 
2002). Taking these evidences together a complex view has emerged from the studies 
focused on the coupling between transcription and pre-mRNA processing suggesting 
that both recruitment of factors to the CTD and RNA Pol II kinetic are involved in 
this connection (Komblihtt, de la Mata et al. 2004).
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Figure 1.9: Coupling mRNA transcription and processing.
The production of a correct mRNA is a coordinated and multiple-step process that 
occurs in the nucleus of eukaryotic cells. RNA Pol II, and specifically the C-terminal 
domain (CTD) of its largest subunit directs these processes in a way that links CTD 
phosphorylation changes to different factors binding. These proteins in turn affect the 
subsequent processing steps and/or help to recruit processing/packaging factors to 
the nascent transcript. The maturation of pre-mRNA includes the capping at its 5’ 
end, the introns removal during splicing, and the cleavage and the polyadenylation of 
the 3’ end. After going through the mRNA surveillance system, the matured mRNA 
is exported to the cytoplasm for translation. Each stage of RNA Pol II transcription 
and the steps of co-transcriptional processing are indicated. Figure adapted from Li 
and Manley (Li and Manley 2006).
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1.8 Splicing mutations.
Considering the complexity of the pre-mRNA process, it is not surprising that 
splicing mutations are directly linked with aberrant splicing processes. As a 
consequence the study of the network of interactions between defective splicing and 
occurrence of disease has become a central issue in the medical research field 
(Cartegni, Chew et al. 2002; Faustino and Cooper 2003; Garcia-Bianco, Baraniak et 
al. 2004; Pagani and Baralle 2004). More than a decade ago, it was estimated that at 
least 15% of mutations that cause genetic disease affect pre-mRNA splicing 
(Krawczak, Reiss et al. 1992). In the specific case of NF1 and ATM genes, the 
genomic variations which affect splicing process seem to represent up to 50% of all 
mutations that lead to gene dysfunction (Teraoka, Telatar et al. 1999; Ars, Serra et al. 
2000). At the mRNA processing level, splicing alterations can produce different 
outcomes such as exon skipping, activation of cryptic splice sites or intron retention 
(Buratti, Baralle et al. 2006). In mammals, exon exclusion from the mature transcript 
is the most prevalent splicing outcome followed by the inactivation of the donor site 
(Krawczak, Reiss et al. 1992).
The alteration of splicing processes due to a mutation can produce an erroneous 
mRNA followed by a subsequent loss of function of its translated protein. In other 
cases, a nucleotide substitution can modify the normal level of an alternative spliced 
exon and can result in an imbalance in the different protein isoforms produced 
(Pagani and Baralle 2004).
It is important to notice that the splicing process can be affected by mutations 
dispersed throughout any given part of a gene sequence including splice sites, exons 
and introns (Fig. 1.10) but the functional mechanisms of many of these mutations 
remains poorly characterised (Pagani and Baralle 2004).
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Figure 1.10: Splicing mutations.
Genomic variants (GVs) can affect all the different cis-acting regulatory elements: 
the canonical 5’ and 3’ splice site and the accessory elements, enhancers (red 
rectangles) and silences (blue rectangles). Exonic genomic variants (eGVs), even if 
they can affect splicing, are usually classified for their effect at the proteins level as 
missense, nonsense or synonymous mutations. Intronic variants (iGVs) might be 
located within approximately 50 bp from the splice sites or deep in the introns and 
ofter are considered polymorphism. Figure adapted from Pagani and Baralle (Pagani 
and Baralle 2004)
In the specific case of ATM and NF1 genes the 13% and 11% of splicing mutations, 
respectively, have been erroneously classified as frameshift, missense or nonsense 
mutations if the analysis had been limited to the effect at the protein level (Pagani 
and Baralle 2004). Moreover, the presence of mutations can affect the mRNA 
secondary structure (Buratti and Baralle 2004). In addition to the cis-acting elements 
variants, mutations associated with trans-acting factors can result in a more general 
splicing defect whereas proteins involved in a specific splicing event can affect a 
particular subset of spliced mRNAs. Therefore, components of the basal splicing 
machinery, if mutated, have the potential to target a huge number of mRNAs 
(Faustino and Cooper 2003). In general mutations affecting spliceosome components 
result in cell lethality both in yeast and metazoans (Golling, Amsterdam et al. 2002) 
but in the particular case of SMN1, involved in snRNPs assembly, the homozygous 
loss of this gene causes spinal muscular atrophy (SMA) (Wirth 2000).
67
Detailed knowledge about the connection between splicing mutations and disease 
can have a significant impact on the diagnosis and for the treatment of genetic 
diseases. The adequate classification of mutations in term of effect at mRNA and/or 
protein level is essential for the development of new therapeutic strategies and 
compounds (Cartegni, Chew et al. 2002; Pagani and Baralle 2004).
1.8.1 Canonical splice site mutations.
Splicing signals are frequent targets of mutations in genetic diseases and cancer (Fig. 
1.10). Most of the changes are single-point mutations affecting the conserved 
consensus signal sequences at the donor or acceptor splice sites (Pagani and Baralle 
2004). Consensus sequences are limited to 9 bases at the 5’ exon/intron junction and 
4 bases at the 3’ intron/exon junction (Shapiro and Senapathy 1987). It has been 
shown that mutations occurring in one of the first two bases (GU) in intron, 
immediately downstream of 5’ss, as well as AG in intron, immediately upstream of 
3’ss completely abolish splicing (Langford, Klinz et al. 1984). Subsequently, a study 
of more than a hundred splice-site mutations showed that point mutations affecting 
the 5’ss were more common than those at the 3’ss (62% vs 26%) (Krawczak, Reiss et 
al. 1992). At the 5’ss, mutations affecting the GT residue at position +1, +2 are the 
most common (Krawczak, Reiss et al. 1992), followed by mutations at position +5 
(Pohlenz, Dumitrescu et al. 2002). Mutations at these positions are thought 
significantly to reduce the pairing of the donor splice site with the complementary 
site in the U1 snRNP, which is one of the first steps in the complex process of pre 
mRNA splicing (Krawczak, Reiss et al. 1992; Kramer 1996). In fact, cotransfection 
experiments with U1 snRNA mutant complementary to the nucleotide substitution in 
this region showed rescue the aberrant splicing in the NF1 exon 3 (Buratti, Baralle et
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al. 2004). As for the 5’ss, it was shown that mutations affecting the 3’ss at the 
conserved -2 and -1 sites (A and G dinucleotides respectively) are most common and 
have the effect of completely abolishing splicing (Langford, Klinz et al. 1984), 
although mutations affecting the +1 site are also observed (Ikeda, Takagi et al. 2001). 
Mutation of the adenine residue involved in the lariat formation strongly reduces 
splicing efficiency of the downstream exon (Reed and Maniatis 1988). Indeed, the 
use of the normal 3’ss can be restored either improving the match of a cryptic branch 
site to the branch site consensus or by introducing mutant U2 snRNA with greater 
complementarity to the cryptic branch site (Zhuang and Weiner 1989).
1.8.2 Exonic and intronic mutations.
Nucleotide substitutions that involve accessory sequences can be classified as loss or 
gain of function splicing mutations if the splicing element considered is 
destroyed/weakened or created/enhanced, respectively (Faustino and Cooper 2003; 
Garcia-Bianco, Baraniak et al. 2004).
A well-studied example in which the effect of a splicing mutation on an exonic 
regulatory sequence has been analyzed is represented by exon 7 in the SMN1/SMN2 
genes (Fig. 1.11). SMN1 and SMN2 represent two nearly identical copies of the 
survival motor neuron gene in humans. SMN1 predominantly produces full-length 
transcripts, whereas SMN2 mostly produces transcripts lacking exon 7. Deletion of 
SMN1 coupled with the inability of SMN2 to compensate for the loss of SMN1 leads 
to spinal muscular atrophy (SMA), the second most common autosomal recessive 
genetic disorder in humans (Lefebvre, Burglen et al. 1995; Wirth, Brichta et al. 
2006). Comparison between SMN1 and SMN2 revealed a critical C to T substitution 
at the sixth position (C6U transition in transcript) of exon 7 of SMN2 sufficient to
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cause exon skipping (Lorson, Hahnen et al. 1999; Monani, Lorson et al. 1999). It is 
generally believed that the rescue of SMN2 exon 7 skipping holds the promise for 
cure of SMA, due to the deletion of the SMN1 gene. However, the mechanism by 
which C6U promotes SMN2 exon 7 skipping remains a complex issue (Singh 2007). 
The single nucleotide substitution C6U was reported to create one or a combination 
of situations including the abrogation of an enhancer, the creation of a silencer or 
both events together (Singh 2007). Based on in vitro experiments and on ESEfinder 
predictions, an initial analysis suggested the “loss of function model” (Fig. 1.1 la) as a 
potential mechanism (Cartegni and Krainer 2002). According to this model, the 
presence of the C6U variant in SMN2 exon 7 abrogates an essential enhancer 
element of the exon associated with the splicing factor ASF/SF2 (Cartegni, Hastings 
et al. 2006). However, several evidences against the loss of function model came 
from in vivo experiments suggesting the “gain of function model” (Fig. 1.1 lb), as the 
more probable mechanism (Kashima and Manley 2003). In this case, the C6U 
substitution creates an exonic splicing silencer (ESS) associated with splicing factor 
hnRNP Al and with exon 7 skipping (Kashima and Manley 2003). Strongest 
evidence in support of hnRNP A l model came from an RNA interference (RNAi) 
experiment in which depletion of hnRNP Al promoted exon 7 inclusion in SMN2 
(Kashima, Rao et al. 2007). This classical view of mutations influencing an exon 
recognition by affecting either an ESE or an ESS in some instances does not fully 
represent the complexities of the splicing regulation.
For example in the case of neurofibromatosis type-1 gene (NF-1) mutations within 
exon 37 have been reported as causing both the skipping of exons 36-37 together and 
the skipping of exon 37 alone. These mutations, localized within an ESE region, 
interfere with the exon 37 definition but also affect the proper recognition of the 
upstream exon 36 (Messiaen, Callens et al. 1997; Baralle, Skoko et al. 2006).
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Figure 1.11: Enhancer disruption and creation of silencer models.
SMN1 and SMN2 represent two nearly identical copies of the survival motor neuron 
gene in humans. Homozygous loss of function of the survival motor neuron 1 
(SMN1) gene causes spinal muscular atrophy (SMA). SMN2 differs from SMN1 for 
a translationally silent C—>T substitution at +6 position in exon 7 that causes 
approximately the 80% of exon 7 skipping. The exclusion of this exon from the 
mRNA produces a truncated unstable protein. Two models have been proposed to 
explain how this mutation causes exon 7 skipping.
a) In the loss of function model the presence of the single point mutation might cause 
the inactivation of an exonic splicing enhancer (ESE), located in the 5’ region of 
exon 7, binding site for ASF/SF2 protein.
b) In the gain of function model the C to T substitution creates a new exonic splicing 
silencer (ESS) able to bind the negative splicing factor hnRNP A l, leading to exon 7 
exclusion. Figure taken from Pagani and Baralle (Pagani and Baralle 2004).
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In a recent study the ESE region was extensively mapped by point mutation showing 
that this element is not only required for the definition of exon 37, but also 
contributes towards the identification of the upstream exon 36. Intriguingly, it has 
been reported that both these exons need an extremely wide genomic context to 
obtain the in vivo splicing pattern indicating that their correct definition relies on the 
intrinsic properties of the exons themselves but also on the genomic environment 
within which they are located (Baralle, Skoko et al. 2006).
As reported for the exon 12 of CFTR gene, the exon inclusion/exclusion regulation 
can be even more intricate (Pagani, Stuani et al. 2003). Skipping of this exon 
removes a highly conserved region encoding part of the first nucleotide-binding fold 
of CFTR producing a non-functional protein (Delaney, Rich et al. 1993).
The systematic study of natural and artificial mutation within the exon 12 sequence 
allowed the mapping of two particular exonic regulatory elements involved in 
splicing regulation. Most of the nucleotide substitutions studied in CFTR exon 12 
context showed a change in the splicing pattern either increasing exon skipping or 
promoting exon inclusion (Pagani, Stuani et al. 2003). Whereas exonic regulatory 
splicing elements found in both constitutive and alternative exons are classically 
divided into enhancers and silencers (Cartegni, Chew et al. 2002), in the case of 
CFTR exon 12 the experiments clearly showed an overlapping enhancer and silencer 
region with neither a pure enhancer nor a silencer behaviour. This result defined a 
new type of splicing element with a composite regulatory function named CERES 
(composite exon regulatory element of splicing) (Pagani, Stuani et al. 2003).
The identification of CERES with similar overlapping enhancer and silencer 
functions in other exons, such as the CFTR exon 9, indicates a common splicing 
regulatory role of these elements (Pagani, Buratti et al. 2003).
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Even if most of the studies have focused on the splice sites and exonic mutations, 
intronic variants located within approximately 50 bp to the splice sites but also 
deeply in an intron sequence have been reported to cause splicing defects (Pagani 
and Baralle 2004). Most commonly, these intronic variants create new splice sites 
able to define the boundaries of a cryptic exon (Buratti, Baralle et al. 2006). A 
different mechanism has been proposed in the case of the ATM gene, in which a 
mutation can affect the splicing efficiency of the intron reported. A four bases 
deletion in intron 20 in the ATM gene, 2 kb and 0.6 kb from the preceding and 
following exons, respectively, has led to the discovery of an unknown intronic 
splicing element involved in the efficient pre-mRNA processing of long introns 
(Lewandowska, Stuani et al. 2005). The disruption of this intronic processivity 
element results in the activation of a pseudo exon leading to an erroneous mRNA and 
consequently to the disease phenotype (Pagani, Buratti et al. 2002).
1.8.3 Secondary structure and mutations.
Changes in RNA secondary structure due to the presence of mutations have been 
involved in pathogenic processes, as described for the NF-1 gene (Hoffmeyer, 
Numberg et al. 1998; Kaufmann, Leistner et al. 2002), the dystrophin gene (Matsuo, 
Nishio et al. 1992), and the CFTR gene (Hefferon, Groman et al. 2004). These 
examples derived from association studies between in silico predictions of pre- 
mRNA secondary structures and splicing activity.
The role of the secondary structure in the generation of human disease has been 
studied extensively in the case of tau exon 10 mutations (Grover, Houlden et al. 
1999; Varani, Hasegawa et al. 1999; Jiang, Cote et al. 2000; Varani, Spillantini et al. 
2000). The mutations in the intronic region near the 5’ss of exon 10 strongly
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correlate with the disruption of a characteristic stem-loop structure and the stability 
of this secondary structure determines the ratio of tau exon 10+/- transcripts (Varani, 
Hasegawa et al. 1999). An increase in the ratio of tau mRNAs containing exon 10 
results in the production of an aberrant protein isoform that leads to neuro­
degeneration (Grover, Houlden et al. 1999). Extensive mutational analyses (Grover, 
Houlden et al. 1999) and functional studies to monitor U1 snRNP binding to the 
splice site have shown that mutations which destabilize the helix result in an 
increased splice site usage owing to an increase in U1 snRNP binding (Jiang, Cote et 
al. 2000).
1.8.4 A G to T substitution in BRCA1 exon 18 causes a splicing defect.
In 1998 Mazoyer at al reported the case of a nonsense-mediated exon skipping event 
in the Breast Cancer 1 gene (BRCA1), in one breast and ovarian cancer family that 
contains four breast and four ovarian cancer cases (Mazoyer, Puget et al. 1998). By 
PCR amplification and subsequent agarose gel analysis they identified, in affected 
family members, a fragment of BRCA1 cDNA covering exons 16-22 able to produce 
two bands of equal intensity one corresponding to the expected length (596 bp) and 
one slightly shorter. Direct sequencing of both amplified bands revealed a 78 bp in­
frame deletion in the short fragment corresponding to the entire exon 18 exclusion 
(Mazoyer, Puget et al. 1998). Alternative removal of exon 18 does not occur 
naturally (Xu, Chambers et al. 1997). Thus, in order to identify the basis of BRCA1 
exon 18 skipping, a genomic DNA fragment, encompassing part of intron 17, all of 
exon 18, and part of intron 19, was amplified by PCR and analyzed for mutations in 
all the basic splicing consensus sequences: the 3’ss and 5’ss and the predicted 
branchpoint position. However, the only mutation detected was a G to T substitution
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in position +6 of exon 18 (nucleotide 5199, codon 1694), which changes a glutamic 
acid into a stop codon (Glul694ter) (Fig. 1.12). Specific cDNA amplification 
showed that only a wild-type exon 18 sequence was found in all carriers, which 
implies that the mutant allele produces only mRNA in which exon 18 had been 
skipped (Mazoyer, Puget et al. 1998). Although the Glul694ter mutation would be 
expected to lead to the truncation of 169 amino acids from the BRCA1 protein, it has 
been showed to cause an in frame deletion of 26 amino acids (Aspl692-Phel717) 
due to exon 18 skipping. At the BRCA1 protein level this deletion disrupts the first 
BRCT domain, specifically removing part of block D, the most highly conserved 
motif within this domain (Callebaut and Momon 1997). The block D is organized 
around a conserved aromatic residue, a Trp that in presence of the G to T mutation is 
changed to Gly because of the creation of a new junction between exon 17 and 19. 
How this nonsense mutation causes exon skipping has been unclear. The ESE 
disruption was the first proposed mechanism although Glul694Ter mutation does not 
occur in a typical purine-rich segment (Liu, Cartegni et al. 2001). BRCA1 exon 18 
wild-type and mutant sequences were analyzed by ASF/SF2, SC35, SRp40 and 
SRp55 motif-scoring matrices (Cartegni, Wang et al. 2003). Multiple high-score 
motifs of each type are distributed throughout this exon. As reported in figure 1.13 
the analysis of the G to T mutated exon at position +6 predicts the specific disruption 
of the first of three high-score ASF/SF2 motifs.
To study the exon-skipping mechanism, a wild type and mutant minigenes were 
analyzed for splicing in vitro. Whereas the wild-type exon 18 was efficiently 
included, the G to T mutant exon 18 was totally excluded. The correlation between 
the first ASF/SF2 high-score motif disruption and the splicing patterns suggested that 
the nonsense mutation disrupted an ESE (Liu, Cartegni et al. 2001). The study of two 
artificial BRCA1 exon 18 mutants and four additional high-score heptamers showed
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a correlation between ESEfinder prediction and in vitro splicing pattern, further 
indicating the ESE disruption as the putative mechanism (Liu, Cartegni et al. 2001)
+6
Tag  (GIu 1694Ter)
j ag-AT GCT GAG TTT GTG TGT GAA CGG ACA
| ( D ) A E F V  C E R T
| CTG AAA TAT TTT CTA GGA ATT GCG GGA
! L K Y F L G  I A GI
J
| GGA AAA TGG GTA GTT AGC TAT TTC T -g t
| G K W  V V S  Y F ( W)
\
Figure 1.12: BRCA1 exon 18 sequence WT and G6T mutant.
Schematic representation of BRCA1 exon 18 (78pb) sequence (capital letter) flanked 
by short dinucleotides from the 5’ and 3’ splice site. The letters below each DNA 
codon sequence represent the corresponding aminoacid. The arrow indicates the 
position +6 in which the G to T substitution occurs. The T point mutation creates a 
stop codon (TAG) and causes the inappropriate skipping of the entire constitutive 
exon 18 in vivo. Exon 18 skipping results in the retention of the same reading frame 
and the removal of 26 amino acids (Mazoyer, Puget et al. 1998).
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Figure 1.13: High score SR protein motifs in BRCA1 exon 18 WT and G6T 
mutant.
(A) Effect of point mutation on ASF/SF2 motif score. The graphic representation of 
ASF/SF2 consensus motif is shown and the height of each letter reflects the 
frequency of that nucleotide at that particular position. The degenerate ASF/SF2 
consensus motif is aligned to the first 14 nt of exon 18 WT and mutated position +6 
(grey boxed). The blue horizontal line under the WT sequence indicates the position 
of the first ASF/SF2 motif recognised within the exon 18 by ESEfinder program. The 
ASF/SF2 motif scores calculated for the WT and mutated sequence are shown on the 
right.
(B) SR motif distribution in BRCA1 exon 18 WT and G6T mutant. The 78nt 
sequence of exon 18 WT (top) and G6T mutated (bottom) were analyzed by 
ESEfinder program. Multiple high-score motifs of each type are distributed 
throughout the exon 18, red for ASF/SF2, blue for SC35, green for SRp40 and 
yellow for SRp55. Exon 18 mutated sequence showed the specific disruption of the 
first high-score ASF/SF2 motifs (arrow) by the G6T substitution.
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1.9 BRCA1 gene.
BRCA1 was the first breast and ovarian cancer susceptibility gene to be identified by 
linkage analysis of families with multiple cases of early onset breast and ovarian 
cancer (Miki, Swensen et al. 1994). Indeed, at least half of familial breast cancer 
cases can be linked to mutations within the BRCA1 gene (Futreal, Liu et al. 1994). 
Cancer cells isolated from BRCA1-associated tumors show a classic loss-of- 
heterozygosity pattern at the BRCA1 loci, classifying this gene as a prototypical 
growth suppressor (Neuhausen and Marshall 1994).
The BRCA1 gene, mapped to chromosome 17ql2, is 100 Kb in length, contains 24 
exons and encodes a large protein of 1863 amino acids which has been shown to 
localize predominantly in the nucleus (Chen, Li et al. 1996). BRCA1 does not share 
any significant structural or sequence homology to any known proteins. There are, 
however, three main features that are important for its overall function. A RING 
finger motif, containing a conserved pattern of cysteine and histidine residues, 
located at the extreme N-terminal end of BRCA1 (Miki, Swensen et al. 1994). This 
motif is thought to be important for its association with a number of proteins and in 
particular to BRCA1-associated ring domain 1 (BARD1) (Wu, Wang et al. 1996). 
BARD1 binds to BRCA1 and forms a heterodimer with ubiquitin-ligase activity 
(Hashizume, Fukuda et al. 2001). The central region of BRCA1, which constitutes 
about 60% of the protein, is encoded only by exon 11 and contains two nuclear 
localization signals (Chen, Li et al. 1996). Several proteins, including DNA repair 
proteins, tumor suppressors and transcription activator/repressor factors associate 
directly or indirectly with this part of BRCA1 (Deng and Brodie 2000). In the C- 
terminal part there are two highly conserved BRCT domains that are also present in a 
group of proteins involved in DNA damage repair and cell cycle control (Bork, 
Hofmann et al. 1997). BRCT domains behave as phosphopeptide-binding motifs
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ideal for protein targeting (Manke, Lowery et al. 2003; Yu, Chini et al. 2003). C- 
terminal truncations of up to eight aminoacids can be tolerated by the BRCA1 
protein but further deletion results in drastic BRCT folding defects (Williams and 
Glover 2003).
Numerous studies have reported a role of BRCA1 in transcription regulation, even 
though it is not itself a sequence specific DNA binding transcription factor (Rosen, 
Fan et al. 2006). BRCA1 was found to associate with the RNA pol II complex, 
suggesting its involvement in the basal transcription regulation (Scully, Anderson et 
al. 1997; Haile and Parvin 1999). BRCA1 is linked to RNA pol II, in part, through 
the RNA helicase A enzyme (Anderson, Schlegel et al. 1998) and binds 
preferentially to RNA pol II complexes containing a polyphosphorylated p220 
subunit (Krum, Miranda et al. 2003). Indeed, BRCA1 regulates the phosphorylation 
state of RNA pol II p220 subunit through the CDK-activating kinase (CAK) 
(Moisan, Larochelle et al. 2004). The precise function of BRCA1 in the RNA pol II 
complex is unclear. However, BRCA1 associates with BARD1 and exhibits an 
ubiquitin ligase activity (Hashizume, Fukuda et al. 2001), suggesting that it may 
mediate ubiquitination and degradation of the RNApol II enzyme components, upon 
transcriptional blockage in response to DNA damage (Parvin 2001).
BRCA1 was also described as recruiting a SWI/SNF-like chromatin-remodeling 
complex (Bochar, Wang et al. 2000) and mediating a large-scale chromatin- 
unfolding activity through the cofactor of BRCA1 (COBRA 1) (Narita, Yamaguchi et 
al. 2003).
Moreover, the interaction of BRCA1 with different sequence-specific DNA binding 
factors also contributes to stimulating or inhibiting transcription. For example 
BRCA1 stabilizes p53 and promotes its transcriptional activity (Zhang, 
Somasundaram et al. 1998), interacts with STAT1 factor involved in the growth
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arrest following interferon gamma (IFNy) treatment (Ouchi, Lee et al. 2000), binds 
directly and represses the estrogen receptor (ER-a) (Fan, Ma et al. 2001) and 
regulates many other transcription factors (Rosen, Fan et al. 2006).
BRCA1 has also been implicated in maintaining genomic integrity through its 
involvement in the DNA damage pathway and in the cell cycle control. BRCA1 has 
been linked with non-transcriptional and transcriptional aspects of the DNA double­
strand breaks (DSB) response pathway. The assembly of a DNA repair complex at 
sites of DNA damage is an extremely rapid BRCA1-dependent function that does not 
involve transcription. In response to different forms of DNA damage, BRCA1 can be 
hyperphosphorylated by ATM (ataxia-telangiectasia mutated), ATR (ATM and 
Rad3-related), and/or the CHK2 kinase (Ting and Lee 2004), which allows its re­
localization from transcriptional to DNA repair complexes (Parvin 2001). When 
BRCA1 interacts with DNA repair factors it forms a BRCA1-associated genome 
surveillance complex (BASC) that includes proteins involved in DSB repair, 
mismatch repair, DNA replication and recombination proteins (Wang, Cortez et al. 
2000).
If the DNA damage is too severe, the secondary response phase is activated. BRCA1 
is also involved in this second step of DSB pathway producing a delay in cell cycle 
progression and promoting the transcription of certain DNA repair and checkpoint 
genes (Mullan, Quinn et al. 2006). Indeed, BRCA1 has also been consistently linked 
to cell cycle control by producing cell cycle arrest at different phases. Several studies 
have supported a role for BRCA1 in the activation of p21 leading to Gl/S arrest (Li, 
Chen et al. 1999). BRCA1 is also required for intra-S and G2/M phase cell cycle 
checkpoints (Xu, Kim et al. 2001), in particular by inhibiting the transcription of 
cyclinB (MacLachlan, Somasundaram et al. 2000) and stimulating the production of 
a number of G2/M checkpoint regulatory genes (Yarden, Pardo-Reoyo et al. 2002).
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It is evident that BRCA1 is a multifunctional protein that can suppress tumor 
formation through numerous and important cellular mechanisms such as DNA repair 
pathway, cell cycle control and transcription regulation (Yoshida and Miki 2004). 
Even if all these diverse roles associated with BRCA1 are so general the loss of 
BRCA1 function leads to breast and ovarian cancer (Narod and Foulkes 2004). An 
aberrant transcriptional control by BRCA1 remains the principal explanation for the 
tissue specificity of these tumors. BRCA1 is transcriptionally associated with the 
repression of estrogen receptor (ERa) and its loss could lead to an increase in ERa 
levels, which in turn stimulates cellular estrogen metabolism (Yoshida and Miki 
2004). Further studies will provide a better understanding of the tumorigenic 
pathway involving the loss of BRCA1 and identify targets for treatment of breast and 
ovarian cancers.
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2 AIM OF THE PROJECT
Numerous studies have indicated that exonic mutations independently from their 
predicted effect on the aminoacid sequence can affect pre-mRNA splicing cis-acting 
regulatory sequences located within the same exon. As a result, every nucleotide 
variation must to be considered as a potential candidate to cause splicing alterations 
even if classified as missense, nonsense or translationally-silent (Cartegni, Chew et 
al. 2002; Pagani and Baralle 2004).
The aim of this thesis is to increase the present knowledge about the role of exonic 
sequences in splicing regulation and, moreover provide an explanation of the 
mechanism of exon skipping caused by exonic mutations.
The BRCA1 exon 18 system was chosen as a model in which a naturally occurring G 
to T mutation, at position +6, induces exon skipping. This research project was 
particularly focused on the role of ASF/SF2 in regulating normal and pathological 
BRCA1 exon 18 splicing and the characterization of cis-acting elements and the 
trans-acting factors involved.
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3 RESULTS
3.1 Regulatory role of ASF/SF2 on WT and T6 mutant BRCA1 exon 18 
splicing.
3.1.1 Analysis ofASF/SF2 binding specificity against WT and U6 mutant 
synthetic RNAs.
The exonic sequence of BRCA1 exon 18 from position +4 to +10 has been 
previously suggested to be an ESE that interacts with the ASF/SF2 splicing factor 
(Liu, Cartegni et al. 2001). Moreover, the natural G6 to T mutation was predicted to 
abrogate this ESE and consequently ASF/SF2 binding. However, this evidence was 
based mainly on a computer-assisted program (ESEfinder) and the in vitro analysis 
of a limited number of mutants (Liu, Cartegni et al. 2001).
To test directly the interaction between exon 18 and ASF/SF2 and evaluate the role 
of this splicing factor in the splicing regulation, a classical pull down assay was 
performed using as a targets two synthetic RNA oligonucleotides (20 nt) 
corresponding to the first part of exon 18 WT and U6 (Fig. 3.1.1 A). These two RNA 
were covalently linked via their 3’ end to agarose beads and incubated in a HeLa 
nuclear extract. Proteins that remained tightly bound to RNA, after the washing 
steps, were separated on a SDS-PAGE gel, transferred to PVDF filters and probed 
for the presence of ASF/SF2 with a specific antibody (Fig. 3.1.1B). The results in 
figure 3.1.1 show that WT and U6 mutant RNAs bind to ASF/SF2 with a similar 
efficiency. This experiment was performed three times and confirmed the absence of 
any significant difference in the binding affinity between the two RNAs. The data 
obtained by this in vitro binding assay showed that despite the presence of the 
mutation, ASF/SF2 binds to both exon 18 WT and U6 sequences with similar 
efficiency (Fig. 3.1.1B, lanes 2-3).
A
1 15
Wt ugcagAUGCUGAGUUUGUGU 
U6 ugcagAUGCUUAGUUUGUGU
B
NE WT U6
ASF/SF2
Figure 3.1.1: Western blot of pulldown analysis of BRCA1 exon 18 WT and U6 
RNAs to determine the binding of ASF/SF2.
(A) Nucleotide sequences, WT and U6, of BRCA1 exon 18 synthetic RNAs. Exonic 
and intronic sequences are shown in upper and lower case, respectively, and the 
mutated nucleotide U in position +6 is underlined.
(B) Western blot analysis of ASF/SF2. A pulldown experiment of BRCA1 exon 18 
WT and U6 RNAs was followed by western blot using an antibody against ASF/SF2. 
Both RNAs were able to pulldown ASF/SF2 equally (lane 2 and 3). The nuclear 
extract sample (NE) corresponds to l/20th of the amount used for the pull down 
assay. The pulldown picture is representative of three independent experiments. This 
pulldown analysis contains an intrinsic limitation due to the difficult normalization of 
the amount of RNAs among the different samples. This limitation can affect a 
precise quantification of the small differences in ASF/SF2 binding between the two 
samples (see the text).
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3.1.2 Analysis o f ASF/SF2 binding specificity against WT and U6 mutant and 
developing a new pulldown strategy.
The classical pulldown method used to test the binding capability of ASF/SF2 factor 
contains an intrinsic limitation due to the difficult normalization of the amount of 
RNAs among the different samples. In fact, the binding efficiency might be affected 
by erroneous quantification of the input RNA, to a different amount of 
oligonucleotides attached to the beads and/or to a higher level of degradation in one 
of the samples. All together these limitations can affect a precise quantification of the 
data, raising the possibilities that small differences in the binding efficiency among 
the samples cannot be detected.
In order to verify whether ASF/SF2 binds equally to the two RNAs, as observed 
(Fig. 3.1.IB, lanes 2-3), the original pull down methodology was improved by 
including an “internal control” for the amount of RNA used during the experiment. 
In this case, the progress made on the pulldown technique was the possibility to 
normalise the amount of RNA that remains linked to the agarose beads. The two 
target sequences, WT and T6 BRCA1 exon 18, were linked to a UG motif already 
described in literature to be bound efficiently by the specific protein TDP43 (Buratti, 
Dork et al. 2001). This protein contains two RNA recognition motif (RRM) domains 
with distinct RNA/DNA binding characteristics and has a high affinity for single­
stranded UG stretches, starting from a minimum number of six UG (or TG), and 
increasing its affinity together with the number of repeats (Buratti and Baralle 2001). 
As reported in detail in figure 3.1.2A, we transcribed in vitro a RNA that comprise: 
the first part of BRCA1 exon 18 WT or U6, a (U)s spacer and a sequence composed 
by six UG dinucleotide repeats. The two transcribed RNAs were linked to agarose 
beads via 3’ end and incubated in a HeLa nuclear extract.
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^  1 15
GUGuWGUGUGUuuuuuugcagAIJGCIJGAGXJUUGIJGlJ—  Wt
Gt7GC7Gt7Gt7Gt7GOuuuuuugcagAUGCUUAGUUUGUGU —  U6
(  A S F /S F 2 )
GUGUGC/GC/Gt/Gt^uuuuGCACCUGAUGGUGAAGAAGACACUGCAGAGC —  EDA
B Uo«trfead ONA 1. In vitro transcribed 
RNA
Ic
2. Binding to adipic acid 
dehydrazide beads
Incubation with 
protein extractI
4. repeated cycles of 
centrifugation and washing
5. SDS-PAGE analysis
6. Western Blot 
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2nd Ab HRP
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V TDP43
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A SF/SF2
Figure 3.1.2: Modified pulldown analysis (see the chapter 3.1.2)
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Proteins that remained tightly bound to RNA after the washing steps were separated 
on SDS-PAGE gel, transferred to PVDF filters and probed for the presence of the 
target protein with specific antibodies (Fig. 3.1.2B). During the pulldown assay, the 
UG repeats, present in each RNA, are specifically recognised by TDP43. By 
performing western blot against this protein, the pulldown was normalized for the 
RNA amount. Subsequently, the membrane was probed for ASF/SF2 (Fig. 3.1.2C). 
This new strategy gave the opportunity of precisely comparing the different samples 
analysed to the TDP43 standard binding.
As reported in figure 3.1.3, the pull-down assay was followed by Western blot 
probed with ASF/SF2 and TDP34 antibodies. Relative to the signal of TDP43 the 
WT and U6 mutant RNAs bound to ASF/SF2 with a similar efficiency (Fig. 3.1.3B, 
lanes 2-3). Moreover, including an ASF/SF2 purine-rich enhancer as a positive 
control allowed the binding capability of the BRCA1 sequences to be estimated. In 
this case, the UG motif was linked to a previously described enhancer sequence 
located in the alternatively spliced fibronectin EDA exon (Lavigueur, La Branche et 
al. 1993; Caputi, Casari et al. 1994). This positive control clearly indicated a lower 
binding capability of ASF/SF2 for both exon 18 WT and U6 sequences (Fig. 3.1.3B, 
lane 1 vs. lanes 2-3). These results are in accordance with the data obtained with the 
classical pull down carried out with synthetic RNAs and suggest that the U6 
mutation does not disrupt an ASF/SF2 binding site. Both sequences can bind to 
ASF/SF2 with lower efficiency in comparison to a classical ASF/SF2 enhancer.
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A (J D P 4 3 )
(UG)6 - (u)5 -  ugcagAUGCUGAGUUUGUGU - WT
(UG)6 - (u)5 -  ugcagAUGCUUAGUUUGUGU - U6
(UG)6 - (u)5 - GCACCUGAUGGUGAAGAAGACACUGCAGAGC - EDA
B
NE EDA WT U6
ASF/SF2
TDP43
Figure 3.1.3: Western blot of pull-down analysis anti-ASF/SF2 normalized for 
TDP43 binding.
(A) Schematic representation of the in vitro transcribed RNA sequences that contain 
(UG)6 repeats, (U)5 spacer, part of intron 17 (lower case) and the first nucleotides of 
exon 18 WT and U6 mutant (upper case). The substituted nucleotide is underlined. 
The bottom lane shows the EDA sequence, linked to the UGs and Us repeats, used as 
positive control for ASF/SF2 binding. (B) Binding analysis of ASF/SF2 protein. 
After in vitro transcription, RNA was pulled down and Western blot analysis was 
carried out using ASF/SF2 and TDP43 antibodies. TDP43, in this case, was used to 
normalize the assay for the amount of RNA. Both WT and U6 RNAs were able to 
pulldown ASF/SF2 protein although with less efficiency if compared with the EDA 
positive control. The nuclear extract sample (NE) corresponds to l/20th of the 
amount used for the pull down assay. The pulldown picture is representative of three 
independent experiments. As the picture shows, both WT and U6 RNA are able to 
pull down ASF/SF2 protein. The WT and U6 bind approximately only 10% of 
ASF/SF2, compared to the EDA sample and normalized for TDP43. The binding was 
determined by the evaluation of the relative intensity of the bands.
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3.1.3 Evaluation of WT and T6 mutant BRCA1 exon 18 splicing efficiency by 
hybrid minigenes.
The G to T substitution at the exonic position +6 was previously reported to induce a 
significant BRCA1 exon 18 skipping in patients derived cells (Mazoyer, Puget et al. 
1998). A functional splicing analysis was carried out in order to evaluate in vivo the 
effect of this mutation and to study in detail its disease-causing mechanism. For this 
purpose, I prepared two hybrid minigenes (Fig. 3.1.4). The hybrid minigene (pTB), 
previously used in other studies focused on aberrant splicing (Muro, Caputi et al. 
1999; Pagani, Buratti et al. 2002; Pagani, Stuani et al. 2003), was the first system 
chosed to investigate the regulation of BRCA1 exon 18 splicing. The pTB hybrid 
minigene was generated by cloning the genomic DNA fragment of exon 18 (78 bp) 
including part of the flanking intron 17 (292 bp) and intron 18 (240 bp) into a 
construct consisting of the a-globin and fibronectin intron-exon sequences (Fig. 
3.1.4A). In the second minigene developed, pBRA, exon 18 was placed in a more 
physiological context. The amplified region from BRCA1 gene also included introns 
17 (the size was reduced from 3655 bp to 1857 bp to facilitate the cloning step), the 
entire intron 18 and parts of exon 17 and 19 were cloned in the context of a-globin 
three exons minigenes (Fig. 3.1.4B). Furthermore, to facilitate the subsequent 
mutagenesis analysis, a unique restriction EcoRI site was introduced within the 
intron 18 sequence of both minigenes (see materials and methods).
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A pTB WT
BRCA1
IVS17
Ndel-  Pstl
E D B -1
292bp
IVS18
EcoRI . Ndel
Ex 18
78bp 240bp EDB+1
B pBRA WT
BRCA1
IVS17 IVS18
Ndel Pstl EcoRINdel
1408bp 325bp
Ex 18
Figure 3.1.4: Schematic representation of the hybrid minigene systems.
(A) Schematic representation of the pTB hybrid minigene system. Dark grey, shaded 
and white boxes respectively represent a-globin, fibronectin EDB exons and human 
BRCA1 exon 18, with introns shown as thick lines. Exon 18 and parts of its flanking 
introns were cloned in the pTB plasmid using the restriction enzymes Ndel. 
Transcription is under the control of the minimal a-globin promoter and SV40 
enhancer (big arrow at the 5’-end). The small black superimposed arrows represent 
the position of the primers used for the RT-PCR analysis after transient transfection 
of the minigene. The grey dotted lines show exon 18 splicing, inclusion and 
exclusion forms of mRNA. The position of unique Pstl and EcoRI restriction sites 
used for subsequent cloning is shown.
(B) Schematic representation of the pBRA hybrid minigene system. Dark grey and 
white boxes represent a-globin and BRCA1 exons, respectively. In this case EDB 
exons where replaced by part of exon 17 and exon 19 with flanking intronic 
sequences (IVS). The length of BRCA1 sequences is shown; the size of intron 17 
was reduced from 3655 nt to 1857 nt to facilitate the cloning procedure. The large 
black arrow at the 5’ end indicates the minimal a-globin promoter and SV40 
enhancer. And the two small arrows show the primers position used for RT-PCR. 
The two alternative splicing possibilities, exon 18 inclusion and exclusion, are 
indicated by dotted lines. The position of the unique Pstl and EcoRI restriction sites 
used for subsequent cloning are reported.
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As a first approach, both the pTB and pBRA systems were tested for the ability to 
reproduce the exon 18 WT and the T6 splicing pattern, as described in patients cells 
(Mazoyer, Puget et al. 1998). By site-directed mutagenesis a T substitution in 
position +6 of exon 18 was inserted in both pTB and pBRA minigenes (Fig. 3.1.5A). 
Transient transfection of WT and mutated constructs was performed in Hep3B cells 
and the transcrips derived were analysed by RT-PCR amplification with specific 
primers. The primers ALFA 2-3 and BRA 2 were used for the pTB while the BRC 90 
and GLO 800 were specific for the pBRA transcript. The PCR products showed the 
presence of a unique band of 336 bp for the pTB WT minigene (Fig. 3.1.5B, lane 1) 
and a band of 244 bp for pBRA WT construct (Fig. 3.1.5C, lane 1), both 
corresponding to the fully included exon 18 in the mature transcript. This experiment 
was performed in triplicate and the subsequent sequence of the band confirmed the 
full BRCA1 exon 18 inclusion.
As expected, no transcript corresponding exon 18 skipping was detectable in the WT 
splicing profile and no endogenous-derived BRCA1 PCR products were observed.
In the case of both minigenes carrying the T6 substitution two amplified bands were 
generated. The sequence of the purified PCR products showed that the upper band 
corresponded to BRCA1 exon 18 full included and the lower band to the complete 
exon exclusion from the mRNA. In Hep3B the pTB T6 minigene showed 50 % of 
exon 18 inclusion (Fig. 3.1.5B, lane 2) whereas the T6 mutated exon 18 placed in the 
pBRA context was predominantly skipped, with only 20% of it being included (Fig. 
3.1.5C, lane 2). Both minigenes were able to mimic the exon skipping effect of the 
T6 mutant described in vivo. Experiments were then performed on pBRA as it 
contains the more physiological context and showed slightly higher exon skipping.
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Figure 3.1.5: BRCA1 exon 18 +6 G>T is a splicing mutation.
(A) Schematic representation of the exon 18. In the lower part of the picture, a few 
bases from intron 17 (lower case) and exon 18 (from position +1 to +14) are shown, 
divided in codon triplets (upper case). The G to T natural mutation (E1694X) in 
position +6 is indicated (Mazoyer, Puget et al. 1998).
(B) (C) Splicing pattern analyses of the RT-PCR products derived from RNA of 
transfected cells, separated on a 2% agarose gel. The T6 mutation affects the exon 18 
inclusion in both minigenes context. Two products are seen on agarose 
electrophoresis, with the lower band representing a product lacking exon 18 and the 
upper band representing a product including exon 18, as indicated schematically on 
the right of both gels. The WT exon 18 is fully included in each construct (lanes IB 
and 1C). The T6 exon 18 is excluded in both minigenes in different amount 
depending on the surrounding minigene context (lanes 2B and 2C). The percentages 
of exon 18 inclusion, obtained from three independent transfections, are indicated 
below each lane number.
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3.1.4 Effect o f ASF/SF2 in vivo overexpression on BRCA1 exon 18 WT and T6 
splicing.
The in vitro pulldown analysis showed that ASF/SF2 binding is not affected by the 
presence of +6 G to T mutation within BRCA1 exon 18 (Fig. 3.1.1 and 3.1.3). On the 
other hand, accordingly to the ESEfinder prediction, the presence of the T6 mutation 
abrogates the ASF/SF2 binding site within the BRCA 1 exon 18 sequence. Thus, we 
decided to investigate the effect of ASF/SF2 on the BRCA1 exon 18 splicing 
regulation in co-transfection experiments.
The ASF/SF2 coding plasmid (+), or the empty vector (-) as a control, were 
transfected together with the pBRA minigenes, WT or T6 mutant. Total RNA was 
extracted and a RT-PCR was carried out with a specific primer set and the amplified 
products were analysed by electrophoresis on agarose gel (Fig. 3.1.6). Surprisingly, 
overexpression of ASF/SF2 in cells transfected with the pBRA T6 plasmid showed 
an increase in the percentage of exon 18 inclusion. The experiment was repeated 
three times and the the percentage of exon 18 inclusion increased from 20% up to 
55% in the presence of ASF/SF2 (Fig. 3.1.6, lanes 3-4). The cotransfection of the 
empty expression vector did not affect the splicing of pBRA T6 trascripts which 
showed the same profile of exon 18 skipping (Fig. 3.1.6, lane 3). A positive effect 
was not detectable for the exon 18 WT minigene that is already fully included in the 
absence of ASF/SF2 overexpression (Fig. 3.1.6, lanes 1-2). In conclusion, 
cotransfection of ASF/SF2 induced a significant increase in the percentage of exon 
18 inclusion in the T6 mutant context, whereas no effect was detected for the WT.
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A
WT T6
ASF/SF2 " + - +
ex18 + 
ex18 -
100 100 20 55 % ex18+
Figure 3.1.6: In vivo over-expression of ASF/SF2 promotes T6 exon 18 
inclusions.
(A) HeLa cells were transiently transfected with WT or T6 pBRA minigenes as 
indicated, along with ASF/SF2-coding plasmid (+), or with the empty vector (-). 
Splicing patterns were analysed by separating the RT-PCR products on agarose gel. 
The identity of the transcripts, exon 18 inclusion (ex 18+) and exon 18 exclusion 
(ex 18-), is shown schematically at the right side of the gel. The percentages of exon 
18 inclusion, obtained from three independent transfections, are reported below each 
lane. Although quantification of ASF/SF2 was not performed in this specific 
experiment, the ASF/SF2- coding plasmid was previously used in other similar over­
expression assays (Caceres, Stamm et al. 1994; Pagani, Buratti et al. 2003; Pagani, 
Stuani et al. 2003).
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3.1.5 Effect o f in vivo siRNA mediated depletion of ASF/SF2 on BRCA1 exon 18 
WT and T6 splicing
In the co-transfection experiment the T6 mutated exon 18 exclusion was partially 
recovered by ASF/SF2 overexpression, suggesting a possible role of this protein in 
the T6 splicing regulation. If this were the case, the specific knock down of ASF/SF2 
would be expected to increase the ratio of the mRNA species that skip exon 18 
carrying the T6 mutation.
The in vivo depletion of ASF/SF2 was obtained by transient siRNA treatment of 
HeLa cells. In order to test whether the siRNA effectively reduces the ASF/SF2 
expression we checked the siRNA oligonucleotides effect on protein level. The 
experiments were performed in HeLa cells because they showed an efficient 
ASF/SF2 siRNA-mediated depletion. After this treatment, cell lysates were collected 
and analyzed by western blot assay for ASF/SF2 protein expression. In cells 
transfected with siRNA(+), but not cells treated with luciferase siRNA (-), we 
observed a strong reduction in the ASF/SF2 levels. The expression of a housekeeping 
gene (tubulin) was also checked by western blot, as control (Fig. 3.1.7A, lanes 1-2). 
Once verified the effective depletion of ASF/SF2, the WT and T6 pBRA constructs 
were transfected in siRNA treated cells. After 48 h cells were collected and divided 
in two samples: one for detect the level of endogenous ASF/SF2 by western blot and 
the second for the analyses of the splicing pattern by RT-PCR. The RNA analysis 
showed that ASF/SF2 depletion induced a nearly complete exclusion of T6 exon 18 
from the mature mRNA. The percentage of exon 18 inclusion decreased from 20% in 
the case of the control to quite total exon exclusion in ASF/SF2 depleted cells (Fig. 
3.1.7B, lanes 3-4). On the contrary, WT BRCA1 exon 18 did not respond to 
ASF/SF2 depletion, showing complete exon inclusion (Fig. 3.1.7B, lanes 1-2). As
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internal control for ASF/SF2 depletion, the endogenous RNA of Ron gene was 
analysed by RT-PCR. It was previously reported that the Ron exon 11 splicing is 
regulated by the ASF/SF2 factor. Overexpression of ASF/SF2 induces skipping of 
exon 11 promoting the production of the Delta Ron protein, a constitutive active 
isoform of the tyrosine kinase receptor for the macrophage stimulating protein. Vice 
versa, low levels of ASF/SF2 obtained by siRNA experiments are accompanied by 
the inclusion of exon 11, which leads to the production of the full-length Ron mRNA 
(Ghigna, Giordano et al. 2005).The RT-PCR performed as a control on the 
endogenous RON showed an increase in exon inclusion from 15% to 45% (Fig. 
3.1.7C, lane 1-2), confirming that the removal of ASF/SF2 protein from HeLa cells 
affected the splicing of an endogenous transcript.
The in vivo analysis results, together with the pull down data, do not support the idea 
of ASF/SF2 binding disruption due to the T6 mutation within exon 18.
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Figure 3.1.7: In vivo depletion of ASF/SF2 induces T6 exon 18 skipping.
(A) The upper panel shows the western blot analysis of protein extracts from HeLa 
cells treated with either ASF/SF2 siRNA (+) or a control siRNALuc (-). The 
normalization of the protein loaded was checked using an antibody against tubulin, 
as reported in the lower panel. The siRNA experiment is representative of at least 
three independent experiments. (B) The gel picture shows the RT-PCR products 
after transfection of the WT or T6 pBRA plasmid minigenes into ASF/SF2 siRNA- 
treated (+) and luciferase control-treated (-) HeLa cells. On the right of the gel is 
reported the mRNA processing outcomes. An increase of T6 exon 18 skipping was 
observed in the siRNA treated cells (lane 3). The percentage of BRCA1 exon 18 
inclusion is indicated below each lane. (C) RT-PCR analysis performed on 
endogenous RON as internal control for the siRNA treatment. Two splicing products 
were seen after the amplification of the RNA: the upper band includes RON exon 
while the lower band ARON that lacks this exon. Note that the removal of ASF/SF2 
rescues partially the RON inclusion (lane 1) as previously reported (Ghigna, 
Giordano et al. 2005).
Tubulin
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3.2 Mapping of the splicing regulatory element within BRCA1 exon 18.
3.2.1 Single point mutation analysis o f the exon 18 regulatory element.
To assess the relationship between the exonic regulatory regions and exon 18 
skipping, I investigated the splicing contribution of the cis-acting elements 
surrounding the position +6. If the region analyzed is a pure enhancer element, the 
majority of the single substitution at this element is expected to destroy its function 
and leads to exon 18 skipping. For this purpose a large panel of pBRA minigenes, 
with a series of single point mutations from position +4 to +11, was constructed by 
PCR with specific primers on pBRA WT as template (Fig. 3.2.1 A). All the 
substitutions were introduced within the region that matches with the putative 
ASF/SF2 enhancer binding site predicted by the ESEfinder program, from position 
+4 to +10 (Liu, Cartegni et al. 2001). A total number of 21 minigenes was generated 
substituting each nucleotide position with the three possible alternatives. The 
minigenes were transfected into Hep3B cells, analyzed by RT-PCR and the splicing 
pattern evaluated on agarose gel. As a control pBRA WT minigene was also included 
in the experiment (Fig. 3.2.IB).
Interestingly, out of 21 substitutions only the natural mutant T6 resulted in a very 
low level of exon 18 inclusion of about 25 % (Fig. 3.2. IB, lane 10).
Two additional single substitutions in position +4 (T4) and +6 (A6) partially affected 
the splicing pattern, causing 90 % and 80% of exon 18 inclusion, respectively (Fig. 
3.2.1B, lanes 4, 8). The majority of the mutants (18 out of 21) showed the same 
pattern of the WT construct with complete exon inclusion.
Thus, the systematic site-direct mutagenesis showed a very few number of exon 18 
skipping mutants, suggesting that the BRCA1 exon 18 region surrounding the +6 
position does not behave like an exonic splicing enhancer.
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Figure 3.2.1: Single point mutation analysis of the exon 18 putative regulatory 
region.
(A) Schematic representation of the BRCA1 exons and introns cloned in the pBRA 
minigene. Part of intron 17 and BRCA1 exon 18 sequences are shown in lower and 
upper case, respectively. The predicted Exonic Splicing Enhancer (Liu, Cartegni et 
al. 2001), putative binding site for ASF/SF2, is boxed in light grey. The black 
arrows, from position +4 to +11, indicate the nucleotide where the all three possible 
single point mutations were introduced.
(B) Splicing pattern analysis. The agarose gel shows the RT-PCR products of WT 
and mutants minigenes after transient transfection into Hep3B cell line. The position 
of the two splicing forms corresponding to exon 18 inclusion (ex 18+) and exclusion 
(ex 18-) are indicated on the right of the picture. The grey boxes highlight the mutated 
nucleotides that induced exon skipping (lane 4, 8 and 10) and percentage of exon 18 
inclusion is indicated below each lane. All the other mutants analysed that do not 
affect the proper exon 18 recognition are considered 100%.
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3.2.2 Double point mutation analysis o f the exon 18 splicing regulatory element.
The analysis with the single site-directed mutagenesis was more compatible with the 
creation of a negative element by the T6 substitution rather than the abrogation of a 
pre-existing enhancer sequence. Previous studies of another splicing mutation, 
described in the SMN2 exon 7 (Kashima and Manley 2003) and Dystrophin exon 31 
(Disset, Bourgeois et al. 2006), demonstrated that the mechanism of exon skipping 
could be due to the creation of a silencer element. In the BRCA1 exon 18 model, the 
only mutation able to produce a high percentage of exon skipping was the T6 natural 
mutation, suggesting a negative effect of this substitution on the correct exon 
definition.
In order to map this putative silencer element within BRCA1 exon 18, a series of 
point mutations from position +4 to +9 were introduced in the context of T6 
substitution (Fig. 3.2.2A). The nucleotides substitutions were inserted by site- 
directed mutagenesis by PCR on pBRA T6 as template. The resulting minigenes 
were transiently transfected into Hep3B cells, and analysed by RT-PCR. The splicing 
profile of each double mutant was compared to the pattern of the pBRA T6 plasmid. 
As shown in figure 3.2.2B, the double mutants’ analysis resulted in a variable 
splicing pattern. The majority of the double site-directed variants increased the 
splicing efficiency compared to the single T6 minigene. In particular, all the 
substitutions in position +7 and +8 restored almost completely the exon 18 inclusion 
(Fig. 3.2.2B, lanes 9-14). Also the three mutants in position +5 and two in position 
+9 (T6A9 and T6C9) increased partially the splicing of exon 18, showing a 
percentage of exon inclusion of an average of 60% (Fig. 3.2.2B, lanes 6-8, 15 and 
16). The only double mutant that did not show any effect was the T6G9, with a 
splicing pattern comparable with the single mutant T6, with only 20% of exon
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inclusion (Fig. 3.2.2B, lane 17). On the contrary, the substitutions at positions +4 
inserted in the context of the T6 natural variant resulted in a complete exon 18 
exclusion (Fig. 3.2.2B, lanes 3-5). This systematic double point mutation analysis 
strongly suggested that the naturally occurring mutation T6 creates a sequence with 
splicing inhibitory properties. In particular, we noticed that the presence of a TAG 
sequence in position +6 to +8 is essential for splicing inhibition. All mutations within 
this sequence restored exon 18 inclusion, supporting the hypothesis that this triplet 
plays an inhibitory role. Thus, the TAG at position +6 therefore appears to be the 
core” silencer element involved. The function of TAG motif in splicing silencing has 
been previously related to hnRNP A1 (Burd and Dreyfuss 1994; Del Gatto, Gesnel et 
al. 1996). The above results showed that the most of the tested mutations promote 
exon 18 inclusion suggesting that the BRCA1 exon 18 splicing, carrying the T6 
mutation, is inhibited because of a silencer element.
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Figure 3.2.2: Double point mutation analysis of the exon 18 putative regulatory 
region.
(A) BRCA1 exons and introns cloned in the pBRA minigene are schematically 
reported. Part of intron 17 and BRCA1 exon 18 sequences are reported in lower and 
upper case, respectively. The positions of single point mutations, all introduced in the 
context of the 6T exon 18 sequence, are indicated by black arrows. The position of 
the double mutation +10A/+11G is also indicated below the sequence and it was the 
only one introduced in the exon 18 context.
(B) Splicing pattern analysis. The constructs were transiently transfected into Hep3B 
cells and the total RNA analysed by RT-PCR. The two splicing possibilities are 
indicated on the right of the gel. The mutations that create a stop codon are marked 
by an asterisk (lanes 2, 12 and 18). The majority of the mutants analysed restored 
partially or totally exon 18 inclusion compare to the T6 mutant. The mutants in 
position +4 further increase exon 18 exclusion. The percentages of BRCA1 exon 18 
inclusion are reported below for every mutant analysed.
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3.2.3 Analysis o f silencer sequences in the BRCA1 exon 18 context.
Whereas single mutations had no significant effect in the exon 18 WT splicing, most 
of the double point mutations restored exon 18 inclusion in the presence of the T6 
substitution. These results would not be expected if the mutated element were part of 
an ESE. Vice versa, these data are consistent with the hypothesis that the G to T 
transversion creates a negative-acting ESS within BRCA1 exon 18. This putative 
silencer sequence contains a TAG motif, previously identified in hnRNP 
A 1-dependent ESS either by characterizing other gene sequences (Kashima and 
Manley 2003; Disset, Bourgeois et al. 2006; Kashima, Rao et al. 2007) either by 
performing hnRNP A l SELEX analysis (Burd and Dreyfuss 1994). On the base of 
these previous data, we wanted to evaluate the effect of two known negative splicing 
regulatory sequences in the pBRA minigene context: the “TAGACA” from the 
SMN2 gene, exon 7 (Kashima and Manley 2003; Kashima, Rao et al. 2007) and the 
“TAGGGA” hnRNP A l SELEX motif (Burd and Dreyfuss 1994). As a control, we 
also cloned the sequence of SMN1 (CAGACA) that should not have any inhibitory 
effect on splicing process. The sequences were inserted by PCR site-directed 
mutagenesis in the region from position +6 to +11 (Fig. 3.2.3A). The resulting hybrid 
minigenes were transiently transfected into Hep3B cells, and the splicing patterns 
analysed by RT-PCR. Exon 18 splicing was affected by the insertion of the selex A l 
sequence at the same level as the T6 mutant, showing 20% of exon inclusion (Fig. 
3.2.2B, lane 5). The SMN2 sequence in pBRA context showed a lower but still 
negative effect with 50% of exon 18 inclusion, whereas the control SMN1, which 
does not contain TAG, did not affect mRNA processing (Fig. 3.2.3B, lanes 4 and 3, 
respectively). The presence of these heterologous silencer sequences within BRCA1
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exon 18 mimicked the effect of the original exonic regulatory element containing the 
T6 mutation.
A deletion from position +4 to +9 of exon 18 was also evaluated in the pBRA A4-9 
construct. The analysis of the PCR product of the pBRA A4-9 did not show any 
variation in the splicing pattern in comparison with pBRA WT (Fig. 3.2.3B, lane 6) 
further ruling out the presence of a strong enhancer at the 5’ end of exon 18.
As the G to T mutation in position +6 creates a premature termination codon within 
the exon coding sequence, we compared the results obtained with other mutants that 
also introduce a stop codon. This was done in order to exclude the potential 
involvement of the NMD pathway in the T6 exon 18 splicing. Thus, we compared 
the single T6 mutation with other mutations that created a stop codon within the exon 
18 sequence. In particular two double mutations, T6A8 and 10A11G, and the A4-9 
deletion create premature termination codons. In this case, and in contrast to the T6 
mutant, the functional splicing analysis showed a complete inclusion of the exons 
(Fig. 3.2.2B, lanes 12 and 18; Fig. 3.2.3B lane 6). BRCA1 exon 18 stop codon and 
their role in triggering mRNA degradation was also recently studied (Perrin-Vidoz, 
Sinilnikova et al. 2002). In this analysis, performed by blocking translation with 
puromycin treatment, they showed that the steady-state level of mRNA carrying the 
T6 mutation in vivo was not affected (Perrin-Vidoz, Sinilnikova et al. 2002) 
indicating that this nonsense mutation did not trigger by NMD degradation.
Collecting the data obtained the single mutation G to T at position 6 of BRCA1 exon 
18 is not involved in exon 18 splicing by creating a silencer element.
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Figure 3.2.3: Analysis of silencer sequences in the BRCA1 exon 18 context.
(A) A scheme of BRCA1 exons and introns cloned in the pBRA minigene is 
reported. Part of BRCA1 intron 17 (lower case) and exon 18 (upper case) sequences 
are reported. The mutated nucleotides for each construct are highlighted in bold and 
the deleted region from position +4 to +9 is represented by dotted lines.
(B) Splicing pattern analysis. RT-PCR products of transfected Hep3B cells were 
separated on agarose gel. The position of the exon 18 inclusion and exclusion bands 
is indicated schematically on the right. The pBRA-SMN2 and selex A1 minigenes 
produced exon 18 skipping whereas SMN1 and A4-9 variants do not affect exon 18 
recognition. The percentages of BRCA1 exon 18 inclusion are indicated below each 
lane.
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3.2.4 Lack o f Correlation between ASF/SF2 SR Protein Score Matrix and 
BRCA1 Exon 18 Splicing
In some exons, the SR protein score motif has been found to correlate with splicing 
efficiency, therefore raising the possibility of predicting the effect of single base 
substitutions on exon skipping (Liu, Cartegni et al. 2001; Cartegni, Chew et al. 
2002).
The ASF/SF2, SC35, SRp40 and SRp55 motif-scoring matrices were used to analyse 
the entire BRCA1 exon 18 WT and T6 mutant sequences (Cartegni, Wang et al. 
2003). The ESEfinder output showed multiple high-score motifs (3 matches for 
ASF/SF2, 2 for SC35, 1 for SRp40, and 4 for SRp55) distributed throughout the 
exon. The G to T substitution at position +6 specifically disrupts the first of three 
high-score ASF/SF2 motifs, reducing the score from 2.143 to 0.079 (below the 
threshold). ESEfinder program was also used to calculate ASF/SF2 dependent ESE 
motif scores of all the mutants analysed by functional splicing assay in order to test a 
possible correlation between the in silico approach versus the in vivo results (Table 
3.2.1).
As reported in figure 3.2.IB, only three single mutants, T6, A6 and T4 affected the 
splicing of BRCA1 exon 18, leading to different percentage of exon skipping. All the 
three single substitutions disrupted the first high-score ASF/SF2 motif and, as 
predicted by the ESEfinder, produced exon 18 skipping. On the contrary, the 
program identified a higher number of single mutations able to disrupt the first 
predicted ASF/SF2 binding site, which did not correlates with the in vivo results. The 
majority of the mutants (18 out of 21) splicing pattern were not distinguishable from 
the WT construct showing complete exon 18 inclusion. The opposite situation was 
detected when the double mutants were searched for the ASF/SF2 high score motif.
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In this case even though the substitutions in position +7 and +8, in the pBRA T6 
context, restored almost completely the exon 18 inclusion the ESEfinder analysis 
predicted the disruption of the first ASF/SF2 binding site, in position +4. In addition 
three mutants in position +5 (T6A5, T6C5, T6G5) and two in position +9 (T6A9 and 
T6C9) that increased the correct splicing of exon 18, reaching a percentage of exon 
inclusion of an average of 60%, were not recognised by the program as putative 
ASF/SF2 binding site. On the other hand, the T6G9 double mutant that showed a 
splicing pattern comparable with the single mutant T6 (only 20% of exon inclusion), 
did not correlate with the predicted positive ASF/SF2 score value. The only evident 
correlation was obtained for the double mutants in position +4 (T6A4, T6G4, T6T4) 
in which the total skipping of exon 18 reported in vivo was in agreement with the 
under threshold ASF/SF2 score calculated by the program. SMN1 sequence had a 
good match for ASF/SF2 motif and gave total exon 18 inclusion. The other two 
hybrid sequences analyzed, SMN2 and selexAl, correlated with the prediction, 
showing low level of exon inclusion and lower score for ASF/SF2 binding. When the 
putative ESE was totally removed, in the A4-9 construct, as expected the ESEfinder 
program predicted the disruption of ASF/SF2 score value but in vivo the exon was 
fully recognized and included in the pre-mRNA.
All the results reported in the table 3.2.1 indicate that the currently available SR 
protein high score motifs does not explain the complex regulation of BRCA1 exon 
18 and, in this context, any individual change in SR motif score cannot predict the 
splicing efficiency. We did not find any consistent correlation between in vivo 
splicing pattern and the ESEfinder prediction.
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Table 3.2.1
Minigene(a) Sequence^ % Exon 18 incIusion(c)
SF2/ASF(d)j 
Thr= 1.956 |
WT ATGCTGAGTTTGTG 100% 2.142(4) |
A4 ATGATGAGTTTGTG 97% -0.362(4) |
G4 ATGGTGAGTTTGTG 100% 0.566(4) |
T4 ATGTTGAGTTTGTG 90% -0.807(4) |
A5 AT GCAGAGTTTGTG 99% 3.265(4)1
C5 ATGCCGAGTTTGTG 100% 1.540(4)
G5 ATGCGGAGTTTGTG 99% 2.818(4)1
A6 ATGCTAAGTTTGTG 80% 0.079(4)1
C6 ATGCTCAGTTTGTG 47% 2.389(4) 1
T6 ATGCTTAGTTTGTG 98% 0.079(4))
C7 ATGCTGCGTTTGTG 100% 1.149(4)|
G7~ rAfGCTGGGTTTGTG 98% -0.766(4) 1
T7 ATGCTGTGTTTGTG 97% -0.308(4) |
_ _ _
rATGCTGAATTTGTG 96% 0.223(4)
C8 ATGCTGACTTTGTG 98% 2.747(4) |
T8 ATGCTGATTTTGTG 100% 0.223(4) i
A9 ATGCTGAGATTGTG 100% 1.685(4)|
C9 ATGCTGAGCTTGTG 99% 1.685(4) |
G9 ATGCTGAGGTTGTG 100% 4.263(4) 1
A10 ATGCTGAGTATGTG 96% 2^6(4)!
G10 ATGCTGAGTGTGTG 95% 1.769(4) 1
G il ATGCTGAGTTGGTG 98% 2.142(4)|
T6A4 ATGATTAGTTTGTG 1%
T6G4 ATGGTT AGTTTGTG 0% -1.498(4)
T6T4 ATGTTTAGTTTGTG 0% -2.871(4) 1
T6A5 ATGCATAGTTTGTG 54% 1.202(4) I
T6C5 ATGCCTAGTTTGTG 68% -0.524(4) 1
T6G5 ATGCGT AGTTTGTG 78% 0.754(4) |
T6C7 ATGCTTCGTTTGTG 98% -0.914(4)1
T6G7 ATGCTTGGTTTGTG 95% -2.829(4) I
T6T7 ATGCTTTGTTTGTG 92% -2.371(4) 1
T6A8 ATGCTTAATTTGTG 100% -1.840(4)1
T6C8 ATGCTTACTTTGTG 98% 0.683(4) 1
T6T8 ATGCTTATTTTGTG 96% -1.840(4)1
T6A9 ATGCTT AGATTGTG 66% -0.378(4)1
T6C9 ATGCTT AGCTTGTG 57% -0.378(4)
T6G9 ATGCTT AGGTTGTG 25% 2.199(4)1
SMN1 ATGCTCAGACAGTG 96% 3.038(6)1
SMN2 ATGCTTAGACAGTG 45% -2.232(4)
selexAl ATGCTT AGGGAGTG 23% 1.826(4)
A4-9 ATG----- TTGTG 98% -3.632(4)J
SR High-score motifs (a) The 41 minigenes used in transfection experiments, in the 
same order as they are reported in the figures, (b) Nucleotide sequence from position 
+1 to +14 around the putative ESEmotifs. The mutated nucleotides are reported in 
bold.(c) Average of exon 18 inclusion percentages (d) ASF/SF2 score. High-score 
motifs are shown in black whereas the lower-scores are reported in red. The 
threshold value is 1.956. (e-f) SC35 and SRp55 new binding sites. The high-score 
values acquired by the presence of the mutations are reported.
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3.3 Identification of nuclear proteins binding to the splicing regulatory 
element of the BRC Al exon 18 T6 mutant.
3.3.1 Pull down assay and identification o f splicing factors differentially binding 
to BRCA1 exon 18 WT and U6 RNAs.
Based on the systematic mutagenesis, the T6 mutation seems to create a sequence 
with silencer properties. This negative sequence may bind one or more splicing 
factors with an inhibitory role in the BRCA1 exon 18 splicing regulation. In order to 
identify specific trans-acting factor(s) binding to BRCA1 exon 18 T6 mutant I 
performed a RNA pull-down analysis. The pull down experiment was carried out 
using the two synthetic RNA oligonucleotides (20nt) corresponding to the first part 
of exon 18 and containing either the WT or the natural U6 mutation (Fig. 3.3.1 A). 
These small RNAs were covalently linked to adipic acid dehydrazide agarose beads 
via 3’ end and incubated with HeLa nuclear extract. After the washing steps the 
proteins, tightly bound to the RNA, were separated on SDS-PAGE gel and visualized 
by Coomassie Blue staining. The figure 3.3.IB shows the result of pull down assay 
after Coomassie staining in which most of the bands were present in both WT and 
U6 sequences. Interestingly, the U6 exon 18 RNA showed two bands not present in 
the WT lane. Vice versa, no additional bands were specifically detected to bind the 
WT sequence. The two specific bands with an apparent molecular weight of -50 and 
38 kDa were excised from the gel and sequenced using electrospray mass 
spectrometric analysis. Next, a database search revealed that the band of 35 kDa was 
a doublet corresponding to both hnRNP A l and its close homologue hnRNP A2 
splicing factor.
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Figure 3.3.1: Identification of the proteins able to bind the BRCA1 exon 18 U6 
RNA sequence.
(A) Sequences of the BRCA1 RNA oligonucleotides. Intronic and exonic sequences 
are shown in lower and upper case, respectively, and the mutated nucleotide U6 is 
underlined.
(B) Coomassie stained gel of a pull-down assay. The target RNAs were linked to 
adipic beads and, incubated with HeLa nuclear extract. After several washing steps 
the proteins were loaded on SDS-Page gel and stained with Coomassie. The arrows 
indicate two bands of about 50 and 38 kDa present only in the U6 lane. The two 
bands were analysed by mass spectrometry analysis and the proteins were identified 
as DAZAP1 (1) and hnRNP A1/A2 (2), respectively.
47.5-
32.5-
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The sequence of the band of 50 kDa matched with the Deleted in Azoospermia 
Associated Protein 1, named DAZAP1. HnRNP A l and hnRNP A2 have been 
described as “negative” splicing regulators in different gene systems and in several 
cases showed a high binding affinity for RNA sequences containing the TAG motif 
(Burd and Dreyfuss 1994; Kashima and Manley 2003; Disset, Bourgeois et al. 2006; 
Kashima, Rao et al. 2007). In contrast to hnRNP factors, relatively little is known 
concerning the DAZAP1 and its role in splicing process. DAZAP1 shares a similar 
structure with the member of the hnRNP protein family (Dreyfuss, Matunis et al. 
1993; Akindahunsi, Bandiera et al. 2005) and is present in the nucleus of somatic 
cells as a component of the hnRNP particles (Lin and Yen 2006). To date the role for 
DAZAP1 has been connected with the mRNA transport and stability (Lin and Yen 
2006; Morton, Yang et al. 2006).
3.3.2 Pulldown analysis ofBRCAl exon 18 WT and U6 RNAs probed with 
hnRNP A l, -A2 and DAZAP1.
To study more in detail the differential binding efficiency of the splicing factors 
identified a pulldown assay including the “internal control” was performed. As 
described for ASF/SF2, the original pull down methodology was improved by 
linking the first part of BRCA1 exon 18 WT or U6 mutat to six UG dinucleotide 
repeats for TDP43 binding normalization (Fig. 3.3.2A).
The followed procedure is described in figure 3.1.2B: the target RNAs were TV- 
transcribed in vitro, treated with periodate in order to oxidize its 3’ end making it 
able to bind the agarose beads. Next, incubation with nuclear extract was performed 
and numerous washes allowed the elimination of all the nuclear proteins with no 
affinity for our RNA.
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Figure 3.3.2: Western blot of pulldown analysis of BRCA1 exon 18 WT and U6 
RNAs to determine the presence of hnRNP Al, -A2 and DAZAP1.
(A) Schematic representation of the RNA sequence transcribed in vitro (upper panel) 
that contains (UG)6 repeats, a (U)5 spacer and the target BRCA1 sequences. The 
mutagenized nucleotide is underlined. (B) Binding analysis of hnRNP A l, A2 and 
DAZAP1. The RNAs were in vitro transcribed, covalently linked to agarose beads 
and incubated with HeLa nuclear extract. The pulled down proteins were then 
analysed by western blotting with anti-hnRNP A l, hnRNP A2, DAZAP1 and TDP43 
polyclonal antibodies. Immunoblottings were detected using the ECL method. The 
nuclear extract sample corresponds to l/20th of the amount used for the pull-down 
assay. The pulldown picture is representative of three independent experiments. As 
the picture shows, the U6 RNA is able to pull down hnRNP A l, -A2 and DAZAP1 
proteins. The WT binds approximately only 10 and 15% of DAZAP1 and hnRNP 
A l, -A2 proteins respectively, compared to the U6 RNA, normalized for TDP43. The 
percentage of binding was determined by the evaluation of the relative intensity of 
the bands.
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Finally, complexes of proteins-RNA were separated in a SDS-page gel, blotted onto 
PVDF filters and evaluated using polyclonal antibodies against DAZAP1, hnRNP 
A1/A2. As shown in figure 3.3.2B the membrane was initially probed against 
TDP43, to normalize the experiment for the amount of bound RNA (Fig. 3.3.2B, 
lower panel) followed by incubation with DAZAP1 and hnRNP A1/A2 antibodies. In 
the presence of a comparable amount of pulled down TDP43, the U6 but not the WT 
mutant, bound very efficiently to DAZAP1 (Fig. 3.3.2B, upper panel lanes 2-3) and 
hnRNP A1/A2, whereas no signals were visible in the WT lane (Fig. 3.3.2B, middle 
panel, lanes 2-3). Thus, DAZAP1 together with hnRNP A1/A2 bind specifically to 
the BRCA1 exon 18 carrying the T6 natural mutation and can be responsible of the 
exon skipping phenotype.
3.3.3 Electro-mobility shift assay (EMSA) o f BRCA1 exon 18 WT and mutants.
The RNA binding specificity of DAZAP1 and both hnRNP A1-A2 was also tested 
directly by electro-mobility shift assay (EMSA). In this case, the EMSA analysis was 
carried out with purified hnRNP A l, hnRNP A2 and DAZAP1 GST-tagged proteins 
(Fig. 3.3.3B). To perform the EMSA experiments we used the same target RNAs, 
WT and the U6 exon 18 sequences, utilized for the pulldown assay. An additional 
RNA oligonucleotide, which carries the double mutation G4U6, was chosen as target 
RNA (Fig. 3.3.3A). This mutant induced complete exon 18 skipping in the functional 
splicing assay analysis (Fig. 3.2.2B, lane 4) showing a more negative nature 
compared to the single T6 mutant. Labelled WT and mutants RNAs were incubated 
with each different recombinant protein to let the binding reaction formed. Then the 
RNA-protein complexes were resolved on a native acrylamide gel in order to check 
any binding differences between the RNAs and proteins interaction. The analysis
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showed for each protein a similar binding pattern (Fig. 3.3.3C). It is visible a band of 
shifted material with the RNAs carrying the U6 and G4U6 mutations, whereas no 
complexes are formed in the presence of WT sequence. In the case of G4U6 RNA 
the complex signal resulted stronger than that one formed by the interaction between 
the proteins and the U6 RNA. These differences in binding are visible for all the 
three proteins analysed indicating a higher binding affinity for the double mutant 
sequence.
This EMSA study indicates that DAZAP1 and hnRNP A1-A2 proteins specifically 
recognize the U6 mutation as in the pulldown experiment. Furthermore, the binding 
efficiency showed by the WT, U6 and G4U6 RNAs against the three splicing factors 
was in agreement with the percentage of exon 18 skipping obtained by the functional 
splicing assay. Considering that the hnRNP A l, -A2 and DAZAP1 proteins could 
play an inhibitory role through exon T6 recognition, its partial exclusion from the 
pre-mRNA transcript could be considered due to the creation of a new binding site 
for the proteins identified. On the other hand, the exon 18 WT does not contain any 
binding site for these proteins; it is correctly recognised by the spliceosomal 
machinery and fully included in the mRNA.
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Figure 3.3.3: Electro mobility shift assay (EMSA) binding analysis of BRCA1 
exon 18 WT and mutants.
(A) Oligonucleotide sequences used for EMSA analysis. The RNAs are 20 bp long, 5 
nucleotides from intron 17 and 15 from exon 18 (capital letters) WT, U6 and G4U6. 
The mutated positions are underlined.
(B) Coomassie blue staining of the purified GST- proteins. The tagged proteins were 
expressed in BL21 (DE3) bacteria (Novagen) under the induction of IPTG. 
Purification of the proteins was carried out according to the manufacturer's 
instructions (see materials and methods).
(C) EMSA assay using purified human GST-hnRNP A l, A2 and DAZAP1 proteins 
with WT, U6 and G4U6 RNA oligonucleotides. Labelled RNAs were incubated with 
different GST-proteins as indicated. The RNA-protein complexes were resolved on 
5% polyacrylamide gel. As a control only the WT RNA was loaded in the first lane 
of each gel. The position of the free RNA and of the shifted material complexes is 
indicated on the right of the gels.
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3.4 Functional analysis of hnRNP Al, -A2 and DAZAP1 in BRCA1 splicing 
regulation.
3.4.1 Effect o f hnRNP A l, -A2 and DAZAP1 over expression on WT and T6 exon 
18 splicing.
The EMSA analysis together with the RNA pulldown experiments strongly indicated 
that the BRCA1 exon 18 +6 G to T substitution creates a new binding site for hnRNP 
A l, A2 and DAZAP1 proteins. In order to highlight the functional role of these 
trans-acting factors in the BRCA1 exon 18 splicing regulation an in vivo approach 
was set up. A transfection experiment was performed in Hep3B cells in which pBRA 
T6 hybrid minigene together with the single or different combinations of hnRNP A l, 
-A2 and DAZAP1 coding plasmids (+), or the empty vector (-) as a control. The 
minigene pBRA WT was also analysed in the presence of the three coding plasmids. 
Total RNA was extracted and a RT-PCR was carried out with a specific primer set. 
Figure 3.4.1 A reports the splicing pattern analysed by agarose gel electrophoresis. 
The pBRA T6 minigene splicing was not affected by the ovexpression of each single 
splicing factor, hnRNP A l, hnRNP A2 or DAZAP1, showing a percentage of exon 
inclusion equal to the control, of about 20% (Fig. 3.4.1 A, lane 1-3 vs. lane 8). In 
order to test whether the different splicing factors could induce an effect on exon 18 
splicing when co-expressed, we performed the overexpression experiment combining 
each splicing factor with a second one and moreover transfecting all the three factors 
together. Surprisingly, neither the overexpression of the double coding plasmids in 
all the three possible combinations (Fig. 3.4.1 A, lanes 4-6) neither the triple co­
transfection (Fig. 3.1.4A, lane 7) interfered with the splicing processing of pBRA T6 
plasmid that showed the same percentage of inclusion observed for the control (Fig. 
3.4.1, lane 8).
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A T6 BRCA1
hnRNPAI + - - + - + + -
hnRNPA2 - + - -  + + + -
DAZAP1 - + + + - + -
ex18 + 
ex18 -
% ex18+
Figure 3.4.1: Effect of hnRNP Al, -A2 and DAZAP1 overexpression on T6 exon 
18 splicing.
(A) Hep3B cells were transfected with the indicated exon 18 minigene pBRA T6 
mutant either in presence of the empty vector (-) or with the splicing factor coding 
plasmid of interest (+). Total RNA was extracted and splicing variants detected by 
RT-PCR were resolved on 2% agarose gel. The identity of the transcripts, exon 18 
inclusion (ex 18+) and exon 18 exclusion (ex 18-), is shown schematically at the right 
side of the gel.
No effect was observed in the case of the exon 18 WT minigene and overexpression 
of the three splicing factors together did not change the splicing profile of the exon 
18 WT that remained 100% of inclusion (Fig. 3.4.1B, lane 1-2).
Co-transfection with hnRNP A l, A2 and DAZAP1 expression vectors should result 
in an inhibition of exon 18 splicing taking into account the putative negative role of 
these splicing factors. The absence of a negative effect on exon 18 T6 mutant could 
be explained by a possible saturation of the system due to the high expression level 
of these proteins within the cells. In addition, considering the fact that exon 18 T6 is 
nearly skipped (-80%) in the absence of any co-transfected factors, the detection of
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any negative effect on splicing may be difficult to achieve. Thus, the complete 
absence of any response to hnRNP A l, A2 and DAZAP1 overexpression in the 
pBRA T6 minigene do not exclude their real involvement in exon 18 splicing 
regulation.
3.4.2 siRNA against hnRNP A l, A2 and DAZAP1 affects BRCA1 T6 exon 18 
splicing.
In order to evaluate a possible functional role of hnRNP A l, A2 and DAZAP1 on 
BRCA1 exon 18 splicing I performed depletion of the target proteins by siRNA 
treatment. This represents a more suitable system to investigate whether these 
splicing factors are involved in the aberrant splicing of the mutated exon 18. If their 
binding, as supposed, promotes exon 18 skipping, the specific knock down of these 
proteins should increase the inclusion of the exon into the mature RNA.
To test whether the siRNA oligonucleotides against hnRNP A l, hnRNP A2 and 
DAZAP1 effectively reduces the target protein levels a transient transfection of these 
small RNAs in HeLa cell line was set up. Both single and different combinations 
(double and triple) of siRNA transfections were performed against these splicing 
factors. After two round of treatment the cells were collected, total proteins extracted 
and the silencing effect analysed by western blot using antibodies against each 
protein of interest. All the siRNAs induced a strong reduction in the target proteins 
level, whereas the cells transfected with an unrelated siRNA, against the Luciferase 
gene, did not show any variation in the proteins content. As internal control for the 
western blot analysis, to normalise the amount of loaded proteins, the expression 
level of tubulin gene was detected.
118
siRNA hnRNPAI + - - + —  + + -
siRNA hnRNPA2 + - -  + + + -
siRNA DAZAP1 - + + + -  + - NE
hnRNPAI
hnRNPA2
DAZAP1
Tubulin
1 2 3 4 5 6 7
Figure 3.4.2: Knock down of hnRNP Al, -A2 and DAZAP1 proteins performed 
by siRNA treatment.
Western blot analysis of HeLa cells treated (+) with the indicated different siRNAs 
anti-hnRNP A l, -A2 and DAZAP1 proteins, alone or indifferent combinations. The 
control luciferase siRNA corresponds to lane 8. The analysis was performed using 
only one siRNA against each target. The western blot was carried out with 
polyclonal antibodies against each target protein and tubulin probing as a control of 
total protein loading. NE indicates the nuclear extract. The percentage of silencing of 
each protein reaches about the 80-90%. The siRNA experiment reported is 
representative of at least three independent experiments. The band indicated with an 
asterisk in the DAZAP1 blot corresponds to a unspecific protein detected by the 
polyclonal antibody against DAZAP1.
The cells treated with the different siRNAs were then transfected with the pBRA T6 
plasmid and collected. Total RNA was extracted from half of the pellet whereas the 
second half served for total proteins analysis. In this way, splicing was evaluated by 
RT-PCR performed on total RNA extract and at the same time, the silencing effect 
was analysed by western blot using antibodies against each protein of interest. HeLa
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cells transfected with the corresponding siRNAs showed, as described above, a 
strong reduction in hnRNP A l, A2 and DAZAP1 levels, whereas no effect was 
detected in the luciferase control (Fig. 3.4.2, lanes 1-7 vs. 8). The siRNA treatment 
against DAZAP1 induced also a small reduction in the amount of hnRNP A l and 
hnRNP A2 (Fig. 3.4.2, lane 3) possibly related to a regulatory effect of DAZAP1 on 
hnRNP A1/A2 splicing and/or stability (Lin and Yen 2006). The combined siRNA- 
mediated knockdown of the three inhibitory splicing factors increased the percentage 
of exon inclusion of the T6 mutant from 20% to about 55% (Fig. 3.4.3A, lane 7 vs. 
8). A slightly smaller effect on mutated exon 18 recovery was observed for the 
simultaneous siRNA-mediated depletion of hnRNP Al and hnRNP A2 (Fig. 3.4.2B, 
lane 6), with about 45% of exon inclusion. In the case of the other two double 
combinations of hnRNP A1/DAZAP1 and hnRNP A2/DAZAP1 silencing, the 
splicing pattern of pBRA T6 minigene was not affected, resulting in 20% of exon 
inclusion (Fig. 3.4.2B, lanes 4-5 vs. 8). Depletion of each factor alone also showed 
no change in the percentage of the exon 18 inclusion in comparison to the not treated 
sample (Fig. 3.4.2B, 1-3 lanes vs. 8).
As a control for hnRNP A1/A2 silencing efficiency, pBRA T6 minigene was 
transfected together with the pSMN2 construct. Depletion of hnRNP A l and -A2 
was reported to rescue significantly of the SMN2 exon 7 skipping (Cartegni, 
Hastings et al. 2006; Kashima, Rao et al. 2007). Indeed, the pSMN2 splicing pattern 
responded to both hnRNP Al and hnRNP A2 depletion increasing the exon 7 
inclusion from 10% to 50% (Fig. 3.4.4A). As additional siRNA control, we tested 
whether the depletion of all the three splicing factors together could affect the proper 
exon 18 WT inclusion. The splicing pattern analysis, reported in figure 3.4.4B, 
showed that the siRNA treatment did not affect the 100% exon 18 WT inclusion. The 
depletion of hnRNP A l, -A2 and DAZAP1 factors affected exon 18 T6 splicing,
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showing a functional role of the proteins identified and characterized by in vitro 
binding analysis. Overall, the single substitution G to T creates a silencer element, 
which is recognized by the hnRNP A l and hnRNP A2 and the DAZAP1 splicing 
factors.
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Figure 3.4.3: siRNA against hnRNP Al, A2 and DAZAP1 affects BRCA1 T6 
exon 18 splicing.
(A) siRNA-treated (+) and untreated (-) cells were transfected with pBRA T6 
minigene plasmid. Total RNA was prepared and analyzed by RT-PCR. The splicing 
products obtained were separated on 2% agarose gels and stained with ethidium 
bromide. The identity of the transcripts including exon 18 (ex 18+) and lacking exon 
18 (exl8-) is indicated. (B) The graph is the quantification of three independent 
experiments expressed as means + SD.
121
A pSMN2
siRNA hnRNPAI +  -
siRNA hnRNPA2 + -
  ex7 +
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Figure 3.4.4: siRNA treatment on SMN2 exon 7 minigene system and pBRA WT 
as controls.
(A) Effect of double siRNA against hnRNP Al and hnRNP A2 on the splicing 
pattern of the control pSMN2 minigene. pSMN2 and pBRCAl T6 minigenes were 
cotransfected in the siRNA hnRNP A l and hnRNP A2 treated cells and analysed 
with specific primers for pSMN2. The identity of the transcript with inclusion or 
exclusion of the SMN2 exon 7 is indicated.
(B) Effect of siRNA against hnRNP A l, -A2 and DAZAP1 on the WT pBRA 
minigene.
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3.5 Mapping exonic regulatory elements within BRCA1 exon 18 sequence.
3.5.1 Serial deletions analysis within BRCA1 exon 18.
In order to identify additional BRCA1 exonic splicing regulatory element(s), I 
prepared several minigenes that contained a series of consecutive deletions along the 
BRCA1 exon 18 WT and carrying the T6 mutation (Fig. 3.5.1 A, 3.5.2A). The 
deletions (~10nt) were produced in the exon sequence by overlapping PCR and the 
resulting pBRA minigenes were transiently transfected in Hep3B cells. Total RNA 
was extracted, RT-PCR was performed and the amplified products were analysed by 
electrophoresis on agarose gel.
All the deletions analysed in the context of the pBRA WT had no effect on the exon 
18 splicing showing 100% exon inclusion (Fig. 3.5.IB) consistent with the absence 
of strong enhancer sequence in the WT exon 18. On the other hand, some of the 
deletions produced had an effect in the pBRA T6 context. Because each deletion was 
performed in the context of exon 18 T6 mutant, each splicing profile was compared 
with the pBRA T6 plasmid. As shown in figure 3.5.2B the majority of deletions 
within the mutated minigene context affected positively or negatively the percentage 
of exon inclusion, in comparison to the T6 mutant. Deletion of the sequences 
between positions 23-32 in T6 induced complete exon 18 skipping (Fig. 3.5.2B, lane 
4), indicating that this sequence contains an enhancer, which becames relevant only 
in the context of the T6 mutant. Some of the deletions had a positive effect on the 
splicing pattern. In comparison to the T6 mutant, the T6A35-44 and T6A64-74 
minigenes, increased the percentage of exon inclusion up to 90% and 100%, 
respectively (Fig. 3.5.2B, lane 5 and 7). These results suggested the presence of two 
silencer elements located at position 35-44 and 64-74. Interestingly the deletions 
disrupted a nucleotide sequences that include one or two “TAG” elements, which
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maybe involved in the negative regulation of exon 18 together with the TAG located 
at position +6. Two deletions, the T6A12-21 and T6A47-57 minigenes, did not show 
any effect on the splicing pattern comparable with the T6 mutant (Fig. 3.5.IB, lanes 
3 and 6). Furthermore, a possible connection between the two 4-9 and 23-32 deleted 
regions was tested by creating the A4-9/A23-32 minigene (Fig. 3.5.2A). These two 
deletions alone had no effect in the context of the exon 18 WT splicing whereas the 
23-32 deletion induced exon skipping only when associated to the T6 mutant (Fig. 
3.5.2B, lanes 4). The minigene carrying the double deletions (4-9 and A23-32) 
induced a partial exon 18 skipping (Fig. 3.5.2B, lane 8). This data suggested the 
presence of two nearby enhancer sequences, which may contribute in an additive 
manner to the definition of the WT exon. The extent of splicing inhibition mediated 
by the A23-32 deletion in the context of the single T6 substitution is more severe 
than the splicing inhibition mediated by the presence of the A4-9 deletion (Fig. 
3.5.2B, lane 4 vs. 8). In fact, the T6A23-32 minigene induced complete exon 
exclusion, whereas the A4-9/A23-32 minigene showed partial exon skipping with 
only 50% of exon inclusion. This result is consistent with the strong inhibitory effect 
mediated by the binding of hnRNP A1/A2 and DAZAP1 on the T6 mutant region.
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ATGCTGAGTTTGTGTGTGAACGGACACTGAAATATTTTCTAGGAATTGCGGGAGGAAAATGGGTAGTTAGCTATTTCT WT 
ATGCTTAGTTTGTGTGTGAACGGACACTGAAATATTTTCTAGGAATTGCGGGAGGAAAATGGGTAGTTAGCTATTTCT T6
ATG-------------TTGTGTGTGAACGGACAC.TGAAATATTTTCTAGGAATTGCGGGAGGAAAATGGGTAGTTAGCTA.TTTCT A 4 - 9
ATGCTGAGTTT----------------------GGACACTGAAATATTTTCTAiGGAATTGCGGGAGGAAAATGGGTAGTTAGCTATTTCT WT A 1 2 - 2 1
ATGCXGAGTTTGTGTGTGAACG----------------------TATTTTCTAGGAATTGCGGGAGGAAAATGGGTAGTTAGCTATTTCT WT A 2 3 - 3 2
ATGCTGAGTTTGTGTGTGAACGGACACTGAAATA----------------------ATTGCGGGAGGAAAATGGGTAGTTAGCTATTTCT WT A 3 5 - 4 4
ATGCTGAGTTTGTGTGTGAACGGACACTGAAATATTTTCTAGGAAT------------------------ AATGGGTAGTTAGCTA'TTTCT WT A 4 7 - 5 7
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Figure 3.5.1: Splicing effect of single deletions performed on BRCA1 exon 18 
WT sequence.
(A) The central part of pBRA minigene containing the BRCA1 exons and introns is 
indicated schematically. The entire sequence of exon 18 WT (78bp) is reported 
below. The G to T substitution in position +6 is highlighted in bold. The single 
deletions performed within BRCA1 exon 18 WT sequence are indicated by dashed 
lines. The exact position of each deletion within exon 18 is reported by a number on 
the right of the sequence.
(B) Splicing pattern analysis. The minigenes reported above were transfected in 
Hep3B cells and the total RNA analysed by RT-PCR. The two resulting splicing 
products corresponding to exon 18 inclusion (ex 18+) and exclusion (ex 18-) are 
indicated on the right. None of the deletions affected the exon 18 splicing. The only 
percentage of exon 18 inclusion reported is referred to the pBRA T6 minigene. All 
the constructs, a part T6, are considered 100% included.
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ATGCTTAGTTT----------------------GGACACTGAAATATTTTCTAGGAATTGCGGGAGGAAAATGGGTAGTTAGCTATTTCT 1 6  A 1 2 - 2 1
ATGCTTAGTTTGTGTGTGAACG----------------------TATTTTCTAGGAATTGCGGGAGGAAAATGGGTAGTTAGCTATTTCT T 6  A 2 3 - 3 2
ATGCTTAGTTTGTGTGTGAAC03ACACTGAAATA----------------------ATTGCGGGAGGAAAATGGGTAGTTAGCTATTTCT T 6 A 3 5 -4 4
ATGCTTAGTTTGTGTGTGAACGGACACTGAAATATTTTCTAGGAAT------------------------AATGGGTAGTTAGCTATTTCT T6 A 4 7 -5 7
ATGCTTAGTTTGTGTGTGAACGGACACTGAAATATTTTCTAGGAATTGCGGGAGGAAAATGGG------------------------ TTCT T6 A 6 4 -7 4
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Figure 3.5.2: Splicing effect of single deletions performed on BRCA1 exon 18 T6 
sequence.
(A) Scheme of pBRA WT construct that comprises BRCA1 exons and introns 
sequences. The 78nt of exon 18 WT is reported below. The G to T mutation in 
position +6 is highlighte in bold and the TAG motives are underlined. The single 
deletions performed within BRCA1 exon 18 T6 context and the double deletion (A4- 
9/A23-32) are indicated by dashed lines.
(B) Splicing pattern analysis. The minigenes indicated above were transfected in 
Hep3B cells and the total RNA analysed by RT-PCR. The two resulting splicing 
products corresponding to exon 18 inclusion (ex 18+) and exclusion (ex 18-) are 
indicated. Some of the deletions analysed affected negatively (A23-32) or positively 
(A35-44 and A64-74) the T6 exon 18 splicing. The percentage of exon inclusion in 
each case is shown.
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3.5.2 Effect o f ASF/SF2 overexpression in exon 18 T6 deleted minigenes.
In order to identify potential splicing regulatory sequences that could mediate the 
ASF/SF2 enhancing effect, observed on the T6 mutant in co-transfection 
experiments, (Fig. 3.1.6) the different minigenes carrying the deletions in the T6 
context were co-trasfected with ASF/SF2.
Overexpression of ASF/SF2 increased the percentage of exon inclusion, from 20% to 
55%, in two deleted constructs, T6A12-21, and T6A47-54 in a similar manner as 
detected for the single T6 mutant, (Fig. 3.5.3, lanes 4 and 10). The T6A35-44 
minigene also responded to ASF/SF2 showing full inclusion of exon 18 (Fig. 3.5.3, 
lane 8). The already fully included T6A64-74 minigene was not affected by the 
increasing amount of ASF/SF2 protein (Fig. 3.5.3, lane 12). The minigene that did 
not respond to ASF/SF2 overexpresssion, showing complete exon 18 exclusion, was 
the construct carrying the T6 mutation plus the 23-32 deletion (Fig. 3.5.3, lane 6). 
This result suggested that the 23-32 element is an enhancer which stimulates BRCA1 
exon 18 splicing through ASF/SF2 only in the context of the T6 mutant.
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Figure 3.5.3: Effect of ASF/SF2 overexpression on exon 18 T6 deleted 
minigenes.
(A) The T6 deleted constructs, described before in Fig. 3.5.2, were cotransfected 
either with the ASF/SF2 coding plasmid (+) or with the corresponding empty vector 
(-). Splicing patterns were analysed by separating the RT-PCR products on agarose 
gel. The identity of the transcripts, exon 18 inclusion (ex 18+) and exon 18 exclusion 
(ex 18-), is shown schematically at the right side of the gel.
ASF/SF2 overexpression increased the percentage of exon 18 inclusion in all the 
constructs except for T6 A23-32 minigene that remaned totally excluded. The 
percentages of exon 18 inclusion are reported below each lane.
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4 DISCUSSION
Several studies have identified a large number of exonic point mutations that, 
independently from their effect on the coding sequence, cause splicing defects 
inducing exon skipping. In several gene systems, like NF1, ATM, and CFTR, such 
exonic point mutations have been identified as the cause of disease inducing different 
degrees of exon skipping (Teraoka, Telatar et al. 1999; Ars, Serra et al. 2000; Pagani, 
Buratti et al. 2003; Pagani, Stuani et al. 2003). Notwithstanding the relative high 
frequency of this type of defects in human pathology and the growing interest in 
developing appropriate therapeutic strategies, the mechanism of exon skipping due to 
exonic mutation is not completely understood. There is evidence that indicates that 
these types of mutations affect functional exonic splicing regulatory elements 
(enhancer and silencer), but in some cases the underlying mechanism is still 
controversial (Cartegni, Chew et al. 2002; Pagani and Baralle 2004).
The natural G6T transversion in BRCA1 exon 18 was originally reported to induce 
exon skipping and was used as a model to explore the composition of splicing 
regulatory elements and the mechanism of defective splicing. Krainer and colleagues 
used this system, by evaluating a limited number of site-directed mutants by in vitro 
splicing assays along with the ESEfinder computer-assisted analysis, to propose a 
general model of defective splicing due to exonic mutations. In 2001 they suggested 
that the G6T mutation in BRCA1 exon 18, induces exon skipping because it disrupts 
an exonic splicing enhancer binding site for the ASF/SF2 protein (Liu, Cartegni et al. 
2001). This model was supported by an ESE motif computer assisted analysis of 50 
mutations previously reported to induce exon skipping in different human disease 
genes (more than half of the single-base substitutions reduced or eliminated at least
one ESE high-score motif) (Liu, Cartegni et al. 2001) and on a more detailed analysis 
of the SMN1/2 exon 7 genes (Cartegni and Krainer 2002). In the case of SMN genes, 
they originally reported a reduced binding to ASF/SF2 in SMN2 with respect to 
SMN1 and a series of site-directed mutants whose effect on pre mRNA splicing was 
compatible with the ESEfinder scores. However, other evidence in the SMN1/2 case 
later challenged this original observation. A site-directed mutagenesis analysis was 
more compatible with sequence with an Extended Inhibitory Context (Singh, 
Androphy et al. 2004). Most importantly, siRNA-mediated depletion of ASF/SF2 did 
not induce exon skipping of the normal SMN1 gene (Kashima, Rao et al. 2007). 
These results were followed by the opposite proposal that disease-causing mutations 
can induce exon skipping through the creation of a novel exonic splicing inhibitory 
sequences (Kashima and Manley 2003; Kashima, Rao et al. 2007).
To understand the mechanism of defective splicing induced by exonic mutations in 
this thesis we have extensively evaluated the BRCA1 exon 18 splicing model. Our 
data does not indicate a major role of ASF/SF2 in the aberrant splicing of this exon, 
but on the contrary indicate that the T6 mutation creates a silencer element that binds 
to the inhibitory splicing factors hnRNP A1/A2 and DAZAP1.
4.1 The T6 mutant does not disrupt an ASF/SF2-dependent splicing enhancer.
In this thesis we extensively explored the role of ASF/SF2 in the regulation of 
BRCA1 exon 18 splicing. Several lines of evidence indicate that this splicing factor 
is not directly involved in the BRCA1 exon skipping induced by the +6G to T 
mutation. We evaluated the role of ASF/SF2 by direct binding to the WT and mutant 
RNA sequences using a modified pull down assay, by performing a systematic site- 
directed mutagenesis using hybrid minigenes and we further tested the in vivo 
overexpression and depletion of ASF/SF2 on BRCA1 exon 18 splicing efficiency.
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The first approach toward the characterization of the putative ASF/SF2 enhancer 
involved in BRCA1 exon 18 definition, was a classical pull down assay. Using this 
technique followed by western blot analysis, we found that both WT and T6 mutant 
seem to bind equally to ASF/SF2 (Fig. 3.1.IB, lanes 2, 3). To exclude technical 
limitation due to the difficult normalization of RNAs among the samples we set up a 
modified pull down assay. In this experiment the efficiency of ASF/SF2 binding was 
carefully evaluated by linking BRCA1 RNA targets to a (UG) repeats, recognized by 
the TDP43 factor, allowing an accurate normalization of the amount of proteins 
pulled down. The normalization confirmed the result obtained by the RNAs without 
the UG tail, detecting an equal signal of ASF/SF2 for both WT and T6 mutant (Fig. 
3.1.3B, lanes 2, 3). In addition, the WT and mutant BRCA1 sequences showed a low 
level of interaction with ASF/SF2 compared with the classical GAA-rich fibronectin 
EDA enhancer signal (Fig. 3.1.3B lane 1). This strong difference with a classical 
ASF/SF2 enhancer suggests that the affinity of the splicing factor for WT and mutant 
BRCA1 sequences may be very low and have a secondary role in the exon 18 
definition. To follow this observation we performed siRNA mediated depletion of 
ASF/SF2. As shown figure 3.1.7 the nearly complete depletion of this splicing factor 
did not change the splicing pattern in the WT minigene. Delta Ron was used as 
control which as expected, is unaffected by ASF/SF2 silencing. This result is 
consistent with a non-essential role for ASF/SF2 in the natural BRCA1 exon 18 
definition. In addition, the lack of a strong ASF/SF2 enhancer at the 5’ end of 
BRCA1, disrupted by the T6 mutant, was also shown by single site-directed 
mutagenesis analysis (Fig. 3.2.IB). This approach is particularly useful to test the 
composition of the splicing regulatory element in its original context. Site-direct 
mutagenesis analysis in hybrid minigenes has identified the composition of splicing 
regulatory elements in several cases: both in exons, (Pagani, Buratti et al. 2003;
Pagani, Stuani et al. 2003) and in introns (Pagani, Buratti et al. 2000). In the case of 
SMN2 exon 7, a similar analysis showed a sequence with an extended inhibitory 
complex (Singh, Androphy et al. 2004). Among 21 subsequent point mutations 
inserted along the 5’ end of BRCA1 exon 18 only the natural T6 substitution induced 
a severe exon skipping and only two (A6 and T4), showed partial exon skipping (Fig. 
3.2.IB, lanes 4, 8, 10). Most of the point substitutions had no effect on the normal 
exon 18 splicing pattern (Fig. 3.2.IB) as well as the complete deletion of the 
sequence between positions +4 to +9 (A 4-9 pBRA construct) (Fig. 3.2.3B, lane 6). 
We also used the ESEfinder tool to calculate ASF/SF2 dependent ESE motif scores 
of all the mutants analysed in order to test a possible correlation between the in silico 
approach versus our in vivo results, as previously done for the SMN1/2 systems 
(Cartegni, Hastings et al. 2006). The comparative analysis performed showed that the 
ESEfinder ASF/SF2 score of all the substitution performed within exon 18 did not 
correlate with the splicing pattern obtained by the in vivo functional assay (Table 
3.2.1). These data showed that simple prediction of an ASF/SF2 high score binding 
motif in the 5’ region of exon 18 does not necessarily result in a strong enhancer 
element regulated by high binding affinity in the in vivo situation. Indeed, ESEfinder 
program predictions have shown only a partial correlation with the in vivo analysis of 
several gene systems such as dystrophin (Disset 2006), CFTR (Pagani, Buratti et al. 
2003; Pagani, Stuani et al. 2003) and SMN2 (Kashima and Manley 2003; Kashima, 
Rao et al. 2007). Thus, the predictive power of this in silico approach has failed to 
establish a clear connection between splicing and abolishment/creation of a 
regulatory element, as shown for the BRCA1 exon 18 and the other reported cases. 
Collectively, these data strongly indicate that ASF/SF2 does not have a major role in 
BRCA1 exon 18 regulation and that the T6 mutant does not disrupt an ASF/SF2 
binding site.
132
4.2 The T6 mutation creates a sequence with splicing inhibitory function.
As our in vitro and in vivo analysis indicated that ASF/SF2 is neither involved in the 
regulation of exon 18 WT nor responsible for the T6 mutant exon skipping. We 
therefore tested whether the natural mutation creates an exonic splicing silencer. The 
BRCA1 exon 18 silencer element was mapped by analyzing a series of double site 
directed mutants in the +4 to +9 region containing the T6 variant. Through functional 
splicing analysis of the minigenes carrying double mutations we showed that the T6 
substitution creates a sequence with preferential silencer properties. The majority of 
point mutations showed a positive effect on T6 exon 18 splicing, partially or totally 
restoring its inclusion (Fig. 3.2.2B). In particular the substitutions that affected the 
central “TAG” triplet, between positions +6 and +8, completely recovered exon 18 
inclusion (Fig. 3.2.2B, lanes 9-14) indicating the negative role of this motif in 
splicing regulation. This ESS sequence, containing the TAG motif, resembled a 
typical sequence recognized by hnRNP A l splicing factor. This triplet was 
previously found in silencer elements described in other gene models (Kashima and 
Manley 2003; Disset, Bourgeois et al. 2006; Kashima, Rao et al. 2007), in the 
hnRNP Al SELEX sequence (Burd and Dreyfuss 1994), and in the screening of a 
large number of putative silencer elements (Wang, Rolish et al. 2004). Due to the 
high similarity between the mutation described in the SMN2 exon 7 and the one 
reported for the BRCA1 exon 18 we have also evaluated the SMN1/2 exon 7 
sequences (Kashima and Manley 2003; Kashima, Rao et al. 2007), and the SELEX 
hnRNP Al motif (Burd and Dreyfuss 1994)(Fig. 3.2.3A). The SMN2 and SELEX 
motif sequences embedded in the BRCA1 exon 18 context produced exon skipping 
further reinforcing the idea that TAG motif plays a central role in the inhibitory 
activity of the silencer sequence (Fig. 3.2.3B, lanes 4, 5).
4.3 The T6 mutant creates a splicing silencer that binds to hnRNP Al, hnRNP 
A2 and DAZAP1.
Concerning the trans-acting factors involved in BRCA1 T6 exon 18 splicing, we 
have characterized three proteins assembled on the sequence carrying the T6 single 
point mutation. Pull down experiments followed by mass spectrometry analysis 
allowed us to identify three inhibitory splicing factors that interact individually and 
specifically with the exonic silencer element created by the T6 mutation: hnRNP A l, 
hnRNP A2 and DAZAP1 (Fig. 3.3.1). Subsequently, we confirmed the binding and 
the specific involvement of these proteins in T6 RNA recognition by western blot 
(Fig. 3.3.2B) and EMSA analysis in which the mutant sequence, differently from the 
WT, binds to all three different proteins (Fig. 3.3.3C). In addition, the G4U6 mutant 
RNA sequence showed a stronger complex signal than the one formed by the 
interaction between the proteins and the U6 RNA, indicating a higher binding 
affinity that was in agreement with the percentage of exon 18 skipping obtained by 
the functional splicing assay.
By means of siRNA experiments, we provide functional evidence that DAZAP1 
together with the hnRNP A1/A2 is involved and probably have a redundant function 
in the splicing regulation of the T6 BRCA1 exon 18, reporting also a novel role for 
DAZAP1 in splicing regulation. The simultaneous treatment with hnRNP A1/A2 
siRNA resulted in a significant recovery of the defective splicing of exon 18 carrying 
the T6 mutation (Fig. 3.4.3A, lane 6). The further depletion of DAZAP1 enhanced 
the T6 exon 18 recovery (Fig. 3.4.3A, lane 7) showing an involvement of DAZAP1 
in the BRCA1 exon 18 splicing reaction. DAZAP1 could participate to the regulation 
of the BRCA1 T6 exon 18 splicing through the recognition of sequences similar to
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the ARE motifs (CUUAGUUU), acting as a negative factor and promoting the exon 
18 exclusion.
The requirement of multiple siRNAs for an efficient rescue of defective T6 splicing 
(Fig. 3.4.3A, lane 7) and the EMSA experiments with purified proteins (Fig. 3.3.3) 
suggested that both hnRNP A1/A2 and DAZAP1 specifically recognise the 
inhibitory sequence. This is further supported by the fact that DAZAP1 co-localizes 
and physically interacts with the splicing repressor proteins hnRNP A l and hnRNP 
Cl (Lin and Yen 2006). However, triple treatment with siRNA for hnRNP A1/A2 
and DAZAP1 did not completely restore BRCA1 exon inclusion. This could be 
explained by the presence of residual amounts of the splicing factors, not completely 
depleted by the siRNAs or by the binding of additional inhibitory splicing factor(s) at 
the silencer element not revealed by the pull-down analysis.
A similar study on BRCA1 T6 mutant was also recently performed by Kashima and 
Manley (Kashima, Rao et al. 2007). In agreement with our findings, they reported 
that ASF/SF2 role is dispensable for the regulation of exon 18 WT and that the 
depletion of ASF/SF2 has a small negative effect on T6 exon 18 inclusion (Kashima, 
Rao et al. 2007). Moreover, they performed UV-crossilinking and D P  experiments 
detecting hnRNP Al binding the T6 mutant but not the WT BRCA1 exon 18 
sequence. In their study, DAZAP1 was not detected, maybe due to the different 
technique used (Kashima, Rao et al. 2007).
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4.4 A novel splicing regulatory role of Deleted in Azoospermia Associated 
Protein 1 (DAZAP1).
The hnRNP A l and hnRNP A2 proteins are well characterised inhibitory splicing 
factors involved in a variety of cellular and viral systems (Chabot, LeBel et al. 2003), 
and have been described as splicing repressors in the regulation of SMN2 exon 7 
splicing (Kashima and Manley 2003; Kashima, Rao et al. 2007).
In contrast to hnRNP A1/A2, few data are available regarding the functional splicing 
properties of the Deleted in Azoospermia Associated Protein 1 (DAZAP1), which 
has been mainly described to be involved in mRNA transport and stability processes 
(Lin and Yen 2006) (Morton, Yang et al. 2006). DAZAP1, also named as proline- 
rich RNA-binding protein (PRRP), was originally isolated through its interaction 
with Deleted in Azoospermia (DAZ) protein in a yeast two-hybrid assay (Tsui, Dai et 
al. 2000). DAZAP1 is expressed at high level in testis, where it was identified 
together with other members of DAZ family, but it was also detected in many other 
human tissues (Tsui, Dai et al. 2000; Dai, Vera et al. 2001) and in several cells lines 
(Rousseau, Morrice et al. 2002; Lin and Yen 2006; Morton, Yang et al. 2006). 
DAZAP1 shares a structure similar to the hnRNP protein family members with two 
RNA-binding domains (RBDs) at the N-terminus (Dreyfuss, Matunis et al. 1993; 
Akindahunsi, Bandiera et al. 2005). The C-terminal portion of DAZAP1 is rich in 
prolines instead of the glycines described for the hnRNP A/B proteins. Human 
DAZAP1 shows a high degree of evolutionary conservation with the orthologs 
isolated from mice and Xenopus (Dai, Vera et al. 2001; Zhao, Jiang et al. 2001). It 
was reported that DAZAP1 binds preferentially in vitro to poly(U) and poly(G) and 
to a lesser degree to poly(A) sequences (Tsui, Dai et al. 2000). Interestingly, SELEX 
experiments determined the RNA ligand for mouse PrrP that should contain two 
conserved sequences, AAUAG and GU1.3AG involved in a two-loop structure (Hori,
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Taguchi et al. 2005). This motif contains the same UAG splicing sequence that we 
showed to be important in the silencing of the BRCA1 T6 mutant exon. Moreover, 
DAZAP1 was identified as one of the proteins able to specifically bind to the ARE 
element (AU-rich element) in the TNFa (Rousseau, Morrice et al. 2002). It was also 
shown that DAZAP1 is a physiological substrate for ERK1/ERK2 and might play a 
role in the regulation of mRNA stability/translation by the classical MAPK cascade 
(Morton, Yang et al. 2006).
DAZ API was detected in the nucleus of somatic cells as a component of the hnRNP 
particles and specifically co-localized with hnRNP A l and hnRNP Cl (Lin and Yen 
2006). Like other hnRNPs, DAZ API has the ability to shuttle between the nucleus 
and cytoplasm using a small conserved C-terminal segment (Lin and Yen 2006). Its 
nuclear localization seems to depend on active transcription, when RNA pol II is 
inhibited, DAZAP1 is retained in the cytoplasm (Lin and Yen 2006).
Taking together the data about DAZAP1, the more probable function of this factor 
might be connected with different steps of mRNA processing (Lin and Yen 2006; 
Morton, Yang et al. 2006) and here we provide the evidence of its inhibitory role in 
splicing regulation of BRCA1 when exon 18 carries a mutation.
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4.5 The BRCA1 exon 18 contains additional weak splicing exonic regulatory 
elements.
To characterize additional splicing regulatory elements we performed a series of 
short consecutive exonic deletions within the BRCA1 minigene WT and mutant. We 
identified several splicing regulatory sequences, which interestingly are functionally 
relevant only in the presence of the T6 mutation (Fig. 3.5.2B) and not in the WT 
minigene (Fig. 3.5.IB.). Some deletions within the T6 exon 18 context affected the 
splicing pattern both reducing and increasing the splicing efficiency (Fig. 3.5.2B). 
We could identify two silencer elements at position 35-44 and 64-74 (Fig. 3.5.2B, 
lane 5, 7) and only one sequence with enhancer properties in position 23-32 (Fig. 
3.5.2B, lane 4). Interestingly, the two regions with silencer properties contain the 
TAG sequence, which could be responsible along with the other TAG sequence 
created by the T6 mutant of a cooperative splicing inhibition (see below the model of 
regulation). To understand if the 23-32 enhancer might be involved in the ASF/SF2- 
dependent splicing enhancement, we performed overexpression experiments. Only 
the minigene containing the A23-32 deletion did not respond to ASF/SF2 (Fig. 
3.5.3A, lane 6), suggesting the presence of a weak ASF/SF2-dependent splicing 
element in the 23-32 deleted region.
This ASF/SF2 dependent enhancer can explain why ASF/SF2 affected the splicing 
efficiency in the T6 BRCA1. In fact differently from the WT, the T6 BRCA1 
minigene responded to changes in the intracellular concentration of ASF/SF2. The 
T6 BRCA1 exon 18 was affected both by siRNA-mediated depletion (Fig. 3.1.7B, 
lane 3) and overexpression of ASF/SF2 (Fig. 3.1.6A, lane 4) by reducing or 
increasing the percentage of exon inclusion, respectively.
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4.6 Models for normal and defective BRCA1 exon 18 splicing.
Our results indicate that the primary determinant of the T6 BRCA1 exon 18 
exclusion is not the disruption of an ASF/SF2 dependent enhancer but the creation of 
a new silencer element recognized specifically by the splicing inhibitory factors 
hnRNP A1/A2 and DAZAP1.
Based on our analysis we propose a model for WT and T6 BRCA1 exon 18 splicing 
regulation (figure 4.1). BRCA1 exon 18 WT may contain two weak ESE regions 
localized at position +4-9 and +23-32 and two downstream silencers at position at 
position 35-44 and 64-74 and its definition is largely dependent on the 3’ and 5’ ss 
(Fig. 4.1 A). The two enhancer regulatory elements are dispensable for the definition 
of the BRCA1 WT exon, as their single deletions did not induce exon skipping (Fig. 
3.5.IB). Only when deleted in combination can they induce exon skipping (Fig. 
3.5.2B, lane 8) and the weak central enhancer element probably mediates its effect 
through its binding to ASF/SF2.
The G to T mutation in position +6 of exon 18 induces exon skipping through the 
creation of a strong silencer regulatory element located at the 5’ end of the exon that 
binds to the inhibitory splicing factors hnRNP A l, hnRNP A2, and DAZAP1. 
Several mechanisms have been proposed to explain hnRNP A l mediated splicing 
repression; our data extended these finding by proposing an involvement of 
DAZAP1 in these models. In the simplest scenario, silencer-bound hnRNP A1/A2 
and DAZ API factors can directly antagonize another key splicing factor involved in 
exon definition. The hnRNP Al, hnRNP A2, and DAZAP1 binding is very close to 
the 3’ss and this could interfere with the early spliceosome assembly by blocking the 
access to general splicing factor such as U2AF65, U2AF35 and/or U2 snRNP to the 
acceptor site (Fig 4. lb) (Tange, Damgaard et al. 2001). However, it is also possible 
that the initial binding of hnRNP A l, hnRNP A2 and DAZAP1 at the T6 sequence
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could nucleate the formation of a chain of inhibitory proteins along the other two 
silencer elements located in the middle and at the end of the exon. These two 
silencers, as the T6 mutant sequence, contain TAG, which might represent the “core” 
sequences involved in this process. This model for cooperative repression involves 
the creation of a “zone of silencing” due to the propagation of the repressor proteins 
that will cover the entire exon 18, leading to its exclusion, as previously suggested 
for a hnRNP Al silencer element described in HIV-1 tat exon 3 systems (Zhu, 
Mayeda et al. 2001).
Recently, a concomitant disruption of an exonic splicing enhancer not dependent on 
ASF/SF2 has been suggested to be involved in the exon skipping induced by the T6 
mutant (Kashima, Rao et al. 2007). The presence of this putative enhancer was 
suggested by the fact that the siRNA-mediated silencing of hnRNP A1/A2 did not 
have a significant effect on T6 aberrant skipping (Kashima, Rao et al. 2007). We 
have carefully evaluated this point by performing co-transfection experiments with 
the SMN2 and T6 BRCA1 minigenes and in both cases we observed that silencing of 
hnRNP A1/A2 rescued both defective exons (Fig. 3.4.4). We do not have a clear 
explanation for these differences in the results. An inhibitory effect on the BRCA1 
recognition may differ depending on the variable concentration of splicing factors, 
like DAZAP1, due to the use of different cell types. These factors might efficiently 
replace hnRNP A1/A2 at the T6 mutant silencer or can act on other inhibitory 
splicing regulatory elements, thus modulating the siRNA rescue splicing efficiency. 
However, even if our results clearly indicate that the T6 mutant creates a strong 
silencer, we cannot exclude the simultaneous disruption of a weak enhancer region 
present in the 5’ end of the BRCA1, as suggested by our double delition analysis 
(Fig. 3.5.2B lane 8), in agreement with Kashima et al. (Kashima, Rao et al. 2007).
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Figure 4.1: Splicing regulatory elements in BRCA1 exon 18 and creation of an
ESS by the T6 mutant. (A) WT exon 18 contains two weak ESEs (light grey boxes) 
and two ESSs (black boxes) and its inclusion is largely dependent on the 3’ and 5’ss 
definition. (B-C) The G to T mutation in position +6 creates a strong silencer element 
at the 5’ end of the exon binding to hnRNP A1/A2 and DAZAP1 and may also 
disrupt a weak splicing enhancer. The ASF/SF2 ESE located in the middle of exon 
18 stimulates BRCA1 exon 18 splicing only in the context of the T6 mutant. The 
mechanism of inhibition could be mediated by blocking 3’ss recognition (B) or by 
forming a zone of silencing that covers the entire exon (C).
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In fact, the partial exon 18 skipping obtained by the double deletion of the 4-9 and 
23-32 regions (Fig. 3.5.2B, lane 8) might be due to the presence of two nearby weak 
enhancer sequences, which may contribute in a synergic manner to the definition of 
the WT exon. Thus, with the limitation provided by the gross deletion analysis, 
which can interfere with RNA secondary structure and acceptor site accessibility or 
reduce the exon definition below a critical threshold, the 5’ end on BRCA1 exon 18 
might contain a weak enhancer, which becomes relevant only when the downstream 
enhancer is deleted.
However, the extent of splicing inhibition mediated by the A23-32 deletion in the 
context of the single T6 substitution was more severe than the splicing inhibition 
mediated by the presence of the A4-9 deletion (Fig. 3.5.2B, lane 4 vs. 8). This result 
indicated that the inhibitory effect of the T6 mutation is more repressive than the 
removal of the weak enhancer between position +4-9, further indicating the creation 
of a silencer element as the main cause of pathological exon 18 skipping.
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FUTURE DIRECTIONS
In this thesis the role of exonic regulatory elements in the aberrant splicing of the 
human BRCA1 exon 18 have been investigated. This study brings some insights into 
the rather complex regulation of BRCA1 exon 18, whose T6 mutation provoke the 
substantial exon 18 skipping.
The data collected in this thesis clearly suggest that the T6 BRCA1 exon 18 splicing 
is modulated by several other cis-acting elements distributed along the exon. These 
elements were identified mainly by large deletion analysis and accordingly, it will be 
necessary to better characterize their specific contribution in the regulation of 
BRCA1 exon 18 splicing. Further experiments will characterize in more detail the 
nucleotide composition and the binding properties of these sequences. In addition, it 
would be important to explore the potential role of intronic regions, which, as 
described for the SMN case (Miyajima, Miyaso et al. 2002; Miyaso, Okumura et al. 
2003; Singh, Singh et al. 2006; Kashima, Rao et al. 2007) might contribute to the 
splicing regulation.
In this thesis a novel role for DAZAP1 in the pre-mRNA splicing regulation has been 
described. An obvious question that needs to be addressed is the involvement of this 
splicing factor in the regulation of the similar SMN1/2 model. The behavior of 
BRCA1 T6 exon 18 mutation in fact, is analogous to that which promotes exon 
skipping in SMN2 exon 7. It will be interesting to compare the two models, in 
particular a possible role of DAZAP1 in the SMN2 exon 7 splicing regulation. 
DAZAP1 might be also involved in the control of other alternative splicing events. 
Using an exon array in DAZAP1 depleted cells it will be possible to study the role of 
this protein in general and/or in specific splicing events.
Co-transfection experiments suggested that the 23-32 region of the BRCA1 exon 18 
is an enhancer element connected to the ASF/SF2 factor. This hypothesis will be 
further explored by performing binding experiment in order to confirm the presence 
of ASF/SF2 factor in the 23-32 exonic region. Moreover, the result obtained by the 
double deleted construct (A4-9/A23-32) supports the notion of a weak ESE in the 
vicinity of position +6, even if not related to ASF/SF2. Additional trans-acting 
factors could be involved in the recognition of this weak enhancer and their presence 
will be investigated by binding experiments.
A more general mechanistic problem will also be considered in order to understand 
the role of hnRNP A l, -A2 and DAZ API complex in the splicing inhibition. This 
binding may inhibit the recognition of the 3’ss by U2AF35 or in interfering with 
subsequent steps of spliceosome assembly. A set up of an in vitro system will allow 
the study of the different splicing steps. It is also possible, as indicated in the model 
(Fig. 4.1), that a cooperative binding of hnRNP A1/A2 and DAZAP1 covers the 
entire exon 18 and produces exon skipping. To this aim, the potential contribution of 
other silencers containing the TAG motifs, localized within the last part of exon 18, 
is going to be checked. The binding of hnRNP A l, -A2 and DAZ API to the first 
inhibitory element, surrounding the position +6, might promote a subsequent 
cooperative binding to the other putative ESSs localized at the end of the exon 18.
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5 MATERIALS AND METHODS
Chemical Reagents.
General chemicals were purchased from Sigma-Aldrich, Merck, Gibco BRL and 
Boehringer.
Standard solutions.
All solutions are identified in the text except for the following:
TE: 10 mM Tris-HCl (pH 7.4), 1 mM EDTA (pH 7.4) 
lOxTBE: 108 g/1 Tris-HCl, 55 g/1 Boric acid, 9.5 g/1 EDTA
6X DNA sample buffer: 0.25 % w/v bromophenol blue, 0.25 % w/v xylene cyanol 
FF, 30 % v/v glycerol in H2O.
5X Running Buffer: 30 g Tris-HCl, 144 g glycine, 5 g SDS in 1L 
IX Blotting buffer: 3.03 g Tris-HCl, 14.4 g glycine, 20% methanol in 1L 
10X Protein sample buffer: 20 % w/v SDS, 1 M DTT, 0.63 M Tris-HCl (pH 7), 0.2 
% w/v bromophenol blue, 20 % v/v glycerol, 10 mM EDTA (pH 7).
PBS IX: 137 mM NaCl, 2.7 mM KC1, 10 mM Na2HP04, 1.8 mM KH2P 0 4, pH7.4
DNA preparation.
Small scale preparation o f plasmid DNA from bacterial cultures.
Single bacterial colony was selected and transferred into 3 ml of LB medium 
containing the ampicillin in a loosely capped 15-ml tube. The culture was incubated 
overnight at 37°C with vigorous shaking. Rapid purification of small amounts of 
recombinant plasmid DNA was performed using the method based on alkaline lysis 
of recombinant bacteria previously described by Sambrook (Sambrook 1989).
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Briefly, the bacterial pellet was resuspend in 100 pi of solution I (10 mM EDTA pH 
8.0, 25 mM Tris-HCl pH 8.0, 50 mM glucose). Then 200 pi of solution II for lysis 
(0.2 M NaOH, 1% SDS) was added and the contents mixed by inversion. Lysis was 
then stopped with 150 pi of solution III for neutralization (60 ml of 5M potassium 
acetate, 11.5 ml of glacial acetic acid, 28.5 ml H2O) and the content was mixed by 
inversion. The bacterial lysate was then centrifuged in an Eppendorf microcentrifuge 
at maximum speed for 5 minutes and the supernatant transferred to a new tube. An 
equal volume of 1:1 v/v phenol: chloroform solution was added to the supernatant. 
The tube was then vortexed and centrifuged as above. The step was repeated with 
aqueous phase and the equal volume of chloroform. The aqueus phase containing 
DNA was then recovered and the DNA was precipitated by adding 2 volumes of 
ethanol. The final pellet was resuspended in 47 pi of dH20 with 3 pi of RNase A 
(Sigma Chemicals Ltd.) from a stock of 20 mg/ml prepared in sterile water and 
boiled for 10 minutes to destroy trace amounts of DNase activity. The DNA sample 
was then digested at 37°C for 1 hour in order to eliminate all the RNA from the 
sample. Routinely, 2-3 pi of such DNA preparation were taken for restriction enzyme 
digestion and sequence analysis.
Large scale preparation o f plasmid DNA from bacterial cultures.
Large-scale and pure preparations of plasmid DNA were necessary in order to 
perform different kind of experiments like transfection, in vitro transcription and 
vectors/inserts preparation. JetStar purification kit (Genomed) was used according to 
the manufacturer’s instructions. In order to get a good amount of plasmid, we used 
an overnight bacterial culture of 50 ml in LB medium.
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Genomic DNA preparation.
Peripheral blood (5 ml) was treated with 20 ml of Lysis Buffer (Sucrose 0.32 M, 
Tris-HCl 10 mM pH 7.5, MgCL 5 mM, Triton X-100 1%) and incubated on ice for 
15 min. The mix was centrifuged 10 min at 1000 g at 4 °C. The pellet was washed 
three times with Fisio Buffer (NaCl 0.075 M, EDTA 0.025 M pH 8) and resuspended 
in 1 ml of Resuspension Buffer (Tris-HCl 10 mM pH 7.5-8, NaCl 0.4 M, EDTA 2 
mM). 200 pi of SDS 10% were added and the mixture was incubated at 37 °C 
overnight to facilitate the extraction. The following day 600 pi of NaCl saturated 
water solution was added and the samples were mixed for 15 seconds to allow the 
protein precipitation. The mix was centrifuged 15 min at 1500g to pellet the proteins. 
The supernatant was recovered and the centrifugation repeated a second time. 
Finally, 1 volume of isopropanol was added to the supernatant to precipitate the 
DNA. Precipitated DNA was removed with a Pasteur, washed in 1 ml of 70% 
ethanol and resuspended in 500 pi of water. The DNA was then checked by 
electrophoresis on a 0.8% w/v agarose gel, quantified by spectrophotometer and 
stored at -20°C until used for PCRs.
RNA preparation from cultured cells.
Cultured cells were washed two times with IX PBS and then RNA TRI reagent, 
purchased from Ambion, was added according to the manufacturer’s instructions. 
Chloroform extraction was performed and supernatant precipitation was obtained by 
adding isopropanol. Then we rinsed the pellet in 70% ethanol. The final pellet was 
resuspended in H2O and stored at -80°C. The RNA quality was checked by 
electrophoresis on a 1% agarose gel. If it was the case half of the resuspended RNA 
could be treated with DNase RNase-free (Roche Diagnostic) in IX DNase buffer. 
The digest was incubated at 37°C for 30 minutes, and then the RNA was purified by
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acid phenol extraction and precipitated by adding 2 volumes of ethanol and 1/10 
volume of 3M NaOAc pH 5.2. The final pellet was resuspended in H2O and frozen at 
-80 °C. The RNA quality was checked again by electrophoresis on 1% agarose gels.
Estimation of nucleic acid concentration.
The concentration of a DNA or RNA sample can be checked by the use of UV 
spectrophotometry. Both RNA and DNA absorb UV light very efficiently making it 
possible to detect and quantify either at low concentrations. The nitrogenous bases in 
nucleotides have an absorption maximum at about 260 nm. An optical density of 1.0 
at 260 nm is usually taken to be equivalent to a concentration of 50 pg/ml for double 
stranded DNA, 40 pg/ml for single stranded DNA and RNA, and approximately 20 
pg/ml for single-stranded oligonucleotide sample. The ratio of the absorbance at 260 
nm/ absorbance at 280 nm is a measure of the purity of a sample; it should be 1.8 for 
pure sample of DNA and 2 for RNA. These values are reduced by protein 
contamination (Sambrook 1989).
Enzymatic modification of DNA.
Restriction enzymes
Restriction enzymes were from New England Biolabs, Inc(USA) or Pharmacia 
Biotech (Sweden). All buffers were also supplied by the same company and were 
used according with the manufacturer’s instructions. For many analytical digests we 
also used 0.5X, IX or 2X concentration of lOx OPA buffer (100 mM Tris-acetate 
(pH 7.5), 100 mM magnesium acetate and 500 mM potassium acetate). For analytical 
digests 100-500 ng DNA were digested in a volume of 20 pi containing the 
appropriate U of the restriction enzyme per pg DNA. The digest was incubated for 2- 
4 hours at the optimal temperature required by the enzyme used. Preparative
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digestions of vectors and inserts were made of 5-10 pg DNA using the appropriate 
condition needed by the restriction enzyme in 100-200 pi reaction volume. 
Enzymatic activity was then removed either by heat inactivation or by phenol- 
chloroform extraction.
DNA Polymerase I, Large (Klenow) fragment.
Klenow enzyme was used to treat PCR products for blunt-end creation by 3' 
overhang removal and 3' recessed end fill-in. Briefly the DNA was dissolved in any 
IX restriction enzyme NEBuffer or IX EcoPol Reaction Buffer and supplemented 
with 33 pM each dNTP if “fill-in” was required (DNA fragments with protruding 
3’ends). Then, 1U of Klenow per pg DNA was added and the mixture was incubated 
15 minutes at RT. The reaction was inactivated by by heating at 75°C for 20 minutes.
T4 Polynucleotide Kinase.
T4 polynucleotide kinase (New England Biolabs Inc) catalyzes the transfer and 
exchange of phosphate from ATP to the 5" -hydroxyl terminus of double-and single­
stranded DNA and RNA to allow subsequent ligation or end-label for probes 
production. The proper units of T4 polynucleotide kinase, IX of its reaction buffer 
(70 mM Tris-HCl pH 7.6, 10 mM MgCL, 5 mM dithiothreitol) and ATP were added 
to the DNA and incubated at 37°C for 30 minutes. The enzyme was inactivated by 
incubation at 65°C for 20 min.
Calf intestal phosphatase (CIP).
Calf intestal phosphatase (CIP), provided from New England Biolabs Inc, catalyzes 
the removal of 5 'phosphate groups from DNA and RNA. Since CIP-treated 
fragments lack the 5 ' phosphoryl termini required by ligases, they cannot self-ligate.
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This property was used to decrease the vector background in cloning strategies. The 
standard reaction was carried out in a final volume of 50-100 pi using 1U of enzyme 
per 0.5 pg DNA at 37°C for 1 hour.
T4 DNA ligase
T4 DNA ligase catalyzes the formation of phosphodiester bonds between 
neighbouring 3 "-hydroxyl- and 5 "-phosphate ends in double-stranded DNA, requiring 
ATP as a cofactor in this reaction. This enzyme was purchased from Roche 
Diagnostic and was used to join double stranded DNA fragments with compatible 
sticky or blunt ends. A standard reaction comprises 20 ng of linearised vector and 5- 
10 fold molar excess of insert in a total volume of 20 pi containing IX ligase buffer 
and 1U of enzyme. Reactions were carried out at room temperature for at least 2-4 
hours. In some ligations synthetic oligonucleotides were used as inserts for the 
reactions. In these cases, amounts added to each reaction to obtain ligation of the 
oligonucleotides in the resulting plasmids were about 50-100 fold molar excess over 
the DNA vector.
Agarose gel electrophoresis of nucleic acid.
DNA samples were size fractionated by electrophoresis in agarose gels ranging in 
concentrations from 0.8 % w/v (large fragments) to 2 % w/v (small fragments). The 
gels contained ethidium bromide (0.5 pg /ml) and IX TBE solution. Horizontal gels 
were used for fast analysis of DNA restriction enzyme digests, estimation of DNA 
concentration, or DNA fragment separation prior to elution from the gel. A fast 
analysis of RNA samples was obtained by using a 1% agarose gel. The gels were 
electrophoresed at 50-80 mA in IX TBE running buffer for a time depending on the
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fragment length expected and gel concentration. DNA was visualized by UV 
transillumination and the result recorded by digital photography.
Elution and purification o f DNA fragments from agarose gels 
This protocol was used to purify both vectors and inserts of DNA for cloning 
purpose. The DNA samples were electrophoresed onto an agarose gel as described 
previously. The DNA was visualized with UV light and the required DNA fragment 
band was excised from the gel. This slab was cut into pieces, and the QIAquick Gel 
Extraction Kit was used according to the manufacturer’s instructions. Briefly, 3 
volumes of Buffer QX1 were added to 1 volume of gel for DNA fragments and then 
incubated at 50 °C for 10 min, vortexing every 5 min. After the gel slice was 
dissolved completely 1 gel volume of isopropanol was added to the sample. The 
mixture was loaded into a prepared column and centrifuged at maximum speed for 1 
min. The flowthrough was discarded. One washing step was performed using 750 pi 
of PE buffer. The bound DNA was eluted with 30-50 pi of sterile water. The amount 
of the recovered DNA was approximately calculated by UV fluorescence of 
intercalated ethidium bromide in agarose gel electrophoresis.
Amplification of selected DNA fragments.
The polymerase chain reaction was performed using both genomic or plasmid DNA 
as templates and following the basic protocols of Roche Diagnostic Taq DNA 
polymerase. The volume of the reaction was 50 pi and comprised: lx Taq buffer, 
dNTP mix (100 pM each), oligonucleotide primers (100 nM each), Taq DNA 
polymerase 2.5-5 U and 100 ng of genomic DNA or 0.1 ng of plasmid. All the 
synthetic DNA oligonucleotides used for PCR amplification were purchased from 
Sigma Aldrich (http://orders.sigma-genosvs.eu.com).The standard amplification
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conditions were the following: 94°C for 3 min for the initial denaturation, 94°C for 
45 s, 54°C for 45 s, 72°C for 45 s for 30 cycles and 72°C for 10 min for the final 
extension. PCRs were optimized to be in the exponential phase of amplification and 
products were routinely fractionated in 2% (w/v) agarose gels.When different PCR 
conditions were used; they are described in each particular case. The amplifications 
were performed on Cetus DNA Thermal Cycler (Perkin Elmer) or on a Gene Amp 
PCR System (Applied Biosystem).
Sequence analysis for cloning purpose.
Sequence analysis of plasmid DNA was performed using CEQ 2000 sequencer 
(Beckman Coulter).The plasmid DNA of interest (approximately 500 ng) was 
purified through a MicroSpin S-400 HR Column (Amersham Pharmacia Biotech). 
The DNA was then amplified by asymmetric PCR (only one primer) using 
fluorescent labeled dideoxy nucleotide terminations according to the manufacturers’ 
instructions. The samples were analyzed by loading them into the automatic 
sequencer. The first two primers listed were specific for the pBluscript KS plasmid 
whereas the other oligonucleotides were annealing in different position along the 
minigene sequence, 
o UNIVERSAL Dir 
5 ’ -GTTTTCCC AGTC ACGAC-3 ’ 
o UNIVERSAL Rev 
5 ’ -GGAAAC AGCTATGACCATG-3 ’ 
o BRC 281 Dir
5 ’ -TC AGCCTCTGATTCTGTC ACC AGG-3 ’ 
o BRC 350 Dir
5 ’ -TGAGGCTCTTTAGCTCCTT AGG-3 ’
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o BRC 474 Rev
5 ’ -CCTAGA A A ATATTTC AGTGTCCGTTC AC-3 ’ 
o BRC 616 Rev
5 ’ -GGTAACTC AG ACTC AGC ATC AGC AA-3 ’
Bacterial culture
The E.coli DH5a strain was used for ligation transformation, plasmid amplification 
and growth. The E.coli BL12 DE3 (Novagen) bacteria were used for protein 
production. Both bacteria strains were maintained in short term as single colonies on 
agar plates at 4°C and for long term storage on glycerol stocks (sterile glycerol to a 
final 30 % v/v concentration to liquid bacterial cultures) stored at -80°C. When 
necessary, from glycerol stocks the bacteria were plated and amplified by an 
overnight incubation in Luria-Bertani medium (per liter: 10 g Difco Bactotryptone, 5 
g Oxid yeast extract, 10 g NaCl, pH 7.5). Bacterial growth media were sterilized 
before use by autoclaving. Ampicillin (Sigma-Aldrich) was added to media to a final 
concentration of 100 pg/ml.
Preparation o f bacterial competent cells.
Bacterial competent cells of both strains were prepared following the method 
described by Chung (Chung, Niemela et al. 1989). E.coli strains were grown 
overnight in 10 ml of LB at 37°C. The following day, 200 ml of fresh LB were added 
and the cells were grown at room temperature for 2-3 h until the OD600 was 0.3 -  
0.4. Then the cells were put in ice and centrifuged at 4°C and 1000 g for 15 minutes. 
The pellet was resuspended in 1/10 volume of cold IX TSS solution (10% v/v PEG, 
5% v/v DMSO, 35 mM MgCb, pH 6.5 in LB medium). The cells were divided into 
aliquot, rapidly frozen in liquid nitrogen and stored at -80°C. Competent cells
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efficiency was tested using 0.1 ng of pUC19 control DNA plasmid. Transformation 
efficiency should be greater than 1 x 106 transformants/pg pUC19 DNA. So the 
competence was deemed satisfactory if this procedure resulted in more than 100 
colonies.
Transformation o f bacteria
Transformations of ligation reactions were performed using half of the initial 
reaction volume. Transformation of positive clones was carried out using lng of the 
DNA plasmid. Briefly the transformation protocol consisted in 30 min of incubation 
on ice of DNA with 50 pi of competent cells followed by a heat shock at 42°C for 2 
minutes. The cells were placed again on ice for 2 minutes and then spread onto 
agarose plates containing the appropriate antibiotic concentration (100 pg/ml of 
ampicillin). The plates were incubated for 12-15 hours at 37°C in order to allow the 
colonies formation. When the DNA inserts were cloned into (3-galactosidase-based 
virgin plasmid (pUC19, Bluscript KS), 30 pi of IPTG 100 mM and 30 pi of X-gal 
(4% v/v in dimethylformamide) were prepared onto the surface of the agarose before 
plating to facilitate the screening of positive clones (white colonies) through 
identification of p-galactosidase activity (blue colonies).
Hybrid minigene constructs.
Transient transfection of minigenes is a commonly used in vivo technique to identify 
the different features of exon regulation during splicing process. It is a good method 
to study specific cis-acting elements that control constitutive and alternative exons, 
the cell-specific splicing pattern and also to identify trans-acting factors that 
recognize these elements and regulate splicing (Cooper 2005).
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A minigene is a “simplified” version of a gene and usually contains a genomic region 
from the gene of interest that includes the alternatively spliced part and its flanking 
genomic seqences. The genomic segment was generated by PCR amplification 
directly from target DNA as template and the oligonucleotides used has to contain 
the restriction enzyme sites at their ends that match restriction sites in the recipient 
plasmid (Cooper 2005). This system, after transient transfection and RNA analysis, 
allowed us to study the splicing outcome.
The minigenes used derived from a basic hybrid construct containing exons from a- 
globin and fibronectin, under the control of the a-globin promoter. The intronic 
region between the two fibronectin exons contains a unique Ndel site in which the 
target genomic segment under study can be inserted. Moreover the two junctions 
between the a-globin exon 3 and the fibronectin exons have a BstEII site. This region 
in the middle of the two restriction sites can be removed and substituted with a large 
genomic region of interest. In this thesis two minigenes have been created: the pTB 
and pBRA. This has been done through PCR amplification of the exon under study 
with its intronic flanking regions, treatment with Klenow-Kinase enzymes as 
described previously, purification from agarose gel and cloning in pBluscript KS 
vector into the restriction site Smal. Following sequencing, in order to check the 
nucleotide sequence to be correct, the subcloning in the minigenes was performed 
using the enzyme restriction site Ndel or BstEII, depending on the case.
The minigene contains at the 5’ end the a-globin gene promoter and SV40 enhancer 
sequences to allow polymerase II transcription in the transfected cell lines. The 
reporter minigene is composed of a-globin (black boxes) and fibronectin exons 
(shaded boxes), whiles at the 3’ end contains a functionally competent 
polyadenylation site, derived from the a-globin gene. The unique Ndel and the 
BstEII sites are indicated.
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pTB minigene.
The BRCA1 genomic region encompassing exon 18 and adjacent intronic sequences 
(289 bp of intron 17, full length exon 18 and 255 bp of intron 18) was amplified with 
BRC 138 Dir and BRC760 Rev primers and blunt ligated in the Smal site of 
pBluscript KS to generate pBS BRA18. Following sequencing in order to check the 
nucleotide sequence to be correct, the subcloning in the pTB minigene was 
performed using the enzyme restriction site Ndel. The the a-globin, the fibronectin 
and BRCA1 18 exons and are in frame, 
o BRC 138 Dir
5 ’ -GGCATATGGAGATCTATAGCTAGCCTTGGCGTCTAGAAGATGG-3 
o BRC 760 Rev
5-AATCCCTAGCTCATATGCTAACATTGCTAGG-3’ 
pBRAminigene. 0
The BRCA1 genomic region containing the last 85 bp of exon 17 and first 1408 bp 
of intron 17 was amplified from normal DNA using BRC90BstEII Dir and BRC1566 
Rev primers and blunt ligated in the Smal site of pBluscript KS to generate pBS 
BRA17. Similarly, the last 334 bp of intron 18 along with 58 bp at the beginning of 
exon 19 were amplified with BRC735 Dir and BRC4451 Rev primers and blunt 
ligated in Smal site of pBluscript KS to generate pBS BRA 19.
The two plasmids, pBS BRA 17 and 19, were sequenced in order to check the 
identity of the DNA sequence. Subsequently, pBS BRA 19 was digested with Ndel 
and Kpnl and cloned in the corresponding sites of pBS BRA17 to generate pBS 
BRA17-19, with Ndel as unique site in the middle. The BstEII- BstEII fragment 
contained in pBS BRA17-19 was then inserted in the unique BstEII site of a 
modified pTB a-globin minigene to obtain pBRAint. pBS BRA18, described
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previously, was digested and subcloned in the pBRAint minigene in the unique Ndel 
site creating the final minigene named pBRA. The final minigene lacks the central 
part of intron 17 (1960 bp) and the a-globin and BRCA1 17, 18 and 19 exons are in 
frame.
o BRC 90 Dir
5’- CTGGTACCAAGTTTGCCAGAAAACACCACATCACTTTAACTAATC -3’ 
o BRC 1566 Rev 
5'- AACACCCAGAGGTCTCC -3’ 
o BRC 735 Dir
5'- TAGCAATGTAGCATATGAGCTAGGGATTTA -3' 
o BRC 4451 Rev
5 ’ - AAC ATCAAGTACTTACCTCATTC AGC-3 ’
PstI -  EcoRI cassette.
On both minigenes an EcoRI site was inserted in intron 18 (49 bases downstream the 
5’ss of exon 18) by overlapping PCR using as template pBS BRA 18. As external 
primers were used the Universal Dir and Rev and as internal the following 
oligonucleotides: 
o BRC 560 EcoRI Dir
5 ’ - AACACCTC AGAATTCCATTTTTAC ACCTAACG-3 ’ 
o BRC 560 EcoRI Rev
5 ’ -GGTGTAAAAATGGAATTCTGAGGTGTT-3 ’
The final amplified fragment, obtained after a second round of PCR performed using 
the external oligos, was Ndel digested and cloned into the two minigenes described 
above, pTBWT or pBRAWT minigenes. The natural PstI (next to the 3’ss of exon
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18) and the artificial EcoRI unique sites create a cassette system, which was used to 
facilitate the subsequent cloning procedures.
pBRA minigenes variants.
All pTB and pBRA constructs carrying point, double or complex mutations were 
generated by site-directed mutagenesis using standard PCR conditions. All the 
nucleotide substitutions were produced using as PCR template pBRA-WT hybrid 
minigene, as primer sense different degenerate oligonucleotides and as antisense 
primer the following: 
o BRC 616 REV
5 ’ -GGTA ACTC AG ACTC AGC ATC AGC A A-3 ’
Most of the different PCR products were gel purified and normally Pstl-EcoRI 
digested and directly cloned in pBRA-WT hybrid minigene or in pTB WT plasmid. 
In some cases digestion was carried out by using different restriction enzymes 
mentioned below. The presence of the mutations in all the constructs was checked by 
a CEQ2000 sequencer (Beckman Coulter, Fullerton, CA) according to the 
manufacturer's instructions and using the primers described before.
Generation o f point mutations within the BRCA1 exon 18 regulatory region.
The sense oligos used to introduce point mutations in BRCA1 exon 18 regulatory 
region were the following: 
o BRC CD4 Dir (D=A, G, T). 
5’-TCATTCTGCAGATGDTGAGTTTGTGTGTGAA-3’ 
o BRC T5V Dir (V=A, C, G).
5 ’ -TCATTCTGCAGATGC VGAGTTTGTGTGTGAA-3 ’
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o BRC G6H Dir (H=A, C, T).
5 ’ -TC ATTCTGCAG ATGCTHAGTTTGTGTGTGAA-3 ’ 
o BRC A7B Dir (B=C, G, T).
5 ’ -TC ATTCTGC AGATGCTGBGTTTGTGTGTGAA-3 ’ 
o BRC G8H Dir (H=A, C, T).
5 ’ -TC ATTCTGCAGATGCTGAHTTTGTGTGTGAA-3 ’ 
o BRC T9V Dir (V=A, C, G).
5 ’ -TC ATTCTGC AG ATGCTGAGVTTGTGTGTGAA-3 ’ 
o BRC T10R Dir (R=A, G).
5 ’ -TC ATTCTGC AG ATGCTGAGTRTGTGTGTG A A-3 ’ 
o B R C llG D ir
5 ’ -TC ATTCTGC AG ATGCTGAGTTGGTGTGTGAA-3 ’
Generation o f double point mutations within the BRCA1 exon 18 regulatory 
region.
The sense oligos used to introduce double point mutations, in the BRCA1 exon 18 
regulatory region were the following: 
o BRC 4D6T Dir (=A, G, T).
5 ’ -TC ATTCTGC AG ATGRTTAGTTTGTGTGTGAA-3 ’ 
o BRC 5V6T Dir (V=A, C, G).
5 ’ -TC ATTCTGC AG ATGCVTAGTTTGTGTGTGAA-3 ’ 
o BRC 6T7B Dir (B=C, G, T).
5 ’ -TC ATTCTGC AG ATGCTTBGTTTGTGTGTGA A-3 ’ 
o BRC 6T8H Dir (H=A, C, T).
5 ’ -TC ATTCTGC AG ATGCTTAHTTTGTGTGTG A A-3 ’
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o BRC 6T9V Dir (V=A, C, G).
5 ’ -TC ATTCTGC AGATGCTTAGVTTGTGTGTGAA-3 ’ 
o BRC 10A11G Dir
5 ’ -TC ATTCTGC AG ATGCTGAGT AGGTGTGTGAA-3 ’
Generation o f complex mutations within the BRCA1 exon 18 regulatory region.
The sense oligos used to introduce complex point mutations, in the BRCA1 exon 18 
regulatory region were the following: 
o BRC SMN1/2 Dir
5 ’ -TCATTCTGCAGATGCTYAGACAGTGTGTGAACGGACACTGAAATATT3 ’ 
o BRC 6hnRNP Alselex Dir
5 ’ -TC ATTCTGCAGATGCTTAGGGAGTGTGTGAACGGACACTGAAATATT3 ’
Generation o f small overlapping deletions within the BRCA1 exon 18.
Most of the small overlapping deletions introduced within exon 18 sequence were 
achieved by a unique PCR amplification using the Dir primers listed below and the 
BRC 616 Rev oligo. 
o BRC Delta 4-9 Dir
5’-TC ATTCTGC AGATGTTGTGTGTGAACGGACACTGAAATATTTTCT AG-3’ 
o BRC Delta 12-21 Dir (K=G, T).
5 ’ -TC ATTCTGC AGATGCTK AGTTTGGAC ACTG A A ATATTTTCT AG-3 ’ 
o BRC Delta 23-32 Dir (K=G, T).
5 ’ -TCATTCTGCAGATGCTKAGTTTGTGTGTGAACGTATTTTCTAGGAATT 
GCG-3’
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o BRC Delta 35-44 Dir (K=G, T).
5 ’ -TC ATTCTGC AGATGCTKAGTTTGTGTGTGAACGGACACTGAAATAATT 
GCGGGAGGAAAATG-3' 
o BRC Delta 4-9/23-32 Dir.
5 ’ -TC ATTCTGC AGATGTTGTGTGTGAACGTATTTTCTAGGAATTGCG-3'
The two delta constructs containing the deletion (-10 bp) within the exon 18 between 
47-57 and 64-74 regions were created by overlapping PCR using suitable primers on 
pBRA WT or T6 minigenes as templates. The first round of PCRs was performed 
using two sets of primers, combining an external primer with an internal one. The 
external oligos were BRC218 Dir and BRC 616 Rev described before. The internal 
primers used were the following: 
o Delta 47-57 Dir
5 ’ -TATTTTCT AGGA AT A ATGGGTAGTTAGCTATTTC-3 ’ 
o Delta 47-57 Rev
5 ’ - ACTACCC ATTATTCCTAG A A AATATTTC AGTGTCCG-3' 
o Delta 64-74 Dir
5 ’ -GGAGGA AA ATGGGTTCTGTA AGTATA ATACTAT-3' 
o Delta 64-74 Rev
5’-TATACTTACAGAAACCCATTTTCCTCCCGCAATTCCTAG-3'
The second round of PCR was carried out using the external primers and as template 
the two amplified products, obtained from the previous two separated PCRs, mixed 
together. All the inserts obtained were cloned by the standard Pstl-EcoRI cassette 
procedure.
Eukaryotic cell lines.
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The cell line used for transfection and cotransfection experiments was Hep3B cells: 
human hepatocellular carcinoma fibroblast-like. The cell line used for siRNA 
experiments was HeLa cells derived from cervical cancer cells.
Maintenance and analysis o f cells in culture.
Both Hep3B and HeLa cells were grown in Dulbecco’s Modiefied Eagle Medium 
(with glutamine, sodium pyruvate, pyriodoxine and 4.5 g/1 glucose) supplemented 
with 10% fetal calf serum (Euro Clone) and antibiotic Antimycotic (Sigma) 
according to the manufacturer’s instruction. A standard 100mm dish containing a 
confluent monolayer of cells was washed with 1XPBS solution, treated with 1-2 ml 
Trypsin (PBS containing 0.045 mM EDTA and 0.1% trypsin) and incubated at 37°C 
for 2 minutes or until cells were dislodged. After adding 5 ml of media, cells were 
precipitated by centrifugation and resuspended in pre-warmed medium. A 
subcultivation ratio of 1:4 to 1:6 was used for Hep3B and a ratio of 1:6 to 1:8 was 
performed for HeLa cells. 1 ml of this cell dilution was added to 10 ml fresh medium 
and plated in a new 100 mm dish.
Transfection o f recombinant DNA.
Hep 3B 3 x 105 cells were plated as described above into 35 mm tissue culture dishes 
in order to reach a final confluence of 40-70%. The DNA used for transfection was 
prepared with JetStar purification kit (Genomed) as previously described. Liposome- 
mediated transfections human hepatocarcinoma cells were performed using DOTAP 
Liposomal Transfection Reagent (Alexis Biochemicals). For 35mm dish we prepared 
separately 1.5 pg of plasmid in final 50 pi of H2O volume and 3 pi of lipofectin in 
47pi H2O for each sample. Then we mixed together the DNA and the lipofectin 
reagent to reach a final volume of lOOpl. This mixture was incubated at room
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temperature for 15-20 minutes to allow the formation of DNA-liposome complexes 
and then added to the cells in 2 ml of serum free culture medium. After 12-18 hours 
the medium was replaced with fresh medium supplemented by 10% FBS, 24 hours 
later, the cells were washed with IX PBS and harvested. Each transfection 
experiments were repeated at least 3 times.
Co-transfection.
For co-transfection experiments, 1.5 pg of the minigene plasmid was co-transfected 
with 1 pg of the plasmid carrying cDNA coding for different proteins. In detailed 
ASF/SF2 and hnRNP A1 coding sequence were cloned into a pCG vector (a kind 
gift from Dr J. Caceres) wherease hnRNP A2 and DAZAP1 cDNA were inseterted 
into pFlag vector.When necessary 0.5 pg of the pCG or pFlag empty vector was used 
as a control.
mRNA functional splicing analysis. 
cDNA synthesis.
In order to synthesize the first-strand cDNA, 3-5 pg of total RNA extracted from the 
cells were mixed with the following components: 200 ng of Random Primers 
(Pharmacia), 1 mM dNTPs mix and strile water to reach the final volume of 12 pi. 
The mixture was then denaturated at 65°C for 5 minutes and quick chilled on ice. 
After denaturation specific solutions, purchased from Invitrogen, were added to the 
reaction: IX first strand buffer (10 mM Tris-HCl ph8.4, 50 mM KCL, 2.5 mM 
MgCb) 10 mM DTT, 200 U of Moloney Murine Leukemia Virus reverse 
transcriptase and 20 U of RNAse inhibitor (Ambion). The final mixture was then 
incubated at least 1 hour at 37°C. 10% of the first strand reaction (2 pi of the cDNA) 
was used as PCR template.
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PCR analysis.
PCR was carried out as described previously using standard cycles in a final reaction 
volume of 30 pi. Oligonucleotides used for that PCR analysis were those specific for 
the minigene system used or for the endogenous RNA of interest. To amplify only 
the messengers derived from the pTB plasmid, the primers Alfa2-3 Dir and Bra2 Rev 
were used because specific for the junction between the alfa-globin exons 2-3 and the 
EDB +1 exon respectively. For the pBRA minigene the PCR was performed with 
BRC90BstDir and Glo800Rev which hybridize to BRCA1 exon 17 and a-globin 
exon 3 sequences, respectively, 
o ALFA 2-3 Dir
5 ’ -CAACTTCAAGCTCCTAAGCCACTGC-3 ’ 
o BRA 2 Rev
5 ’ -TAGGATCCGGTCACC AGGA AGTTGGTTAAATC A-3 ’ 
o BRC 90 DIR
5’-CTGGTACCAAGTTTGCCAGAAAACACCACATCACTTTAACTAATC-3’ 
o GLO 800 REV
5 ’ -GCTC AC AGAAGCCAGGAACTTGTCC AGG-3 ’
In the case of SMN2 plasmid the standard PCR conditions were changed according 
to Cartegni work (Cartegni, Hastings et al. 2006). Briefly, the amplification 
conditions were the following: 94°C for 3 min for the initial denaturation, 94°C for 
30 s, 58°C for 1 min, 72°C for lmin for 30 cycles and 72°C for 10 min for the final 
extension. The oligonucleotides sequences were taken from the same published work 
(Cartegni, Hastings et al. 2006). 
o pCIFwdB
5 ’ -GACTC ACTATAGGCTAGCCTCG-3 ’
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o SMN8-300+5’R
5 ’ - AAGTACTT ACCTGA A ATCT AATCC ACATTC A A ATTTTCTC A ACTG-3 ’
In the case of the endogenous RON amplification, the standard PCR was modified 
according to the previous published work (Ghigna, Giordano et al. 2005). Briefly, the 
number of cycles was increased up to 40 using these conditions: 94°C for 3 min for 
the initial denaturation, 94°C for 45 s, 56°C for 45 s, 72°C for 45 s and72°C for 10 
min for the final extension. The oligonucleotides sequences were described 
previously (Ghigna, Giordano et al. 2005). 
o DELTA Ron 2507 Dir 
5 ’ -CCTGAATATGTGGTCCGAGACCCCC AG-3 ’ 
o DELTA Ron 2991 Rev 
5 ’ -CTAGCTGCTTCCTCCGCC ACCAGTA-3 ’
The analysis of the amplified products, 5 ul of each PCR reaction, was performed by 
gel electrophoresis on a 1.5% or 2% agarose gel. The identity of the resulting 
splicing products was verified by direct sequence analysis. ImageJ 1.38 software 
(http://rsb.info.nih.gov/ii/) was used in order to quantify the ratio between exon 
inclusion/skipping. The variability among different experiments was always <20%.
In silico predictions.
In silico analysis was performed using the free access ESEfinder 
(http://rulai.cshl.edu/tools/ESE/)
RNA binding protein analysis.
Denaturing polyacrylamide gel electrophoresis (SDS-PAGE).
Protein samples were added to protein sample buffer (2X final). Conventional slab 
gel SDS PAGE (Laemmli 1970) was performed in vertical gels with the required
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percentage of polyacrylamide (37.5:1 acrylamide:bis-acrylamide, ProtoGel, National 
Diagnostics), depending on each case. The gels were run at 40 mA in IX SDS-PAGE 
running buffer. After running, gels were either stained with coomassie Blue R250 in 
methanol-water-acetic acid 45:45:10 (v/v/v) or electroblotted onto PVDF membrane 
(Amersham Biosciences) for Western Blot analysis.
Affinity purification ofRNA binding proteins.
Two synthetic RNA oligos were generated by Integrated DNA Technologies and 
used as targets for pull down assays, 
o Exon 18 WT
5’- UGCAGAUGCUGAGUUUGUGU -3’ 
o Exon 18 U6
5’- U GC AG AUGCUU AGUUU GU GU -3’
Briefly 12 pg of target BRCA1 RNA oligos were placed in 400 pi of reaction 
mixture (100 mM NaOAC, pH 5.0 and 5mM sodium m-periodate), incubated for 1 h 
in the dark at room temperature, ethanol-precipitated and finally resuspended in 100 
pi of 100 mM NaOAC (pH 5.0). Approx. 400 pi of adipic acid dehydrazide agarose 
beads 50% slurry (Sigma) previously equilibrated with 100 mM NaOAC (pH 5.2) 
were added to each periodate-treated RNA and the mix was incubated for 12 h at 4°C 
on a rotator. The beads with the bound RNA were then washed two times with 1 ml 
of 2 M NaCl, and equilibrated in IX washing buffer (5.2 mM HEPES at pH 7.5, 1 
mM MgCl2, 0.8 mM MgAcetate). Then the beads were incubated, in a final volume 
of 500 pi, with 0.5 mg of HeLa cell nuclear extract (C4, Biotech), IX binding buffer 
(5.2 mM HEPES, pH 7.9, 1 mM MgCl2, 0.8 mM MgAcetate, 0.52 mM DTT, 3.8% 
glycerol, 0.75 mM ATP, ImM GTP) and Heparin (final concentration 1 pg/pl), for 
30 min on a rotator, at room temperature. The beads were then washed four times
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with 1.5 ml of washing buffer before addition of SDS sample buffer and loading on 
SDS-10% polyacrylamide gels. Proteins were visualized by Coomassie brilliant blue 
staining as described above. Protein sequence analysis of the bands excised from the 
gel was performed using an electrospray ionization mass spectrometer (LCQ DECA 
XP-ThermoFinnigam). Protein bands were digested with trypsin and the resulting 
peptides were extracted with water and 60% acetonitrile/1% trifluoroacetic acid. 
Fragments were then analyzed by mass spectrometry and proteins were identified by 
analysis of the peptide MS/MS data with Turbo SEQUEST (ThermoFinnigam) and 
MASCOT (Matrix Science).
In vitro transcription for pull down analysis.
Plasmids for in vitro transcription were generated by annealing the sense and 
antisense oligos purchased from Sigma, for both WT and T6 mutant exon 18 
sequences.
o (UG)6-(U)5 - Exon 18 WT/U6 Dir
5’-CTGTGTGTGTGTGTTTTTTGC AG ATGCTKAGTTTGTGTG -3' 
o (UG)6-(U)5 - Exon 18 WT/U6 Rev
5’-GATCCACACAAACTMAGCATCTGCAAAAAACACACACACACAGAGCT-
3'
This was followed by direct cloning into SacI-BamHI digested pBluescript KS 
vector, under the T7 RNA promoter.
Part of the fibronectin EDA sequence was also cloned following the same procedure 
and used for pull-down analyses, acting as internal control for ASF/SF2 binding, 
o (UG)6-(U)5-EDA
5 ’ -CTGTGTGTGTGTGTTTTTTGC ACCTGATGGTG A AG A AG AC ACTGC AG A 
GC-3’
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Plasmids were first linearized by Hindlll digestion and then in vitro transcribed with 
T7 RNA Polymerase (Promega) according to standard procedures. Briefly 2-5 pg of 
DNA were transcribed using 40 U of T7 RNA polymerase, in the presence of IX 
transcription buffer, and 10 mM DTT, both supplied from Promega, 50 U of RNAsi 
inhibitor and 5 mM each of the four NTPs to a final volume of 100 pi. Following 
incubation for 2 h at 37°C, the RNA was purified using NICK columns (Amersham 
Bioscences), precipitated and resuspended in RNAse-free water. Approx 12-15 pg of 
transcribed and purified RNA were placed in a 400 pi reaction mixture of 100 mM 
NaOAc pH 5.0 and 5 mM sodium m-periodate (Sigma) and processed as described 
above for pull-down assays. After the final centrifugation, 60 pi of SDS-PAGE 
sample buffer were added to the samples, followed by heating for 5 min at 90°C 
before loading on 12% SDS-PAGE. The gel was electroblotted on a PVDF 
membrane according to standard protocols (Amersham Biosciences) and the 
membrane was blocked with IX PBS-5% skimmed milk. Proteins were identified 
using different antibodies and Western blots signals were detected with a 
chemiluminescence kit (ECL, Pierce Biotechnology). Rabbit anti-hnRNP A l serum 
was generously provided by R. Klima and polyclonal antibodies against hnRNP A2 
and TDP43 by E. Buratti (ICGEB, Trieste, Italy). Purified GST-DAZAP1 protein 
was used to immunize a rabbit (New Zeland strain) according to standard protocols, 
to obtain polyclonal antibodies anti DAZAP1. Anti-ASF/SF2 monoclonal antibody 
(mAb 96) was purchased from Zymed Laboratories Inc. and anti-tubulin mAb was 
kindly provided by F. Porro (ICGEB, Trieste, Italy).
Electromobility Shift Assay (EMSA).
Three synthetic RNA oligos exon 18 WT and U6, described previously, and the 
double mutant G4U6 were used as targets for EMSA experiments.
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o Exon 18 G4U6 ~
5 ’ -UGCAGAUGGUUAGUUUGUGU-3 ’
RNA synthetic oligonucleotides (200 ng) were labelled by phosphorylation with [y- 
32P] ATP and T4 polynucleotide kinase for 1 h at 37°C, precipitated and 
resuspended in 200 pi of water. Each binding reaction was made mixing the purified 
protein of interest with the labeled RNA oligo in lx  binding buffer (5.2 mM HEPES, 
pH 7.9, 1 mM MgC12, 0.8 mM MgAcetate, 0.52 mM DTT, 3.8% glycerol, 0.75 mM 
ATP, ImM GTP) to a 20 pi final volume. The reaction was left at room temperature 
for 15-20 minutes before loading the sample on a native polyacrylamide gel (5%) in 
0.5X TBE buffers which was run at 100-120 V at 4 °C for 3-4 h. The protein- 
nucleic acid complexes were visualized using biomax MS films (Kodak). The cDNA 
of each target protein was amplified and cloned in pGEX-3X plasmid (Pharmacia) 
and then expressed in BL21 (DE3) bacteria under the induction of 0.5 mM IPTG. 
The resulting recombinant proteins were purified with glutathione S-Sepharose 4B 
beads (Pharmacia) according to the manufacturer's instructions using imidazole 
buffers for protein elution.
Small interfering RNA (siRNA) transfection.
siRNA transfections were performed in HeLa cells using Oligofectamine Reagent 
(Invitrogen).The sense strands of RNAi oligos (Dharmacon) used for silencing the 
different target proteins were the following:
human hnRNP A l, 5’-CAGCUGAGGAAGCUCUUCA-3\ (Kashima and Manley 
2003);
human hnRNP A2, 5’-GGAACAGUUCCGUAAGCUC-3’ (Kashima and Manley 
2003);
human DAZ-AP1, 5’-GAGACUCUGCGCAGCUACU-3’;
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human ASF/SF2, 5’-ACGAUUGCCGCAUCUACGU-3’ (Cartegni, Hastings et al. 
2006);
luciferase #2 gene control, 5’-GCCAUUCUAUCCUCUAGAGGAUG-3’.
HeLa were plated at 2.5 x 105 cells per well in 60 mm plates to achieve 40-50% 
confluency. The next day, 6 pi Oligofectamine was combined with 24 pi of Opti- 
MEM medium (Invitrogen) and 5-10 pi of 40pM siRNA duplex oligos were diluted 
in a final volume of 400 pi of Opti-MEM medium. The two mixtures were combined 
and left for 20 min at RT. Finally, this mix was added to the cells, which were 
maintained in 1.6 ml of Opti-MEM. After 24h a second round of siRNA transfection 
was performed as described above. Six to eight hours later Opti-MEM was 
exchanged with DMEM medium without antibiotic and the cells were transfected 
with the minigene of interest using Qiagen Effectene transfection reagents. One pg 
of DNA was mixed with 8 pi of Enhancer for each transfection and the mixture was 
incubated at room temperature for 5 minutes to allow the condensation of the DNA. 
Then, 10 pi of Effectene were added to the mixture and an incubation of 10 minutes 
has been performed. After the addition of 500 pi of complete culture DMEM 
medium, the mixture was added to the cells in 4 ml of the same medium and 
incubated at 37°C. After 12 h, HeLa cells were harvested and divided in two parts for 
protein and RNA extractions. RT-PCR from total RNA was performed as described 
above in the transfection protocol. Whole protein extracts were obtained by cell 
sonication in lysis buffer (15 mM HEPES, pH 7.5, 250 mM NaCl, 0.5% NP40, 10% 
glycerol and 1 mM PMSF) and analyzed for hnRNP A l, A2, DAZAP1 and ASF/SF2 
endogenous protein expression by immunoblot analysis using the antibodies 
described above. Tubulin was used as protein loading control. Each siRNA treatment 
experiment was repeated at least three times.
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A disease-causing G-to-T transversion at position + 6  of BRCA1 exon 18 induces exclusion of the exon from 
the mRNA and, as has been suggested by in silico analysis, disrupts an ASF/SF2-dependent splicing enhancer.
We show here using a pulldown assay with an internal standard that wild-type (WT) and mutant T6 sequences 
displayed similar ASF/SF2 binding efficiencies, which were significantly lower than that of a typical exonic 
splicing enhancer derived from the extra domain A exon of fibronectin. Overexpression or small interfering 
RNA (siRNA)-mediated depletion of ASF/SF2 did not affect the splicing of a WT BRCA1 minigene but resulted 
in an increase and decrease of T6 exon 18 inclusion, respectively. Furthermore, extensive mutation analysis 
using hybrid minigenes indicated that the T6 mutant creates a sequence with a prevalently inhibitory function.
Indeed, RNA-protein interaction and siRNA experiments showed that the skipping of T6 BRCA1 exon 18 is due 
to the creation of a splicing factor-dependent silencer. This sequence specifically binds to the known repressor 
protein hnRNPAl/A2 and to DAZAP1, the involvement of which in splicing inhibition we have demonstrated.
Our results indicate that the binding of the splicing factors hnRNPAl/A2 and DAZAP1 is the primary 
determinant of T6 BRCA1 exon 18 exclusion.
Pre-mRNA splicing is an essential step in the gene expres­
sion process, connecting D N A  transcription to protein trans­
lation. The splicing process is catalyzed by the spliceosome, a 
dynamic complex of five small nuclear ribonucleoproteins 
(snRNPs) and a large number of additional proteins (19, 30). 
During pre-mRNA splicing, exon coding sequences must be 
precisely distinguished from noncoding intronic sequences and 
joined together to form mature mRNA (2). To achieve this, 
the splicing machinery requires essential signals located 
around the splice site junctions: 5' and 3' splice sites, polypyrimi­
dine tracts, and branch site sequences (2). However, these 
splice signals alone provide only a part of the information 
required by the spliceosome machinery for an efficient splicing 
process (23, 39). In fact, correct exon definition requires pos­
itive and negative accessory elements broadly referred to as 
exonic splicing enhancers (ESEs) and silencers (ESSs). Most 
ESEs are known to interact with members of the serine/argi- 
nine-rich family, which are splicing factors essential for pro­
moting spliceosome assembly at the correct splice sites (3, 17, 
36). In contrast, ESS sequences have often been found to bind 
specific trans-acting factors belonging to the heterogeneous 
nuclear ribonucleoprotein (hnRNP) family, which plays a role 
in splicing repression (13, 22, 35). In addition, enhancers or 
silencers may in some cases coexist in composite exonic splic­
ing regulatory elements, giving rise to complex effects of nat­
ural and site-directed mutants on splicing (32, 34). Mutations 
in exonic splicing regulatory elements that result in splicing 
alterations are a common event in human pathology (6, 7, 16,
31). The analysis of several gene systems, such as the ATM
* Corresponding author. Mailing address: Human Molecular G enet­
ics, International Center for G enetic Engineering and Biotechnology, 
Padriciano 99, 34012 Trieste, Italy. Phone: 0039-040-375-7342. Fax: 
0039-040-226-555. E-mail: pagani@icgeb.org.
7 Published ahead of print on 7 April 2008.
(40), NF1 (1), CFTR (34), SMN (26), and BRCA1 (27) sys­
tems, has shown that exonic mutations can affect, indepen­
dently from their effect on the amino acid sequence, splicing 
regulatory sequences and induce different splicing defects, in­
cluding exon skipping.
A  clear identification of the nature and location of exonic 
splicing regulatory elements is fundamental to understand the 
effect of genomic variants on splicing and consequently de­
velop appropriate therapeutic strategies. To identify the com­
position of exonic splicing regulatory sequences and thus pre­
dict the splicing phenotype of exonic mutations in human 
genes, several in silico programs have been developed (10,14, 
15, 41, 42). However, this approach does not always correlate 
with the splicing phenotype observed, presenting severe limi­
tations concerning its use in clinical genetics (12, 32, 34).
Notwithstanding the relatively high occurrence of defective 
splicing due to exonic mutations in several disease-related 
genes, the underlying mechanism is still controversial. Two 
different models have been proposed to explain exon skipping 
due to exonic mutations. The enhancer loss model suggests the 
disruption of sequences with enhancer properties, with ASF/ 
SF2 being the main binding factor involved. On the contrary, 
the silencer gain-of-function model implies the creation of a 
silencer sequence by the mutation, which is mostly recognized 
by members of the hnRNP family. These two models have 
been extensively explored in the SMN1/2 systems, in which a 
critical C-to-T synonymous substitution in position 6 induces 
exon 7 skipping (8, 9, 20, 21,37). The natural G-to-T mutation 
at position + 6  of BRCA1 exon 18 (E1694X) presents common 
features with the SMN system. This mutation occurs at the 
same exonic position of SMN2; it has been previously reported 
to be associated with exon skipping (27), and both computer- 
assisted analysis and in vitro splicing analysis of a limited num­
ber of mutants have suggested that it disrupts a putative bind­
ing site for ASF/SF2 (25). However, this binding has never
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been experimentally proven, although the BRCA1 exon 18 
system has been used for the in vitro characterization of new 
ASF/SF2-specific exonic splicing enhancers by systematic evo­
lution of ligands by exponential enrichment (SELEX) (38). 
Small interfering RNA (siRNA) of ASF/SF2 has been recently 
shown not to have any functional effect on wild-type (WT) 
BRCA1 exon 18 splicing, whereas the BRCA1 E1694X mutant 
was found to bind hnRNPAl/A2 (21). However, as depletion 
of both hnRNPAl and hnRNPA2 had no effect on mutant 
BRCA1 splicing, it was suggested that the disruption of en­
hancer binding to an unknown splicing factor contributes to 
mutant exon skipping (21).
Our work evaluates extensively the composition of the splic­
ing-regulatory element affected by the natural G-to-T trans­
version at position + 6  in BRCA1 exon 18. The analysis we 
performed includes systematic site-directed mutagenesis in hy­
brid minigenes, in vitro binding experiments, and siRNA treat­
ment of the splicing factors involved. We find no preferential 
binding of ASF/SF2 to the WT sequence compared with the T6 
mutant. On the contrary, the BRCA1 exon 18 T6 substitution 
creates a sequence with silencer properties that binds to 
hnRNPAl/A2, a known repressor protein, and deleted in 
azoospermia-associated protein 1 (DAZAP1). Altogether, our 
data support the gain-of-function model for defective splicing 
due to the + 6  G-to-T exonic mutation in BRCA1 exon 18.
MATERIALS AND METHODS
Hybrid minigene constructs. The BRCA1 genomic region containing the last 
85 bp of exon 17 and first 1,408 bp of intron 17 was amplified from normal DNA 
using BRC90BstEII Dir (5 '-CTGGTACCAAGTTTGCCAGAAAACACCACA 
TCACTTTAACTAATC-3') and BRC1566 Rev (5'-AACACCCAGAGGTCTC 
CTGTATTACACAAG-3') primers and blunt ligated in the Smal site of pBlue- 
script KS to generate pBS BRA17. Similarly, the last 334 bp of intron 18 along 
with 58 bp at the beginning of exon 19 was amplified with BRC735 Dir (5'-TA 
GCAATGTAGCATATGAGCTAGGGATTTA-3’) and BRC4451 Rev (5'-AA 
CATCAAGTACTTACCTCATTCAGC-3') primers and blunt ligated in the 
Smal site of pBIuscript KS to generate pBS BRA19. Subsequently, pBS BRA19 
was digested with Ndel and Kpnl and cloned in the corresponding sites of pBS 
BRA17 to generate pBS BRA17-19, with Ndel as a unique site. The BstEII- 
BstEII fragment contained in pBS BRA17-19 was then inserted in the unique 
BstEII site of a modified pTB a-globin minigene to obtain pBRAint. The 
BRCA1 genomic region encompassing exon 18 and adjacent intronic sequences 
(289 bp of intron 17, full-length exon 18, and 255 bp of intron 18) was amplified 
with BRC138 Dir (5'-GGCATATGGAGATCTATAGCTAGCCTTGGCGTCT 
AGAAGATGG-3') and BRC760 Rev (5'-AATCCCTAGCTCATATGCTAAC 
ATTGCTAGG-3') primers and cloned in the unique Ndel site of pBRAint. On 
this resulting construct, an EcoRI site was inserted in intron 18 (49 bases down­
stream of the 5 ' splice site of exon 18) by PCR-mediated site-directed mutagen­
esis, creating the final hybrid minigene, named pBRAwt. The natural PstI and 
the artificial EcoRI unique sites create a cassette system, which facilitates sub­
sequent cloning procedures. The final minigene lacks the central part of intron 
17 (1,960 bp), and the a-globin and BRCA1 17, 18, and 19 exons are in frame. 
pBRA minigene variants were generated by PCR site-directed mutagenesis re­
placing the pBRAwt Pstl-EcoRI cassette with the mutated sequence. The con­
structs containing the serial deletions (~10 bp) within exon 18 were created by 
overlapping PCR mutagenesis using suitable primers on pBRA WT or T6 mutant 
minigenes as templates. The identity of each minigene was verified by sequence 
analysis. The pSMN2 construct has been previously reported (8).
Cell culture, transfections, and reverse transcription-PCR (RT-PCR) analy­
sis. Human cell lines (Hep3B and HeLa) were cultured in Dulbecco’s modified 
Eagle’s medium with Glutamax (Invitrogen), in standard conditions. The DNA 
used for transfection was purified using JetStar columns (Genomed). Hep3B 
cells (3 X 105) were transfected with 1.5 pg of each reported plasmid construct, 
employing the DOTAP (l,2-dioleoyl-3-trimethylammonium-propane) liposomal 
transfection reagent (Alexis Biochemicals) according to the manufacturer’s in­
structions. After 12 h, the transfection medium was replaced with fresh medium,
and 24 h later the total RNA was extracted using TRIreagent solution (Ambion). 
Retrotranscription was performed with random primers and Moloney murine 
leukemia virus enzyme (Invitrogen). To amplify only the messengers derived 
from the transfected plasmid, PCR was performed with BRC90BsteII Dir and 
GIo800Rev (5'-GCTCACAGAAGCCAGGAACTTGTCCAGG-3'), which hy­
bridize to BRCA1 exon 17 and a-globin exon 3 sequences, respectively. The 
conditions used for the PCRs were the following: 94°C for 3 min for the initial 
denaturation; 94°C for 45 s, 54°C for 45 s, and 72°C for 45 s for 30 cycles; and 
72°C for 10 min for the final extension. PCRs were optimized to be in the 
exponential phase of amplification, and products were routinely fractionated in 
2% (wt/vol) agarose gels. For protein overexpression experiments, 1.5 pg of the 
minigene was cotransfected with 1 pg of the ASF/SF2 coding sequence cloned 
into a pCG vector (a kind gift from J. Caceres). Amplification of the pSMN2 
minigene was performed with the previously reported oligonucleotides (8). The 
results of all the transfections are representative of at least three independent 
experiments. ImageJ 1.38 software (http://rsb.info.nih.gov/ij/) was used in order 
to quantify the proportion of exon 18 skipping.
Affinity purification of RNA binding proteins. Two synthetic RNA oligonu­
cleotides, exon 18 WT (UGCAGAUGCUGAGUUUGUGU) and U6 (UGCA 
GAUGCUUAGUUUGUGU), were generated by Integrated DNA Technolo­
gies and used as targets for pulldown assays. Twelve micrograms of target 
BRCA1 RNA oligonucleotides was placed in 400 pi of reaction mixture (100 mM 
sodium acetate [NaOAC], pH  5.0, and 5 mM sodium m-periodate 2 ), incubated 
for 1 h in the dark at room temperature, ethanol precipitated, and finally 
resuspended in 100 p i of 100 mM NaOAc (pH 5.0). Approximately 400 p i of 
adipic acid dehydrazide-agarose beads (50% slurry; Sigma) previously equili­
brated with 100 mM NaOAC (pH 5.2) was added to each periodate-treated 
RNA, and the mixture was incubated for 12 h at 4°C on a rotator.
The beads with the bound RNA were then washed two times with 1 ml of 2 M 
NaCl and equilibrated in l x  washing buffer (5.2 mM HEPES, pH  7.5, 1 mM 
MgCl2, 0.8 mM Mg acetate). Then the beads were incubated, in a final volume 
of 500 pi, with 0.5 mg of HeLa cell nuclear extract (C4; Biotech), IX  binding 
buffer (5.2 mM HEPES, pH 7.9, 1 mM MgCl2, 0.8 mM Mg acetate, 0.52 mM 
dithiothreitol, 3.8% glycerol, 0.75 mM ATP, 1 mM GTP), and heparin (final 
concentration, 1 pg/pl) for 30 min on a rotator at room temperature. The beads 
were then washed four times with 1.5 ml of washing buffer before addition of 
sodium dodecyl sulfate (SDS) sample buffer and loading on SDS-10% poly­
acrylamide gels.
Proteins were visualized by Coomassie brilliant blue staining. Protein sequence 
analysis of the bands excised from the gel was performed using an electrospray 
ionization mass spectrometer (LCQ DECA XP; ThermoFinnigan). Protein 
bands were digested with trypsin, and the resulting peptides were extracted with 
water and 60% acetonitrile-1% trifluoroacetic acid. Fragments were then ana­
lyzed by mass spectrometry, and proteins were identified by analysis of the 
peptide tandem mass spectrometry data with Turbo SEQUEST (Thermo­
Finnigan) and MASCOT (Matrix Science).
In vitro transcription and Western blot analysis. Plasmids for in vitro tran­
scription were generated by annealing the sense (5'-CTGTGTGTGTGTGlTTlT 
TGCAGATGCTKAGTTTGTGTG-3') and the antisense (5'-GATCCACACAAA 
CTMAGCATCTGCAAAAAACACACACACACAGAGCT-3') oligonucleotides, 
purchased from Sigma, for both WT and T6 mutant exon 18 sequences. This was 
followed by direct cloning into SacI-BamHI-digested pBluescript vector, under the 
control of the T7 RNA promoter.
Part of the fibronectin extra domain A (EDA) sequence (5'-CTGTGTGTGT 
GTGTTTnTGCACCTGATGGTGAAGAAGACACTGCAGAGC-3') was 
also cloned by following the same procedure and used for pulldown analyses, 
acting as internal control for ASF/SF2 binding.
Plasmids were first linearized by H indlll digestion and then in vitro tran­
scribed with T7 RNA polymerase (Promega) according to standard procedures. 
Approximately 12 to 15 pg of transcribed and purified RNA was placed in a 
400-pl reaction mixture of 100 mM NaOAc, pH 5.0, and 5 mM sodium m- 
periodate (Sigma) and processed as described above for pulldown assays. A fter 
the final centrifugation, 60 pi o f SDS-polyacrylamide gel electrophoresis 
(PAGE) sample buffer was added to the samples, followed by heating for 5 min 
at 90°C before loading onto a 12% SDS-PAGE gel. The gel was electroblotted 
on a polyvinylidene difluoride membrane according to standard protocols (Am- 
ersham Biosciences), and the membrane was blocked with phosphate-buffered 
saline-5% skimmed milk. Proteins were identified using different antibodies, and 
Western blot signals were detected with a chemiluminescence kit (ECL; Pierce 
Biotechnology).
Rabbit anti-hnRNPAl serum was generously provided by R. Klima, and poly­
clonal antibodies against hnRNPA2 and TDP43 were provided by E. Buratti 
(ICGEB, Trieste, Italy). Purified glutathione S-transferase (G ST )-D A Z A Pl
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protein was used to immunize a rabbit (New Zealand strain) according to 
standard protocols to obtain polyclonal anti-DAZAPl antibodies. Anti-ASF/SF2 
monoclonal antibody 96 was purchased from Zymed Laboratories Inc., and 
antitubulin monoclonal antibody was kindly provided by F. Porro (ICGEB, 
Trieste, Italy).
Electromobility shift assay (EMSA). RNA synthetic oligonucleotides (200 ng) 
were labeled by phosphorylation with [y-32P]ATP and T4 polynucleotide kinase 
(New England Biolabs) for 1 h at 37°C, precipitated, and resuspended in 200 jxl 
of water. Each binding reaction was made by mixing the purified protein with the 
labeled RNA oligonucleotide in I X  binding buffer (5.2 mM HEPES, pH 7.9, 1 
mM MgCl2, 0.8 mM Mg acetate, 0.52 mM dithiothreitol, 3.8% glycerol, 0.75 mM 
ATP, 1 mM GTP) to a 20-pi final volume. The reaction mixture was left at room 
temperature for 15 to 20 min before loading the sample on a native polyacryl­
amide gel (5%), which was run at 100 to 120 V at 4°C. The protein-nucleic acid 
complexes were visualized using Biomax MS films (Kodak). The cDNA of each 
target protein was amplified and cloned in pGEX-3X plasmid (Pharmacia) and 
then expressed in BL21(DE3) bacteria (Novagen) under the induction of 0.5 mM 
IPTG (isopropyl-P-D-thiogalactopyranoside). The resulting recombinant pro­
teins were purified with glutathione S-Sepharose 4B beads (Pharmacia) accord­
ing to the manufacturer’s instructions using imidazole buffers for protein elution.
siRNA transfections. siRNA transfections were performed in HeLa cells using 
Oligofectamine reagent (Invitrogen). The sense strands of RNA interference 
oligonucleotides (Dharmacon) used for silencing the different target proteins 
were the following: human hnRN PA l, CAGCUGAGGAAGCUCUUCA, and 
human hnRNPA2, GGAACAGUUCCGUAAGCUC (20); human DAZAP1, 
GAGACUCUGCGCAGCUACU; human ASF/SF2, ACGAUUGCCGCAUCU 
ACGU (8); and luciferase no. 2 gene control, GCCAUUCUAUCCUCUAGA 
GGAUG.
HeLa cells were plated at 2.5 x  105 cells per well in 60-mm plates to achieve 
40 to 50% confluence. The next day, 6 pi Oligofectamine was combined with 24 
pi of Opti-MEM medium (Invitrogen) and 5 to 10 p i of 40 pM  siRNA duplex 
oligonucleotides was diluted in a final volume of 400 p i of Opti-MEM medium. 
The two mixtures were combined and left for 20 min at room temperature. 
Finally, this mixture was added to the cells, which were maintained in 1.6 ml of 
Opti-MEM. After 24 h a second round of siRNA transfection was performed as 
described above. Six to 8 h later Opti-MEM was exchanged with Dulbecco’s 
modified Eagle medium and the cells were transfected with the minigene of 
interest (1 pg) using Qiagen Effectene transfection reagents. On the third day, 
HeLa cells were harvested and divided in two parts for protein and RNA 
extractions. RT-PCR from total RNA was performed as for the transfection 
protocol described above. W hole-protein extracts were obtained by cell sonica- 
tion in lysis buffer (15 mM HEPES, pH  7.5, 250 mM NaCl, 0.5% NP-40, 10% 
glycerol, and 1 mM phenylmethylsulfonyl fluoride) and analyzed for hnRNPAl 
and -A2, DAZAP1, and ASF/SF2 endogenous protein expression by immuno- 
blotting using the antibodies described above. Tubulin was used as protein 
loading control. Each siRNA treatm ent experiment was repeated at least three 
times.
RESULTS
ASF/SF2 affects exon 18 splicing independently from the T6 
mutation. To evaluate the role of ASF/SF2 in the regulation of 
BRCA1 splicing, we set up a modified pulldown assay where 
exon 18 WT or U6 RNAs transcribed in vitro were linked 
through a (U )5 spacer to a sequence composed by six U G  
dinucleotide repeats (Fig. 1A, top). The U G  repeats, which 
specifically bind TDP43 (4), served as an internal standard to 
normalize the amount of RNAs pulled down. An ASF/SF2 
purine-rich enhancer, already described regarding the alterna­
tive splicing of the fibronectin E D A  exon (29), was used as a 
positive control to estimate the binding efficiency of the 
BRCA1 sequences. The pulldown assay was followed by West­
ern blotting and probing with ASF/SF2 and TDP34 antibodies. 
Relative to the binding of TDP43, used as a normalization 
reference, the WT and U6 mutant RNAs bind to ASF/SF2 with 
a similar, low efficiencies in comparison with the binding of 
ASF/SF2 to the strong E D A  enhancer (Fig. 1A, bottom, lanes 
2, 3, and 1, respectively). The low binding efficiencies of both
WT and mutant sequences suggest a common, minor splicing 
enhancing effect of ASF/SF2. These results were confirmed in 
classical pulldown experiments using RNA oligonucleotides 
without the U G  tail (data not shown).
To better evaluate the effect of ASF/SF2 on human BRCA1 
exon 18 splicing, we prepared a pBRA hybrid minigene. The 
pBRA minigene system contains most of the genomic se­
quences of the BRCA1 gene from exon 17 to 19, cloned in 
frame within the a-globin pTB minigene (Fig. IB) (33). We 
tested the in vivo splicing pattern of the pBRA WT and T6 
constructs by transient transfection of HeLa cells followed by 
RT-PCR analysis of the total RNA. The two minigenes spliced 
in different ways: while WT exon 18 was efficiently included 
(Fig. 1C, lane 1), the T6 mutated exon was predominantly 
skipped, with only 20% of it being included (Fig. 1C, lane 3). 
Cotransfection experiments using a plasmid coding for ASF/ 
SF2 showed an increase in the percentage of exon 18 inclusion 
for the T6 mutant minigene (Fig. 1C, lane 4), whereas the 
enhancing effect was not detectable for the WT minigene since 
exon 18 is already fully included in the absence of ASF/SF2 
overexpression (Fig. 1C, lane 2).
We further investigated the in vivo role of ASF/SF2 by 
siRNA treatment of HeLa cells. In this case the WT and T6 
pBRA constructs were transfected in siRNA-treated cells. A f­
ter 24 h cells were collected and analyzed for the level of 
endogenous ASF/SF2 by Western blotting. We observed a 
strong reduction in ASF/SF2 expression in cells transfected 
with siRNA but not in luciferase siRNA-treated cells, used as 
control (Fig. ID , left). RT-PCR analysis of the total RNA  
showed that ASF/SF2 depletion induced a nearly complete 
exclusion of T6 exon 18 from the mature mRNA (Fig. ID , 
right, lane 3). In contrast, WT BRCA1 exon 18 did not respond 
to siRNA treatment (Fig. ID, right, lane 1). Overall, these 
results do not support a direct role for ASF/SF2 in the aberrant 
splicing of T6 mutant exon 18.
The natural G-to-T transition in BRCA1 exon 18 creates a 
sequence with silencer properties. To understand the compo­
sition of the splicing-regulatory element and the effect of the 
G6T natural mutation, we performed systematic site-directed 
mutagenesis. A  series of single point mutations from position 
+ 4  to position +11 were introduced in the pBRA hybrid mini­
gene and evaluated by means of the functional-splicing assay. 
Interestingly, out of 21 substitutions only the natural T6 mu­
tation resulted in a very low level of exon inclusion (20%) (Fig. 
2A, lane 10). Two additional mutations, in positions 4 (T4) and 
6 (A6), partially affected the splicing pattern, causing 85% and 
70% exon inclusion, respectively (Fig. 2A, lanes 4 and 8). As 
the widely spanning mutagenesis analysis seemed more com­
patible with the creation of a negative element by the T6 
variant, we decided to test this putative silencer by introducing 
in the context of the T6 substitution consecutive point muta­
tions from position + 4  to +9. As shown in Fig. 2B, the majority 
of the double site-directed mutations flanking position 6 in­
creased the splicing efficiency compared with that for the single 
T6 variant. In particular, all of the substitutions in positions 7 
and 8 restored almost completely exon inclusion (Fig. 2B, lanes 
9 to 14), and three mutations in position 5 and two in position 
9 (T6A9 and T6C9) increased significantly the splicing effi­
ciency (Fig. 2B, lanes 6 to 8,15, and 16), whereas T6G9 had no 
effect (Fig. 2B, lane 17). In contrast, mutations at position + 4
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FIG. 1. ASF/SF2 affects exon 18 splicing independently from the T6 mutation. (A) Western blot after pulldown analysis o f W T and U 6  
sequences. Shown is a schematic representation of the R N A  sequence transcribed in vitro (top) that contains (U G )6 repeats, a (U )5 spacer, part 
of intron 17 (lowercase), and the first part of WT and T6 exon 18 (uppercase). The mutant nucleotide U 6 is underlined. The bottom lane shows 
the E D A  sequence used as a control for ASF/SF2 binding. TDP43 was used to normalize the assay for the amount of RNA. The nuclear extract 
sample (NE) corresponds to 1/20 o f the amount used for the pulldown assay. (B) Schematic representation of the pBRA hybrid minigene system. 
Dark gray and white boxes represent a-globin and BRCA1 exons, respectively. Thick lines are introns (IVS), and the large black arrow at the 5' 
end indicates the simian virus 40 promoter. The lengths of BRCA1 exon 18 and flanking introns are shown. The primers used for RT-PCR are 
indicated by thin arrows, and the two alternative splicing possibilities, exon 18 inclusion and exclusion, are indicated as dotted lines. The positions 
of the unique PstI and EcoRI restriction sites used for subsequent cloning are shown. At the bottom, a few bases from intron 17 (lowercase) and 
exon 18 (from position +1 to +14) are shown, divided in codon triplets (uppercase). The putative ASF/SF2 binding site predicted by the ESE finder 
program (25) is boxed in light gray. The G-to-T natural mutation (E1694X) is indicated (27). (C) In vivo overexpression o f ASF/SF2 promotes exon 
18 T6 inclusions. HeLa cells were transfected with the WT or T6 pBRA minigene as indicated, along with the ASF/SF2-coding plasmid ( + )  or with 
the empty vector ( - ) .  Splicing patterns were analyzed by separating the RT-PCR products on 2% agarose gel and staining with ethidium bromide. 
The identity o f the transcripts, i.e., including exon 18 (e x l8 + )  and lacking exon 18 ( e x l8 - ) ,  is indicated at the right side o f the gel. The percentages 
of exon 18 inclusion, obtained from three independent transfections, are indicated below the lane numbers. (D ) In vivo depletion of ASF/SF2 
induces complete T6 exon 18 skipping. The left panel shows the Western blot analysis o f extracts from HeLa cells treated with either ASF/SF2 
siRNA (+ )  or a control luciferase siRN A ( —). The amount o f the protein extract was normalized using an antibody against tubulin. The right panel 
shows the RT-PCR results after transfection of the WT or T6 pBRA plasmid minigenes into ASF/SF2 siRNA-treated (lanes 1 and 3) and luciferase 
control-treated (lanes 2 and 4) HeLa cells, and the percentages o f BRCA1 exon 18 inclusion are indicated.
negatively affected splicing, resulting in complete exon 18 skip­
ping (Fig. 2B, lanes 3 to 5). Thus, double substitutions that 
restore normal exon 18 inclusion disrupt the mutant “TAG” 
sequence at the 5' end of exon 18. The “TAG” sequence 
therefore appears to be the core silencer element involved.
On the basis of this assumption, we evaluated splicing-reg­
ulatory sequences derived from the SMN1 and SMN2 genes
(20) and a SELEX A l silencer sequence (5) in the pBRA  
minigene context. These sequences include or do not include 
the “TAG” core element (Fig. 2C, left). Exon 18 splicing was 
affected by the insertion of the SELEX A l sequence at the 
same level as with the T6 mutant (Fig. 2C, lane 5). The SMN2 
sequence in the pBRA minigene showed a lower but still neg­
ative effect, with 50% exon 18 inclusion, whereas SMN1, which 
does not contain TAG, did not affect mRNA processing (Fig. 
2C, lanes 4 and 3, respectively). Finally, a deletion from posi­
tion + 4  to + 9  in the pBRA A4-9 construct did not change the 
splicing pattern in comparison with WT pBRA, further ruling
out the presence of a strong enhancer at the 5' end of exon 18 
(Fig. 2C, lane 6).
An indirect effect of nonsense-mediated decay on splicing in 
this system was excluded, as two nonsense-coding minigenes, 
T6A8 and 10A11G, and the out-of-frame A4-9 mutant showed, 
unlike the T6 variant (E1694X), complete exon inclusion (Fig. 
2B, lanes 12 and 18, and C, lane 6).
Identification of nuclear proteins binding to the splicing- 
regulatory element of the BRCA1 exon 18 T6 mutant. To 
identify the trans-acting factor(s) differentially binding to 
BRCA1 exon 18 WT and mutant sequences, we performed a 
pulldown analysis using two synthetic R NA  oligonucleotides 
containing either the WT or the natural U6 mutated sequence 
(Fig. 3A). Agarose bead-linked RNAs were incubated with 
HeLa nuclear extracts, and the associated proteins were ana­
lyzed by SDS-PAGE followed by Coomassie blue staining. 
Comparison of the patterns of binding proteins showed two 
specific bands of about 50 and 38 kDa that were specifically
D
ow
nloaded 
from 
m
cb.asm
.org 
at ICGEB 
on 
May 
15, 2008
3854 GOINA ET AL. M ol . C ell. B iol.
A 4  1 1uuuu
ugcag AT GCT GAG TIT GTG
10 11
w t A G T  A C G A C T C G T  A C T  A C G A G G
*7..................................................................................
__ ex18 +
ex l8 -
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
85 70 20 % ex18+
4 9
u m
ugcag A T  G C T  T A G  T T T  G T G
10A G 11
wt  6T* A G T A C G
6T
7
C G T A* C T A C G
  ex18 +
ex18-
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 
100 20 0 0 0 54 78 68 98 95 92 100 98 96 66 57 18 100 % ex18+
WT AT. GCT GAG TTT GTG
T6 AT GCT TAG TTT GTG
SMN1 AT GCT CAG ACA GTG
SMN2 AT GCT TAG ACA GTG
s e le x A l AT GCT TAG GGA GTG
A4-9 AT G— ---- - T T GTG
COI-  W to
ex18 +
ex18 -
1 2 3 4 5 6
100 20 96 45 20 98 %ex18+
FIG. 2. The G-to-T transition in BRCA1 exon 18 creates a sequence with silencer properties. (A) Single-point-mutation analysis of the exon 18 
putative regulatory region. Parts of the intron 17 and BRCA1 exon 18 sequences are shown in lowercase and uppercase, respectively. The arrows indicate 
the nucleotide positions where all three possible single point mutations were substituted, from nucleotide 4 to 11. The constructs were transfected into 
Hep3B cells, and the splicing pattern was analyzed by RT-PCR. The splicing products corresponding to exon 18 inclusion (ex l8 + ) and exclusion (ex l8 —) 
are indicated. The gray boxes indicate the mutants that showed exon skipping (lanes 4, 8, and 10). Their percentages of exon 18 inclusion are indicated 
below the lanes. (B) Double-point-mutation analysis. The upper panel shows part of the sequence of intron 17 and exon 18. The positions o f single point 
mutations, introduced in the context of the 6T variant, are indicated by arrows. The position of the 10A G 11 double mutant is indicated. The substitutions 
that create a stop codon are highlighted by an asterisk (lanes 2,12, and 18). The percentages of BRCA1 exon 18 inclusion, calculated as for panel A, are 
indicated below the lanes. (C) Analysis of silencer sequences in the BRCA1 exon 18 context. The left panel shows WT and mutant sequences of BRCA1 
exon 18 from position +1 to +14. The mutant elements are in boldface, and the deletion is represented as a dashed line (A4-9). The splicing profile was 
analyzed as described for panel A. The percentages of BRCA1 exon 18 inclusion are indicated.
pulled down by the U6 but not by the WT RNA (Fig. 3B). 
Sequence analysis of the excised bands and a database search 
revealed that the band of 50 kDa is DAZAP1, also named 
proline-rich RNA-binding protein, and that the band of 35
kDa corresponds to both hnR NPAl and its close homologue 
hnRNPA2 factor.
To investigate in more detail the differential binding effi­
ciency of the splicing-regulatory sequences of BRCA1 exon 18,
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FIG. 3. Identification of nuclear proteins binding to the splicing-regulatory element of the BRCA1 exon 18 T6 mutant. (A) Sequences o f the BRCA1 
RNA oligonucleotides. Intronic and exonic sequences are shown in lowercase and uppercase, respectively, and the mutated nucleotides are underlined. 
(B) Coomassie-stained gel o f a pulldown analysis where HeLa nuclear extracts were incubated with adipic dehydrazide beads derivatized with the target 
RNAs. The arrows indicate two bands of about 50 and 38 kDa, present only in the U 6 lane. The proteins in these bands were sequenced and identified 
as DAZAP1 (1) and hnRNPAl/A2 (2), respectively. (C) Schematic representation of the RNA sequence transcribed in vitro that contains (U G )6 repeats, 
a (U)5 spacer, and the target BRCA1 sequences. The mutagenized nucleotide is underlined. (D) Binding analysis of hnRNPAI and -A2 and DAZAP1 
performed by Western blotting after pulldown assays. After in vitro transcription, RNA was pulled down and the bound proteins were analyzed by 
Western blotting with anti-hnRNPAl, -hnRNPA2, -DAZAP1, and -TDP43 polyclonal antibodies. The nuclear extract sample corresponds to 1/20 of the 
amount used for the pulldown assay. (E) Interaction of purified human GST-hnRNPAl and -A2 and DAZAP1 proteins with WT, U6, and G4U6 RNA  
oligonucleotides monitored by EMSA. Labeled RNAs were incubated with different GST fusion proteins as indicated, and the complexes were resolved 
on a 5% polyacrylamide gel. The free RNA and the formed complex are indicated on the right.
we prepared in vitro T7-transcribed RNAs that contained a 
fixed (U G )6 repeat sequence linked through a poly(U) linker 
to WT and U6 exon 18 (Fig. 3C). After pulldown and SDS- 
PAGE, the proteins were blotted onto polyvinylidene difluo­
ride filters and evaluated using specific antibodies. In the pres­
ence of comparable amounts of pulled down TDP43, the U6  
mutant but not the WT bound very efficiently to DAZAP1 and 
hnRNPAl/A2 (Fig. 3D). These results were also confirmed by
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FIG. 4. In vivo depletion of hnRNPAI and -A2 and DAZAP1 by siRN A treatment partially rescues BRCA1 exon 18 inclusion. (A ) Western 
blot analysis of HeLa cells treated ( + )  with the indicated different siRNAs. NE, nuclear extract. Lane 8 corresponds to the control luciferase 
siRNA. (B) siRNA-treated (+ )  and untreated ( —) cells were transfected with the pBRA T6 minigene plasmid. Total R N A  was prepared and 
analyzed by RT-PCR. The splicing products obtained were separated on 2% agarose gels and stained with ethidium bromide. The identities o f the 
transcripts including exon 18 (e x l8 + )  and lacking exon 18 (e x l8 —) are indicated. The graph is the quantification of three independent experiments 
expressed as means ±  standard deviations. (C) Effect o f siRN A against hnRNPAI, hnRNPA2, and DAZAP1 on the WT pB R C A l minigene. 
(D ) Effect of double siRNA against hnRNPAI and hnRNPA2 on the splicing pattern of the control pSMN2 minigene. pSMN2 and pB R C A l T6 
minigenes were cotransfected in the siRNA hnRNPAI- and hnRNPA2-treated cells and analyzed with specific primers for pSMN2. The identity 
of the transcript with inclusion or exclusion of the SMN2 exon 7 is indicated.
classical pulldown experiments using synthetic RNA oligonu­
cleotides (data not shown).
In order to test the specificity of the three different splicing 
factors for binding to BRCA1, we performed EMSA with pu­
rified hnRNPAI, hnRNPA2, and DAZAP1 GST-tagged pro­
teins. For the EMSA experiments we selected the WT and the 
U6 RNAs and an additional double mutant, G4U6, which 
induced complete exon skipping in a splicing assay (Fig. 2B, 
lane 4). Labeled WT and mutant RNAs were incubated with 
recombinant proteins, and the RNA-protein complexes were 
resolved on a native acrylamide gel. A  band of shifted material 
with the RNAs carrying the T6 and G4T6 mutations is present, 
whereas no complexes are formed by the WT oligonucleotide 
(Fig. 3E). This difference in binding efficiency is visible for all 
the three proteins analyzed, and it is in agreement with the 
percentage of exon skipping detected in the minigene splicing 
assay.
siRNA against hnRNPAI and -A2 and DAZAP1 affects 
BRCA1 T6 exon 18 splicing. hnRNPAI and the related 
hnRNPA2 protein are well-known splicing-inhibitory factors,
whereas no functional role for DAZAP1 in splicing regulation 
has been reported. In order to evaluate the inhibitory role of 
hnRNPAI and -A2 and DAZAP1 in the in vivo splicing of 
BRCA1 exon 18, we used single or combined siRNA against 
these splicing factors. We transiently transfected HeLa cells, 
and the silencing effect was analyzed by Western blotting using 
antibodies against each target protein. At the same time, the 
splicing pattern was evaluated by RT-PCR using total RNA. 
HeLa cells transfected with the corresponding siRNAs showed 
a strong reduction in hnRNPAI and -A2 and DAZAP1 levels 
(Fig. 4A), whereas no effect was detected in the luciferase 
control protein extract (Fig. 4A, lane 8). Unexpectedly, 
DAZAP1 showed a small reduction in the amount of 
hnRNPAI and hnRNPA2 (Fig. 4A, lane 3), possibly related to 
an in vivo physical interaction (24) or to a regulatory effect of 
DAZAP1 on hnRNPAl/A2 splicing and/or stability. In the T6 
mutant, the combined siRNA-mediated knockdown of the 
three splicing-inhibitory factors increased the percentage of 
BRCA1 exon 18 inclusion from 20 to about 55% (Fig. 4B, lane 
7). A  slightly smaller effect was observed for the siRNA-me-
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diated knockdown of hnRNPAl/A2 (Fig. 4B lane 6), with 
about 45% exon inclusion, whereas the individual and double 
(hnR NPA l/DA ZA P1 and hnRNPA2/DAZAPl) siRNAs did 
not change the pattern of splicing (Fig. 4B, lanes 1 to 5). As a 
control for hnRNPAl/A2 silencing efficiency we cotransfected 
the pBRCAlT6 mutant with the pSMN2 minigene in the 
double-siRNA-treated cells. siRNA-mediated silencing of 
hnRNPAI and hnRNPA2 showed, as previously reported (8, 
21), significant rescue of the SMN2 splicing defect (Fig. 4D). 
Exon 18 inclusion in the WT was not affected by siRNA- 
mediated depletion of any of the three splicing-inhibitory fac­
tors (Fig. 4C).
BRCA1 exon 18 contains additional splicing-regulatory se­
quences that are functional only in the context of the T6 
mutant. To identify additional exonic splicing-regulatory ele­
ments that modulate T6 aberrant skipping, we performed sev­
eral consecutive deletions within BRCA1 exon 18. Those de­
letions analyzed in the context of the WT pBRA had no effect 
on normal exon 18 inclusion, indicating the absence of strong 
enhancer sequences in the natural exon (Fig. 5B, lanes 3 to 8). 
On the other hand, some deletions analyzed in the context of 
the T6 mutant resulted in changes in the pattern on splicing. In 
comparison to the T6 mutant, T6A35-44 and T6A64-74, which 
disrupt “TAG” elements, increased the percentage of exon 
inclusion up to 90% and 100%, respectively (Fig. 5C, lanes 5 
and 7), indicating the presence of two downstream silencers at 
positions 35 to 44 and 64 to 74. On the other hand, deletion of 
the sequences between positions 23 and 32 in the T6A23-32 
minigene induced complete exon skipping (Fig. 5C, lane 4), 
indicating the presence of a weak enhancer, which is function­
ally relevant only in the context of the T6 mutant. In a similar 
manner we evaluated also the combined effect of the two 
deletions in positions 4 to 9 and 23 to 32. These deletions alone 
had no effect on splicing but, when combined (A4-9 plus A23-
32), are able to induce partial exon skipping (Fig. 5C, lane 8). 
These data suggest the presence of two nearby weak enhancer 
sequences, which may contribute in a synergic manner to the 
definition of the WT exon. However, in the context of the 
A23-32 deletion the extent of splicing inhibition mediated by 
the single T6 substitution is more severe than the splicing 
inhibition mediated by the A4-9 deletion. In fact, the T6A23-32 
minigene induced complete exon exclusion, whereas A4-9- 
A23-32 showed only partial exon skipping, with 50% exon 
inclusion. This result is consistent with the strong inhibitory 
effect mediated by the binding of hnRNPAl/A2 and DAZAP1 
on the T6 mutant.
To identify potential splicing-regulatory sequences that 
could mediate the ASF/SF2 observed enhancing effect on the 
T6 mutant (Fig. 1C), we also evaluated in cotransfection ex­
periments the effect of this splicing factor on the different 
minigenes with single deletions. Overexpression of ASF/SF2 
increased the percentage of exon inclusion in the single T6 
mutant and in three deletion mutants, T6A12-21, T6A35-44, 
and T6A47-54 (Fig. 5D, lanes 4, 8, and 10), and had no effect 
on the already fully included T6A64-74 minigene (Fig. 5D, lane 
12). On the other hand, overexpression of this splicing factor 
did not induce exon inclusion in the T6A23-32 minigene (Fig. 
5D, lane 6). Thus, the ESE located between nucleotides 23 and 
32 in exon 18 stimulates BRCA1 exon 18 splicing through 
ASF/SF2 only in the context of the T6 mutant.
DISCUSSION
In this paper we provide biochemical and functional evi­
dence that the natural G-to-T transversion at position + 6  of 
BRCA1 exon 18, previously suggested to disrupt an ASF/SF2- 
dependent splicing enhancer, induces defective splicing 
through the creation of a sequence with splicing-inhibitory 
function. We show, in a series of systematic site-directed mu­
tagenesis and pulldown R NA  and EMSA experiments, that the 
mutation creates a splicing silencer element that interacts spe­
cifically with three splicing-inhibitory factors: hnRNPAI, 
hnRNPA2, and DAZAP1. By means of siRNA experiments, 
we found that hnRNPAl/A2 and DAZAP1 are involved in the 
generation of a defective splicing of T6 BRCA1 exon 18. In 
addition, we report a novel role for DAZAP1 in splicing reg­
ulation.
Computer-assisted analysis originally suggested that the nat­
ural G6T transversion in BRCA1 exon 18 disrupts a putative 
binding site for ASF/SF2 and accordingly affects an exonic 
splicing enhancer. Based on this prediction and the functional 
evaluation of a limited number of site-directed mutants in in 
vitro splicing assays, a general model of defective splicing due 
to exonic mutation was proposed consistent with the disruption 
of an ESE-dependent ASF/SF2 binding site (25). Using a mod­
ified pulldown technique followed by Western blot analysis, we 
unexpectedly found that both WT and T6 mutants bind equally 
to ASF/SF2 (Fig. 1A, lanes 2 and 3). Most importantly, com­
pared with the classical GAA-rich fibronectin E D A  enhancer 
(Fig. 1A, lane 1), the WT and mutant BRCA1 sequences show 
a diminished interaction with ASF/SF2, which is unlikely to be 
functional. The efficiency of this binding was carefully evalu­
ated by linking BRCA1 R NA  targets to a (UG) tail which 
specifically binds TDP43 and allows an accurate normalization 
of the amount of proteins pulled down. Consistent with the 
absence of a strong ASF/SF2-dependent enhancer at the 5' 
end of the exon disrupted by the mutation, and in accordance 
with recently published data (21), siRNA-mediated depletion 
of ASF/SF2 did not induce exon exclusion in the WT minigene 
(Fig. ID , lane 1), indicating that ASF/SF2 is not essential for 
BRCA1 exon 18 splicing. Similarly, the lack of a strong en­
hancer at the 5' end o f BRCA1 is also indicated by site- 
directed mutagenesis analysis. In fact, most point substitutions 
along the 5' end of BRCA1 exon 18 (Fig. 2A) and the complete 
deletion of the putative enhancer sequence (A4-9 pBRA con­
struct) have no effect on the splicing pattern (Fig. 2C, lane 6).
On the other hand, we found that the T6 mutant responds to 
siRNA-mediated depletion (Fig. ID , right, lane 3) or overex­
pression of ASF/SF2 (Fig. 1C, lane 4) by reducing or increas­
ing, respectively, the percentage of exon inclusion. A  small 
negative effect by depletion of ASF/SF2 has been also recently 
observed (21). In contrast to what was found for the BRCA1 
exon T6 mutant, the defective splicing of the related SMN2 
exon 7 gene was not affected by either overexpression or de­
pletion of ASF/SF2 (20, 21), suggesting different roles for this 
splicing factor in the two systems. Indeed, in a series of short 
exonic deletions in the WT and T6 BRCA1 minigene contexts 
we identify a series of splicing-regulatory sequences, which are 
functionally relevant only in the presence of the T6 mutation 
(Fig. 5). In particular, the enhancer sequence in position 23 to 
32 mediated ASF/SF2-dependent splicing activation (Fig. 5D).
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FIG. 5. Mapping the exonic regulatory elements within the BRCA1 exon 18 sequence. (A) Schematic representation of the BRCA1 exon 18 deletion 
mutants. The G or T substitution at position + 6  and the deleted nucleotides are indicated, while the TAG motives are underlined. (B and C) Exon 18 WT 
(B) and T6 (Q  serial deletion analysis. The indicated minigenes were transfected into Hep3B cells, and the splicing pattern was analyzed by RT-PCR. The two 
resulting splicing products corresponding to exon 18 inclusion (exl8+) and exclusion (e x l8 -)  are indicated, and the percentage of exon inclusion is reported. 
(D) Overexpression of ASF/SF2 in T6 deletion mutant minigenes. The indicated constructs were cotransfected with the ASF/SF2 coding plasmid (+ )  or with 
the empty vector ( - ) .
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FIG. 6. Splicing-regulatory elements in BRCA1 exon 18 and creation o f an ESS by the T6 mutant. WT exon 18 contains two weak ESEs (striped 
box) and two ESSs (black boxes), and its inclusion is largely dependent on 3' and 5' splice site definition. The G-to-T mutation at position + 6  
creates a strong silencer element at the 5' end of the exon binding to hnRNPA1/A2 and DAZAP1 and may also disrupt a weak splicing enhancer. 
The ASF/SF2 ESE located in the middle o f exon 18 stimulates BRCA1 exon 18 splicing only in the context o f the T6 mutant.
This evidence suggests that the T6 BRCA1-specific response to 
ASF/SF2 in overexpression and siRNA experiments may be 
due to the presence of a binding site for this splicing factor at 
position 23 to 32. This ASF/SF2 ESE stimulates BRCA1 exon 
18 splicing, inducing exon inclusion only in the context of the 
T6 mutant (Fig. 6).
Several lines of evidence indicate that the natural mutation 
studied here creates an exonic splicing silencer. The double- 
site-directed mutation experiments indicate that the majority 
of point mutations affecting the “TAG” core sequence between 
positions + 6  and + 8  completely restore normal splicing (Fig. 
2B). The mutant sequence, different from the WT, binds to 
three different proteins in pulldown assays and EMSA: 
hnRNPAI and the related hnRNPA2 factor and DAZAP1. 
hnRNPAI and hnRNPA2 are well-characterized splicing-in­
hibitory factors involved in a variety of cellular and viral sys­
tems (11) and have been identified as splicing repressors in the 
regulation of SMN2 exon 7 (20, 21). In contrast to hnRNPAI/ 
A2, few data are available regarding the functional properties 
of DAZAP1, which has been mainly implicated in mRNA  
transport and stability (24, 28). Interestingly, SELEX experi­
ments have shown two conserved sequences for the mouse 
homologue, A AU AG  and G U 1_3AG (18), which contain the 
same UAG splicing sequence as the BRCA1 T6 mutant. By 
means of siRNA experiments, we provide functional evidence 
that DAZAP1 and hnRNPAl/A2 are involved and probably 
have a redundant function in the splicing regulation of the 
defective BRCA1 exon 18. Treatment with hnRNPAl/A2  
siRNA resulted in a significant recovery of the defective splic­
ing, which was further enhanced by DAZAP1 depletion (Fig. 
4B). The requirement of multiple siRNAs for an efficient res­
cue of defective T6 splicing and the EMSA experiments with 
purified proteins suggest that hnRNPAl/A2 and DAZAP1 
specifically recognize the inhibitory sequence. This is further 
supported by the fact that DAZAP1 colocalizes and physically 
interacts with the splicing repressor proteins hnRNPAI and 
hnRNPCl (24). However, triple treatment with siRNA for 
hnRNPAl/A2 and DAZAP1 did not completely restore
BRCA1 exon inclusion. This can be explained by the presence 
of residual amounts of the splicing factors, not completely 
depleted by the siRNAs, or to the binding of an additional 
splicing-inhibitory factor(s) at the silencer element not re­
vealed by the pulldown analysis. Even if our results clearly 
indicate that the T6 mutant creates a strong silencer binding to 
hnR NA l/A2 and DAZAP1, we cannot exclude the simulta­
neous disruption of a weak enhancer, as recently suggested
(21). In fact, we observed that the combined deletion of the 5' 
end of BRCA1 exon 18 along with the downstream enhancer 
(A4-9-A23-32) induced partial exon skipping. Thus, with the 
limitation provided by the gross deletion analysis, which can 
interfere with RNA secondary structure and acceptor site ac­
cessibility or reduce the exon definition below a critical thresh­
old, the 5' end on BRCA1 exon 18 might contain a weak 
enhancer, which becomes evident only when the downstream 
enhancer is deleted. This weak enhancer in the WT sequence 
might bind to an unidentified splicing factor(s) or regulate 
RNA secondary structure constraints.
In agreement with our findings, the BRCA1 T6 mutant was 
recently found to bind to hnRNPAI, but its aberrant splicing 
was not corrected by hnRNPAI and hnRNPA2 silencing (21). 
We do not have a clear explanation of these different findings, 
but culture cell lines may show variable concentrations of splic­
ing-inhibitory factors like DAZAP1. These factors can effi­
ciently replace hnR NA PA l/A2 at the T6 mutant silencer or 
can act on other splicing-regulatory elements modulating 
siRNA rescue splicing efficiency. Consistent with this hypoth­
esis, we observed a different cell-type-dependent rescue effi­
ciency of the splicing pattern in siRNA experiments (data not 
shown).
In summary, our results indicate that the primary determi­
nant of the T6 BRCA1 exon 18 exclusion is not the disruption 
of an ASF/SF2-dependent enhancer but the creation of a new 
silencer element recognized specifically by the splicing-inhibi­
tory factors hnRNPAl/A2 and DAZAP1 (Fig. 6). These act as 
repressors that bind to the silencer and inhibit exon recogni­
tion during the splicing process. We have clearly established
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that the basic mechanism affecting splicing due to mutations is 
not always obvious and cannot be simply derived from in silico 
predictions. The creation of exonic splicing silencers may be a 
common event in human pathology and has to be taken into 
account in order to develop therapeutic strategies aimed at 
correcting splicing defects.
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